

Tuesday, June 12, 2018

Volume 49 No. 6



NOTICE – Items in this issue will be listed online weekly and printed monthly.

### 1-800 FLOWERS.COM, INC.

Earnings, 9 mos. to (Consol. – \$000):

	04/01/18	04/02/17
Total Revenues	921,987	954,097
Cost & expenses	844,917	871,284
Deprec., depl. & amort.	24,646	25,656
Operating income	52,424	57,157
Interest expense	2,919	4,796
Other income (expense), net	315	570
Net before taxes	49,820	52,931
Income taxes	806	16,903
<b>Net income</b>	<b>49,014</b>	<b>36,028</b>
Earnings common share		
Primary	\$0.76	\$0.55
Fully Diluted	\$0.73	\$0.53
Common Shares:		
Full Diluted	66,949	67,747
Year-end	64,604	65,335

### 1347 PROPERTY INSURANCE HOLDINGS INC

Earnings, 3 mos. to Mar 31(Consol. – \$000):

	2018	2017
Total Revenues	13,540	8,717
Cost & expenses	7,925	5,814
Operating income	2,320	381
Net before taxes	2,320	381
Income taxes	369	135
<b>Net income</b>	<b>1,951</b>	<b>246</b>
Earnings common share		
Primary	\$0.33	\$0.04
Fully Diluted	\$0.32	\$0.04
Common Shares:		
Full Diluted	6,093	5,957
Year-end	5,985	6,108

### Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	35,987	35,987
Current assets	50,822	50,822
Net property & equip.	432	432
Total assets	127,496	127,496
Liabilities:		
Current liabilities	11,141	11,141
Stockholders' equity	64,552	64,552
Net current assets	39,681	39,681

### ABIOMED, INC.

#### Annual Report

Consolidated Income Statement, Years Ended Mar. 31 (\$):

	2018	2017	2016
		(revised)	(revised)
Total revenue	593,749,000	445,304,000	329,543,000
Cost of revenue	98,581,000	70,627,000	50,419,000
Research & development expenses	75,297,000	66,386,000	49,759,000
Selling, general & administrative expenses	262,734,000	218,153,000	164,261,000
Total costs & expenses	436,612,000	355,166,000	264,439,000
Income (loss) from operations	157,137,000	90,138,000	65,104,000
Investment income (expense), net	3,688,000	1,554,000	395,000
Other income (expense), net	(388,000)	(349,000)	339,000
Total other income (expense)	3,300,000	1,205,000	734,000
Income (loss)			

	2018	2017	2016
before provision for income taxes - United States	134,006,000	78,172,000	54,406,000
Income (loss) before provision for income taxes - foreign	26,431,000	13,170,000	11,432,000
Income (loss) before income tax provision	160,437,000	91,343,000	65,838,000
Current provision (benefit) for income taxes - federal	752,000	7,313,000	1,690,000
Current provision (benefit) for income taxes - state	1,491,000	5,045,000	2,113,000
Current provision (benefit) for income taxes - foreign	3,400,000	1,066,000	1,592,000
Total current provision (benefit) for income taxes	5,643,000	13,424,000	5,395,000
Deferred provision for income taxes - federal	38,848,000	23,008,000	18,769,000
Deferred provision (benefit) for income taxes - state	(1,014,000)	(349,000)	1,284,000
Deferred provision (benefit) for income taxes - foreign	4,790,000	3,144,000	2,243,000
Total deferred provision for income taxes	42,624,000	25,803,000	22,296,000
Income tax provision	48,267,000	39,227,000	27,691,000
<b>Net income (loss)</b>	<b>112,170,000</b>	<b>52,116,000</b>	<b>38,147,000</b>
Weighted average shares outstanding - basic	44,153,000	43,238,000	42,204,000
Weighted average shares outstanding - diluted	45,849,000	44,658,000	44,895,000
Year end shares outstanding	44,375,337	43,673,286	42,596,228
Net income (loss) per share - basic	\$2.54	\$1.21	\$0.90
Net income (loss) per share - diluted	\$2.45	\$1.17	\$0.85
Number of full time employees	1,143	908	747
Number of common stockholders	471	517	492
Number of beneficiary stockholders	74,029	27,110	28,160
Foreign currency translation adjustments		(5,855,000)	2,724,000

Reclassified to conform with 2018 presentation; Approximate; As of May 8, 2018; Approximately; As of May 12, 2017; As of May 12, 2016

### Consolidated Balance Sheet, Years Ended Mar. 31 (\$):

	2018	2017
		(revised)
Cash & cash equivalents	42,975,000	39,040,000
Short-term marketable securities	319,274,000	190,908,000
Trade receivables, gross	70,330,000	54,337,000
Less: allowance for doubtful accounts	320,000	282,000
Accounts receivable, net	70,010,000	54,055,000
Raw materials & supplies	16,481,000	9,784,000
Work-in-progress	23,179,000	16,504,000
Finished goods	10,544,000	8,643,000
Inventories	50,244,000	34,931,000
Prepaid expenses & other current assets	11,808,000	8,024,000
Total current assets	494,271,000	326,958,000
Long-term marketable securities	37,502,000	47,143,000
Land	7,680,000	4,046,000
Building & building improvements	63,700,000	10,900,000
Capital lease asset		16,784,000
Leasehold improvements	2,905,000	34,854,000
Machinery & equipment	42,787,000	27,989,000
Furniture & fixtures	8,104,000	3,899,000
Construction in progress	19,850,000	9,257,000
Property & equipment, total cost	145,026,000	107,729,000
Less: accumulated depreciation	27,859,000	19,952,000
Property & equipment, net	117,167,000	87,777,000
Goodwill	35,808,000	31,045,000
In-process research & development	16,705,000	14,482,000
Long-term deferred tax assets, net	70,746,000	34,723,000
Other assets	14,176,000	8,286,000
Total assets	786,375,000	550,414,000
Accounts payable	23,565,000	20,620,000
Accrued employee compensation	30,330,000	23,290,000
Accrued sales & income taxes	4,562,000	3,180,000
Accrued research & development	3,162,000	2,349,000
Accrued marketing	2,305,000	1,827,000
Accrued professional, legal & accounting fees	1,870,000	2,019,000
Accrued warranty	1,081,000	717,000
Accrued capital expenditures	250,000	2,300,000
Other accrued expenses	2,587,000	2,021,000
Accrued expenses & other liabilities	46,147,000	37,703,000
Deferred revenue	14,970,000	10,495,000
Current portion of capital lease obligation		799,000
Total current liabilities	84,682,000	69,617,000
Other long-term liabilities	776,000	3,251,000
Contingent consideration	10,490,000	9,153,000
Long-term deferred tax liability	903,000	783,000
Capital lease obligation, net of current portion		15,539,000
Total liabilities	96,851,000	98,343,000
Common stock	444,000	437,000
Additional paid in		

capital	619,905,000	565,962,000
Retained earnings (accumulated deficit)	140,457,000	(46,959,000)
Treasury stock at cost	67,078,000	46,763,000
Accumulated other comprehensive income (loss)	(4,204,000)	(20,606,000)
Total stockholders' equity (deficit)	689,524,000	452,071,000

**Recent Dividends:****1. ABIOMED, Inc. common.**

No dividends paid.

**Annual Dividends:****1. ABIOMED, Inc. common.**

No dividends paid.

**ACACIA RESEARCH CORP****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	62,093,000	8,854,000
Cost & expenses	53,123,000	20,430,000
Operating income	8,970,000	(11,576,000)
Other income (expense), net	(41,097,000)	
Net before taxes	(31,920,000)	(10,880,000)
Income taxes	191,000	1,241,000
<b>Net income</b>	<b>(32,111,000)</b>	<b>(12,121,000)</b>
Earnings common share		
Primary	\$(0.63)	\$(0.24)
Fully Diluted	\$(0.63)	\$(0.24)
Common Shares:		
Full Diluted	50,632,958	50,333,056
Year-end	50,647,882	

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	150,289,000
Current assets	188,203,000
Total assets	317,835,000
Liabilities:	
Current liabilities	48,977,000
Stockholders' equity	265,460,000
Net current assets	139,226,000

**ACELRX PHARMACEUTICALS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	343	3,109
Cost & expenses	8,612	15,182
Operating income	(8,269)	(12,073)
<b>Net income</b>	<b>(11,592)</b>	<b>(15,551)</b>
Earnings common share		
Primary	\$(0.23)	\$(0.34)
Fully Diluted	\$(0.23)	\$(0.34)
Common Shares:		
Full Diluted	50,931	45,348
Year-end	50,991	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	43,603
Inventories	666
Current assets	53,658
Net property & equip.	11,067
Total assets	65,813
Liabilities:	
Current liabilities	13,253
Long-term debt	9,494
Stockholders' equity	(46,880)
Net current assets	40,405

**ACLARIS THERAPEUTICS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	1,118	
Cost & expenses	32,066	12,930
Operating income	(30,948)	(12,930)
Other income (expense), net	719	371
<b>Net income</b>	<b>(30,229)</b>	<b>(12,559)</b>
Earnings common share		
Primary	\$(0.98)	\$(0.48)
Fully Diluted	\$(0.98)	\$(0.48)
Common Shares:		
Full Diluted	30,886	26,081
Year-end	30,906	26,097

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	54,881
Current assets	192,256
Net property & equip.	2,191
Total assets	220,622
Liabilities:	
Current liabilities	13,823
Stockholders' equity	200,472
Net current assets	178,433

**ADDUS HOMECARE CORP****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	103,080	93,129
Deprec., depl. & amort.	1,807	1,516
Operating income	4,561	6,961
Interest income	2,322	7
Interest expense	910	651
Other income (expense), net	57	57
Net before taxes	5,973	6,374
Income taxes	1,115	2,115
<b>Net income</b>	<b>4,858</b>	<b>4,259</b>
Earnings common share		
Primary	\$0.42	\$0.37
Fully Diluted	\$0.42	\$0.37
Common Shares:		
Full Diluted	11,696	11,581
Year-end	11,691	11,628

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	63,406
Current assets	154,427
Net property & equip.	7,384
Total assets	272,853
Liabilities:	
Current liabilities	51,382
Long-term debt	39,396
Stockholders' equity	180,821
Net current assets	103,045

**ADVANCED EMISSIONS SOLUTIONS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	3,899,000	9,144,000
Cost & expenses	5,495,000	10,618,000
Deprec., depl. & amort.	116,000	482,000
Operating income	(1,712,000)	(1,956,000)
Other income (expense), net	12,279,000	16,723,000
Net before taxes	10,231,000	14,074,000
Income taxes	2,569,000	5,386,000
<b>Net income</b>	<b>7,662,000</b>	<b>8,688,000</b>
Balance for common	7,637,000	8,588,000
Earnings common share		
Primary	\$0.37	\$0.39
Fully Diluted	\$0.37	\$0.39
Common Shares:		
Full Diluted	20,584,000	22,243,000
Year-end	20,774,046	22,072,056

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	34,757,000
Inventories	122,000
Current assets	41,159,000
Net property & equip.	337,000
Total assets	82,842,000
Liabilities:	
Current liabilities	5,272,000
Stockholders' equity	77,305,000
Net current assets	35,887,000

**ADVERUM BIOTECHNOLOGIES INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	18,162	17,050
Operating income	(17,946)	(16,588)
Other income (expense), net	746	489
<b>Net income</b>	<b>(17,200)</b>	<b>(16,099)</b>
Earnings common share		
Primary	\$(0.30)	\$(0.38)
Fully Diluted	\$(0.30)	\$(0.38)
Common Shares:		
Full Diluted	57,420	42,144
Year-end	62,232	42,780

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	152,716
Current assets	249,198
Net property & equip.	2,820
Total assets	257,158
Liabilities:	
Current liabilities	9,274
Stockholders' equity	246,043
Net current assets	239,924

**AEVI GENOMIC MEDICINE INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	8,735	10,935
Operating income	(8,735)	(10,935)
Other income (expense), net	26	18
<b>Net income</b>	<b>(8,709)</b>	<b>(10,917)</b>
Earnings common share		
Primary	\$(0.15)	\$(0.29)
Fully Diluted	\$(0.15)	\$(0.29)
Common Shares:		
Full Diluted	59,335	37,108
Year-end	59,337	37,110

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	26,520
Current assets	27,321
Net property & equip.	69
Total assets	27,434
Liabilities:	
Current liabilities	4,739
Stockholders' equity	22,695
Net current assets	22,582

**AGROFRESH SOLUTIONS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	38,351,000	32,730,000
Cost & expenses	30,364,000	25,782,000
Operating income	(2,952,000)	(3,497,000)
Interest expense	8,355,000	10,293,000
Other income (expense), net	70,000	40,000
Foreign currency	1,931,000	3,103,000
Net before taxes	(9,306,000)	(10,647,000)
Income taxes	3,570,000	1,382,000
<b>Net income</b>	<b>(12,876,000)</b>	<b>(12,029,000)</b>
Earnings common share		
Primary	\$(0.26)	\$(0.24)
Fully Diluted	\$(0.26)	\$(0.24)
Common Shares:		
Full Diluted	49,741,593	49,661,469
Year-end	50,394,366	50,280,826

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	56,962,000
Inventories	20,612,000
Current assets	165,180,000
Net property & equip.	13,737,000
Total assets	949,556,000
Liabilities:	
Current liabilities	66,117,000
Long-term debt	402,209,000
Stockholders' equity	400,335,000
Net current assets	99,063,000

**AILERON THERAPEUTICS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	7,763	4,589
Operating income	(7,763)	(4,589)
Interest income	175	32
<b>Net income</b>	<b>(7,588)</b>	<b>(4,557)</b>
Pfd. dividends		20
Balance for common	(7,588)	(4,577)
Earnings common share		
Primary	\$(0.52)	\$(10.58)
Fully Diluted	\$(0.52)	\$(10.58)
Common Shares:		
Full Diluted	14,732	432,728
Year-end	14,734	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	
Cash & equivalents	6,782	
Current assets	44,446	
Net property & equip.	134	
Total assets	45,831	
Liabilities:		
Current liabilities	4,856	
Stockholders' equity	40,975	
Net current assets	39,590	

**AIR TRANSPORT SERVICES GROUP, INC.****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	203,040	237,917
Cost & expenses	135,393	183,545
Deprec., depl. & amort.	40,004	36,442
Operating income	27,643	17,930
Interest income	23	32
Interest expense	5,362	3,548
Other income (expense), net	(1,376)	1,692
Net before taxes	20,928	16,106
Income taxes	5,246	6,310
Income contin. oper.	15,682	9,796
<b>Net income</b>	15,878	9,988

**Earnings common share**

Primary	\$0.27	\$0.17
Fully Diluted	\$0.27	\$0.13
Common Shares:		
Full Diluted	59,558	64,949
Year-end	59,081	59,564

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	
Cash & equivalents	47,472	
Inventories	22,256	
Current assets	183,340	
Net property & equip.	1,176,520	
Total assets	1,567,503	
Liabilities:		
Current liabilities	163,347	
Long-term debt	515,595	
Stockholders' equity	408,498	
Net current assets	19,993	

**AKOUSTIS TECHNOLOGIES INC****Earnings, 9 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	1,029,901	468,032
Cost & expenses	16,818,224	7,124,350
Operating income	(15,788,323)	(6,656,318)
Interest income	1,136	970
Other income (expense), net	800,933	(877,490)
<b>Net income</b>	(14,986,254)	(7,532,838)
Earnings common share		
Primary	\$(0.73)	\$(0.46)
Fully Diluted	\$(0.73)	\$(0.46)
Common Shares:		
Full Diluted	20,499,917	16,419,225
Year-end	22,232,200	18,105,349

**ALASKA COMMUNICATIONS SYSTEMS GROUP INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	55,972	56,731
Cost & expenses	41,842	43,100
Deprec., depl. & amort.	8,787	8,903
Operating income	5,343	4,728
Interest expense	3,504	3,845
Other income (expense), net	104	(2,430)
Net before taxes	1,957	(1,540)
Income taxes	(112)	(832)
<b>Net income</b>	2,069	(708)

**Earnings common share**

Primary	\$0.04	\$(0.01)
Fully Diluted	\$0.04	\$(0.01)
Common Shares:		
Full Diluted	53,857	52,011
Year-end	53,111	52,341

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	
Cash & equivalents	5,226	
Inventories	5,681	
Current assets	66,091	
Net property & equip.	366,478	
Total assets	446,552	

Liabilities:		
Current liabilities	55,157	
Long-term debt	167,656	
Stockholders' equity	160,696	
Net current assets	10,934	

**ALIMERA SCIENCES, INC.****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	9,802	6,618
Cost & expenses	13,922	11,463
Operating income	(4,769)	(5,511)
Other income (expense), net	(1,766)	167
Foreign currency	2	(28)
Net before taxes	(6,709)	(6,709)
Income taxes		26
<b>Net income</b>	(7,684)	(6,735)
Earnings common share		
Primary	\$(0.11)	\$(0.10)
Fully Diluted	\$(0.11)	\$(0.10)
Common Shares:		
Full Diluted	69,883	64,863
Year-end	69,987	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	
Cash & equivalents	20,253	
Inventories	1,224	
Current assets	35,858	
Net property & equip.	1,531	
Total assets	56,117	
Liabilities:		
Current liabilities	7,465	
Long-term debt	37,537	
Stockholders' equity	8,551	
Net current assets	28,393	

**ALJ REGIONAL HOLDINGS INC****Earnings, 6 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	190,059,000	156,913,000
Cost & expenses	187,277,000	150,497,000
Operating income	2,782,000	6,416,000
Interest expense	5,453,000	4,718,000
Net before taxes	(2,671,000)	1,698,000
Income taxes	2,987,000	755,000
<b>Net income</b>	(5,658,000)	943,000
Earnings common share		
Primary	\$(0.15)	\$0.03
Fully Diluted	\$(0.15)	\$0.03
Common Shares:		
Full Diluted	37,742,000	35,671,000
Year-end	37,921,116	34,574,641

**ALLIANCE RESOURCE PARTNERS LP****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	457,122	461,080
Cost & expenses	235,048	287,656
Operating income	160,226	108,297
Interest income	65	24
Interest expense	10,858	7,516
Other income (expense), net	6,613	4,233
Net before taxes	156,046	105,038
Income taxes	(10)	(12)
<b>Net income</b>	156,056	105,050
Earnings common share		
Primary	\$1.16	\$1.10
Fully Diluted	\$1.16	\$1.10
Common Shares:		
Full Diluted	130,819	74,503
Year-end	130,903	74,597

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	
Cash & equivalents	28,764	
Inventories	83,944	
Current assets	294,106	
Net property & equip.	1,462,934	
Total assets	2,243,414	
Liabilities:		
Current liabilities	256,493	
Long-term debt	437,337	
Net current assets	37,613	

**ALPHATEC HOLDINGS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	21,307,000	27,978,000
Cost & expenses	21,797,000	31,205,000
Operating income	(667,000)	(3,399,000)
Interest expense	1,707,000	1,981,000
Other income (expense), net	62,000	5,000
Net before taxes	(2,312,000)	(5,375,000)
Income taxes	(458,000)	49,000
Income contin. oper.	(1,854,000)	(5,424,000)
<b>Net income</b>	(1,916,000)	(5,515,000)

**Earnings common share**

Primary	\$(0.09)	\$(0.61)
Fully Diluted	\$(0.09)	\$(0.61)
Common Shares:		
Full Diluted	21,212,000	9,005,000
Year-end	25,547,000	10,858,000

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018	
Cash & equivalents	47,645,000	
Inventories	28,872,000	
Current assets	90,732,000	
Net property & equip.	11,549,000	
Total assets	143,336,000	
Liabilities:		
Current liabilities	34,495,000	
Long-term debt	34,665,000	
Stockholders' equity	31,573,000	
Net current assets	56,237,000	

**ALPINE IMMUNE SCIENCES INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	315	
Cost & expenses	5,900	9,025
Operating income	(5,585)	(9,025)
Interest income		109
Interest expense	78	
Net before taxes	(5,358)	
Income taxes	(52)	
<b>Net income</b>	(5,306)	(8,916)
Earnings common share		
Primary	\$(0.38)	\$(2.28)
Fully Diluted	\$(0.38)	\$(2.28)
Common Shares:		
Full Diluted	13,845	3,911
Year-end	13,846	3,914

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	
Cash & equivalents	7,446	
Current assets	77,987	
Net property & equip.	1,127	
Total assets	80,699	
Liabilities:		
Current liabilities	2,928	
Long-term debt	3,570	
Stockholders' equity	73,881	
Net current assets	75,059	

**ALTIMMUNE INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	8,685,541	3,954,387
Operating income	(5,994,561)	(3,183,323)
Interest income	31,590	
Interest expense	870	
Other income (expense), net	1,798,665	(90,566)
Net before taxes	(4,165,176)	(3,198,912)
Income taxes	(991,638)	(1,001,315)
<b>Net income</b>	(3,173,538)	(2,197,597)
Balance for common	(5,064,859)	
Earnings common share		
Primary	\$(0.25)	\$(0.03)
Fully Diluted	\$(0.25)	\$(0.03)

**Common Shares:**

Full Diluted	20,145,270	68,737,093
Year-end	22,250,337	68,815,195

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018	
Cash & equivalents	4,559,894	
Current assets	19,920,760	
Net property & equip.	1,374,927	

Total assets	60,866,721
Liabilities:	
Current liabilities	5,155,133
Long-term debt	616,371
Stockholders' equity	40,540,232
Net current assets	14,765,627

**AMICUS THERAPEUTICS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	16,696,000	4,169,000
Cost & expenses	71,909,000	55,361,000
Operating income	(56,182,000)	(52,015,000)
Interest income	1,737,000	759,000
Interest expense	4,488,000	4,290,000
Other income (expense), net	7,625,000	610,000
Net before taxes	(51,308,000)	(54,936,000)
Income taxes	(1,392,000)	56,000
<b>Net income</b>	<b>(49,916,000)</b>	<b>(54,992,000)</b>
Balance for common	(49,916,000)	(54,992,000)

**Earnings common share**

Primary	\$(0.28)	\$(0.39)
Fully Diluted	\$(0.28)	\$(0.39)
Common Shares:		
Full Diluted	175,977,700	142,770,629
Year-end	187,972,218	142,829,530

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	114,322,000
Inventories	8,070,000
Current assets	592,033,000
Net property & equip.	8,910,000
Total assets	870,005,000
Liabilities:	
Current liabilities	140,705,000
Long-term debt	166,768,000
Stockholders' equity	521,617,000
Net current assets	451,328,000

**AMTECH SYSTEMS, INC.****Earnings, 6 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	106,394,000	62,079,000
Cost & expenses	98,563,000	63,662,000
Operating income	7,831,000	(1,583,000)
Other income (expense), net	2,000	(91,000)
Net before taxes	7,747,000	(1,790,000)
Income taxes	(1,540,000)	284,000
<b>Net income</b>	<b>9,287,000</b>	<b>(2,074,000)</b>
Earnings common share		
Primary	\$0.63	\$(0.11)
Fully Diluted	\$0.61	\$(0.11)
Common Shares:		
Full Diluted	15,223,000	13,184,000
Year-end	14,896,004	13,200,510

**ANALOG DEVICES INC****Earnings, 6 mos. to (Consol. - \$000):**

	05/05/18	04/29/17
Total Revenues	3,031,677	2,132,431
Cost & expenses	1,948,205	1,633,478
Operating income	869,324	412,103
Interest income	4,004	22,421
Interest expense	132,822	114,250
Other income (expense), net	(105)	(251)
Net before taxes	740,401	320,023
Income taxes	92,398	9,330
<b>Net income</b>	<b>648,003</b>	<b>310,693</b>
Balance for common	645,176	310,611
Earnings common share		
Primary	\$1.75	\$0.96
Fully Diluted	\$1.72	\$0.94
Common Shares:		
Full Diluted	374,430	329,365
Year-end	370,897	367,011

**APPLIED GENETIC TECHNOLOGIES CORP****Earnings, 9 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	18,770	31,128
Cost & expenses	34,375	26,423
Operating income	(15,605)	4,705
Other income (expense), net	(10)	
Gains or losses	866	700

Equity earnings	5	
Net before taxes	(14,749)	5,405
Income taxes	(66)	1,800
<b>Net income</b>	<b>(14,688)</b>	<b>3,605</b>
Earnings common share		
Primary	\$(0.81)	\$0.27
Fully Diluted	\$(0.81)	\$0.27
Common Shares:		
Full Diluted	18,098	18,408
Year-end	18,115	

**APTEVO THERAPEUTICS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	4,071	2,142
Cost & expenses	17,572	14,273
Operating income	(13,501)	(12,131)
Other income (expense), net	(407)	(406)
Net before taxes	(12,537)	(12,537)
Income taxes	(823)	
<b>Net income</b>	<b>(13,854)</b>	<b>(9,945)</b>
Earnings common share		
Primary	\$(0.63)	\$(0.48)
Fully Diluted	\$(0.63)	\$(0.48)
Common Shares:		
Full Diluted	22,025	20,757
Year-end	22,442	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	11,830
Inventories	1,285
Current assets	77,160
Net property & equip.	5,936
Total assets	100,212
Liabilities:	
Current liabilities	17,273
Long-term debt	13,975
Stockholders' equity	68,364
Net current assets	59,887

**ARK RESTAURANTS CORP****Earnings, 6 mos. to (Consol. - \$000):**

	03/31/18	04/01/17
Total Revenues	74,628	73,059
Cost & expenses	71,726	67,808
Operating income	320	2,716
Interest income	28	111
Interest expense	520	276
Net before taxes	(172)	2,551
Income taxes	(1,223)	753
<b>Net income</b>	<b>1,051</b>	<b>1,798</b>
Earnings common share		
Primary	\$0.29	\$0.39
Fully Diluted	\$0.28	\$0.38
Common Shares:		
Full Diluted	3,552	3,541
Year-end	3,437	3,426

**AROTECH CORP****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	27,248,509	22,347,445
Cost & expenses	25,677,790	21,876,117
Operating income	1,055,808	(226,665)
Other income (expense), net	(213,105)	(321,703)
Net before taxes	842,703	(548,368)
Income taxes	247,114	219,940
<b>Net income</b>	<b>595,589</b>	<b>(768,308)</b>
Earnings common share		
Primary	\$0.02	\$(0.03)
Fully Diluted	\$0.02	\$(0.03)
Common Shares:		
Full Diluted	26,447,090	26,169,228
Year-end	26,452,462	

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	8,027,749
Inventories	8,972,001
Current assets	51,927,314
Net property & equip.	9,124,343
Total assets	115,806,439
Liabilities:	
Current liabilities	25,395,576
Long-term debt	8,010,160

Stockholders' equity	71,718,887
Net current assets	26,531,738

**ARSANIS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	10,950	5,827
Operating income	(10,950)	(5,827)
Interest income	216	
Interest expense	267	1,019
Other income (expense), net	371	1,461
<b>Net income</b>	<b>(10,630)</b>	<b>(5,385)</b>
Balance for common	(10,630)	(5,392)
Earnings common share		
Primary	\$(0.74)	\$(10.49)
Fully Diluted	\$(0.74)	\$(10.49)
Common Shares:		
Full Diluted	14,294	514
Year-end	14,294	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	63,999
Current assets	68,525
Net property & equip.	384
Total assets	69,221
Liabilities:	
Current liabilities	9,297
Long-term debt	9,698
Stockholders' equity	48,423
Net current assets	59,228

**ASCENA RETAIL GROUP INC****Earnings, 9 mos. to (Consol. - \$):**

	04/28/18	04/29/17
Net Sales	4,812,000,000	991,700,000
Cost & expenses	4,566,100,000	1,040,400,000
Deprec., depl. & amort.	264,700,000	286,600,000
Operating income	(18,800,000)	305,300,000
Interest expense	82,200,000	76,100,000
Net before taxes	(99,200,000)	381,300,000
Income taxes	(26,300,000)	329,800,000
<b>Net income</b>	<b>(72,900,000)</b>	<b>351,500,000</b>
Earnings common share		
Primary	\$(0.37)	\$(5.40)
Fully Diluted	\$(0.37)	\$(5.40)
Common Shares:		
Full Diluted	195,900,000	194,700,000
Year-end	196,200,000	195,000,000

**ASCENT CAPITAL GROUP, INC.****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	133,753	141,200
Cost & expenses	70,107	59,808
Operating income	6,614	19,718
Interest income	481	395
Interest expense	38,652	37,486
Other income (expense), net	2,065	242
Net before taxes	(29,492)	(17,131)
Income taxes	1,346	1,814
Income contin. oper.		(18,945)
<b>Net income</b>	<b>(30,838)</b>	<b>(18,853)</b>
Earnings common share		
Primary	\$(2.51)	\$(1.55)
Fully Diluted	\$(2.51)	\$(1.55)
Common Shares:		
Full Diluted	12,299	12,134
Year-end	12,384	12,354

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	30,087
Current assets	173,428
Net property & equip.	34,070
Total assets	2,027,558
Liabilities:	
Current liabilities	117,717
Long-term debt	1,783,253
Stockholders' equity	100,612
Net current assets	55,711

**ASTRONICS CORP****Earnings, 3 mos. to (Consol. - \$000):**

	03/31/18	04/01/17
Cost & expenses	172,427	135,462
Operating income	6,632	16,934
Other income (expense), net	(375)	(310)
Net before taxes	3,926	15,491
Income taxes	632	3,904
<b>Net income</b>	<b>3,294</b>	<b>11,587</b>
Earnings common share		
Primary	\$0.12	\$0.40
Fully Diluted	\$0.11	\$0.38
Common Shares:		
Full Diluted	28,708	30,182
Year-end	29,766	29,669

<b>Consolidated Balance Sheet Items, as of (\$000):</b>		
Assets:		
Cash & equivalents	16,387	2018
Inventories	159,961	163,87
Current assets	349,893	349,893
Net property & equip.	124,762	124,762
Total assets	767,570	767,570
Liabilities:		
Current liabilities	122,539	122,539
Long-term debt	273,627	273,627
Stockholders' equity	338,028	338,028
Net current assets	227,354	227,354

**ATRION CORP.**

<b>Earnings, 3 mos. to Mar 31(Consol. – \$000):</b>		
	2018	2017
Total Revenues	39,401	38,504
Cost & expenses	28,035	27,177
Operating income	11,366	11,327
Other income (expense), net	330	148
Gains or losses	(789)	1
Net before taxes	10,907	11,476
Income taxes	2,420	1,526
<b>Net income</b>	<b>8,487</b>	<b>9,950</b>
Earnings common share		
Primary	\$4.58	\$5.42
Fully Diluted	\$4.57	\$5.36
Common Shares:		
Full Diluted	1,856	1,855
Year-end	1,836	1,837

<b>Consolidated Balance Sheet Items, as of (\$000):</b>		
Assets:		
Cash & equivalents	20,181	2018
Inventories	29,907	29,907
Current assets	107,551	107,551
Net property & equip.	67,485	67,485
Total assets	212,253	212,253
Liabilities:		
Current liabilities	11,183	11,183
Stockholders' equity	190,968	190,968
Net current assets	96,368	96,368

**ATYR PHARMA INC**

<b>Earnings, 3 mos. to Mar 31(Consol. – \$000):</b>		
	2018	2017
Cost & expenses	10,220	13,211
Operating income	(10,220)	(13,211)
Other income (expense), net	(447)	(194)
<b>Net income</b>	<b>(10,667)</b>	<b>(13,405)</b>
Earnings common share		
Primary	\$(0.36)	\$(0.56)
Fully Diluted	\$(0.36)	\$(0.56)
Common Shares:		
Full Diluted	29,795	23,739
Year-end	29,829	23,781

<b>Consolidated Balance Sheet Items, as of (\$000):</b>		
Assets:		
Cash & equivalents	21,936	2018
Current assets	76,006	76,006
Net property & equip.	2,374	2,374
Total assets	78,470	78,470
Liabilities:		
Current liabilities	11,022	11,022
Long-term debt	12,950	12,950
Stockholders' equity	54,498	54,498
Net current assets	64,984	64,984

**AVIAT NETWORKS, INC.**

<b>Earnings, 9 mos. to (Consol. – \$000):</b>		
---	--	--

	03/30/18	03/31/17
Total Revenues	179,998	185,443
Cost & expenses	179,695	185,782
Operating income	303	(339)
Interest income	149	168
Interest expense	24	28
Other income (expense), net	(220)	164
Net before taxes	208	(35)
Income taxes	(2,188)	(826)
<b>Net income</b>	<b>2,396</b>	<b>791</b>
Balance for common	1,791	650
Earnings common share		
Primary	\$0.34	\$0.12
Fully Diluted	\$0.32	\$0.12
Common Shares:		
Full Diluted	5,632	5,392
Year-end	5,349	5,349

**AVID TECHNOLOGY, INC.**

<b>Earnings, 3 mos. to Mar 31(Consol. – \$000):</b>		
	2018	2017
Total Revenues	97,937	104,107
Cost & expenses	100,909	100,661
Operating income	(3,335)	3,083
Interest expense	4,846	4,846
Net before taxes	(8,694)	(1,763)
Income taxes	255	152
<b>Net income</b>	<b>(8,949)</b>	<b>(1,915)</b>
Earnings common share		
Primary	\$(0.22)	\$(0.05)
Fully Diluted	\$(0.22)	\$(0.05)
Common Shares:		
Full Diluted	41,404	40,772
Year-end	41,502	41,502

<b>Consolidated Balance Sheet Items, as of (\$000):</b>		
Assets:		
Cash & equivalents	48,016	2018
Inventories	32,887	32,887
Current assets	172,777	172,777
Net property & equip.	20,663	20,663
Total assets	250,781	250,781
Liabilities:		
Current liabilities	192,686	192,686
Long-term debt	203,252	203,252
Stockholders' equity	(171,630)	(171,630)
Net current assets	(19,909)	(19,909)

**AXON ENTERPRISE INC**

<b>Earnings, 3 mos. to Mar 31(Consol. – \$):</b>		
	2018	2017
Net Sales	101,215,000	79,242,000
Cost & expenses	87,632,000	73,892,000
Operating income	13,583,000	5,350,000
Net before taxes	14,846,000	5,556,000
Income taxes	1,920,000	976,000
<b>Net income</b>	<b>12,926,000</b>	<b>4,580,000</b>
Earnings common share		
Primary	\$0.24	\$0.09
Fully Diluted	\$0.24	\$0.09
Common Shares:		
Full Diluted	54,532,000	53,677,000
Year-end	53,307,083	53,307,083

<b>Consolidated Balance Sheet Items, as of (\$):</b>		
Assets:		
Cash & equivalents	92,330,000	2018
Inventories	43,104,000	43,104,000
Current assets	258,970,000	258,970,000
Net property & equip.	31,175,000	31,175,000
Total assets	392,985,000	392,985,000
Liabilities:		
Current liabilities	128,710,000	128,710,000
Stockholders' equity	199,329,000	199,329,000
Net current assets	130,260,000	130,260,000

**AXSOME THERAPEUTICS INC**

<b>Earnings, 3 mos. to Mar 31(Consol. – \$):</b>		
	2018	2017
Cost & expenses	7,163,210	7,672,033
Operating income	(7,163,210)	(7,672,033)
Other income (expense), net	2,673,000	2,673,000
<b>Net income</b>	<b>(4,805,559)</b>	<b>(7,995,039)</b>
Earnings common share		
Primary	\$(0.19)	\$(0.41)
Fully Diluted	\$(0.19)	\$(0.41)

Common Shares:		
Full Diluted	25,501,188	19,537,897
Year-end	25,549,892	23,543,667

<b>Consolidated Balance Sheet Items, as of (\$):</b>		
Assets:		
Cash & equivalents	26,632,695	2018
Current assets	27,753,698	27,753,698
Net property & equip.	70,709	70,709
Total assets	27,939,296	27,939,296
Liabilities:		
Current liabilities	9,420,951	9,420,951
Long-term debt	5,932,191	5,932,191
Stockholders' equity	12,586,154	12,586,154
Net current assets	18,332,747	18,332,747

**BEFUT GLOBAL INC**

<b>Earnings, 3 mos. to Mar 31(Consol. – \$):</b>		
	2018	2017
Cost & expenses	210	182,720
Other income (expense), net	(220)	(220)
<b>Net income</b>	<b>(430)</b>	<b>(182,939)</b>
Earnings common share		
Primary	\$(0.00)	\$(0.00)
Fully Diluted	\$(0.00)	\$(0.00)
Common Shares:		
Year-end	190,830,375	192,030,375

<b>Consolidated Balance Sheet Items, as of (\$):</b>		
Assets:		
Cash & equivalents	13,570	2018
Current assets	763,570	763,570
Net property & equip.	5,000,000	5,000,000
Total assets	5,763,570	5,763,570
Liabilities:		
Stockholders' equity	(783,723)	(783,723)
Net current assets	763,570	763,570

**BIOCRYST PHARMACEUTICALS INC**

<b>Earnings, 3 mos. to Mar 31(Consol. – \$):</b>		
	2018	2017
Total Revenues	3,976,000	9,437,000
Cost & expenses	26,190,000	20,122,000
Operating income	(22,214,000)	(10,685,000)
Interest expense	2,221,000	2,100,000
Gains or losses	(1,804,000)	(1,543,000)
<b>Net income</b>	<b>(25,777,000)</b>	<b>(14,219,000)</b>
Earnings common share		
Primary	\$(0.26)	\$(0.19)
Fully Diluted	\$(0.26)	\$(0.19)
Common Shares:		
Full Diluted	98,592,000	75,167,000
Year-end	98,702,000	80,381,000

<b>Consolidated Balance Sheet Items, as of (\$):</b>		
Assets:		
Cash & equivalents	43,767,000	2018
Inventories	7,000	7,000
Current assets	104,156,000	104,156,000
Net property & equip.	9,395,000	9,395,000
Total assets	155,372,000	155,372,000
Liabilities:		
Current liabilities	75,342,000	75,342,000
Long-term debt	15,114,000	15,114,000
Stockholders' equity	62,054,000	62,054,000
Net current assets	28,814,000	28,814,000

**BIOSCRIP INC**

<b>Earnings, 3 mos. to Mar 31(Consol. – \$000):</b>		
	2018	2017
Total Revenues	168,584	217,810
Cost & expenses	175,037	229,445
Operating income	(12,939)	(18,800)
Net before taxes	(12,939)	(18,800)
Income taxes	48	619
Income contin. oper.	(12,987)	(19,419)
<b>Net income</b>	<b>(13,017)</b>	<b>(19,718)</b>
Balance for common	(15,674)	(22,106)
Earnings common share		
Primary	\$(0.12)	\$(0.18)
Fully Diluted	\$(0.12)	\$(0.18)
Common Shares:		
Full Diluted	127,772	118,783
Year-end	127,697	127,697

<b>Consolidated Balance Sheet Items, as of (\$000):</b>		
---	--	--

Assets:	2018
Cash & equivalents	30,352
Inventories	41,549
Current assets	175,950
Net property & equip.	24,971
Total assets	586,882
Liabilities:	
Current liabilities	103,694
Long-term debt	480,382
Stockholders' equity	(100,212)
Net current assets	72,256

**BIOSPECIFICS TECHNOLOGIES CORP.****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	7,089,409	7,690,619
Cost & expenses	2,680,498	2,680,498
Operating income	4,824,549	5,010,121
Interest income	217,951	101,753
Other income (expense), net	14,678	2,562
Net before taxes	5,057,178	5,114,436
Income taxes	1,078,574	1,769,683
<b>Net income</b>	<b>3,978,604</b>	<b>3,344,753</b>
Earnings common share		
Primary	\$0.55	\$0.47
Fully Diluted	\$0.54	\$0.46
Common Shares:		
Full Diluted	7,303,336	7,332,736
Year-end	7,199,233	7,172,021

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	12,558,901
Current assets	82,705,016
Total assets	86,374,936
Liabilities:	
Current liabilities	4,512,612
Stockholders' equity	81,844,689
Net current assets	78,192,404

**BLUE BIRD CORP****Earnings, 6 mos. to (Consol. - \$):**

	03/31/18	04/01/17
Net Sales	379,177,000	345,311,000
Cost & expenses	381,520,000	339,915,000
Operating income	(2,343,000)	5,396,000
Other income (expense), net	1,190,000	(10,306,000)
Equity earnings	(234,000)	(961,000)
Net before taxes	(4,414,000)	(9,300,000)
Income taxes	1,823,000	(2,564,000)
<b>Net income</b>	<b>(6,003,000)</b>	<b>(5,775,000)</b>
Balance for common	(7,536,000)	(7,745,000)
Earnings common share		
Primary	\$(0.32)	\$(0.34)
Fully Diluted	\$(0.32)	\$(0.34)
Common Shares:		
Full Diluted	23,911,909	22,822,416
Year-end	23,912,188	23,552,859

**BLUEKNIGHT ENERGY PARTNERS LP****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	44,660	46,340
Cost & expenses	38,845	39,783
Operating income	5,815	6,557
Interest expense	3,569	3,030
Other income (expense), net		61
Gains or losses	2,225	
Net before taxes	4,471	3,588
Income taxes	29	46
<b>Net income</b>	<b>4,442</b>	<b>3,542</b>
Earnings common share		
Primary	\$(0.05)	\$(0.08)
Fully Diluted	\$(0.05)	\$(0.08)
Common Shares:		
Full Diluted	40,289	38,146
Year-end	40,321	38,155

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	2,081
Current assets	25,071
Net property & equip.	304,416
Total assets	361,591
Liabilities:	
Current liabilities	25,506

Long-term debt	334,592
Net current assets	(435)

**BRAVO BRIO RESTAURANT GROUP INC**

**Merger Completed** On May 24, 2018, Bugatti Parent, Inc. ("Parent"), an investment affiliate of GP Investments, Ltd. ("GP"), a private equity and alternative investment firm and former owner of Fogo de Chao Churrascaria, LLC, and Spice Private Equity Ltd. ("Spice"), a Swiss investment company focused on private equity investments and an affiliate of GP, wholly-owned subsidiary, Bugatti Merger Sub, Inc. ("Merger Sub"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Parent. As the result of the merger, each common share, no par value per share, of Co. ("Co. Common Shares"), issued and outstanding immediately prior to the Effective Time, other than (i) Co. Common Shares held by Co. as a treasury share or owned by any of Co.'s direct or indirect wholly-owned subsidiaries or owned by Parent, Merger Sub or any other direct or indirect wholly owned subsidiary of Parent immediately prior to the Effective Time and (ii) dissenting shares for which a shareholder has properly exercised dissenters' rights in accordance with Section 1701.85 of the Ohio General Corporation Law (the "OGL") (collectively, "Excluded Shares"), was canceled and converted into the right to receive \$4.05 in cash, without interest and less any applicable withholding taxes (the "Merger Consideration"). In addition, each Co. Common Share issued under either of Co.'s Stock Incentive Plan or Co.'s 2006 Stock Option Plan (collectively, "Co.'s Share Plans") that was invested immediately prior to the Effective Time ("Co. Restricted Shares") was cancelled without any action on the part of the holder thereof in consideration for the right of such holder to receive the Merger Consideration. In addition, each option to purchase Co. Common Shares issued under any Co. Share Plan (collectively, "Co. Options"), whether vested or unvested, that was outstanding immediately prior to the Effective Time was cancelled without any action on the part of the holder thereof in consideration for the right of such holder to receive a cash payment equal to the product of (i) the number of Co. Common Shares subject to such Co. Option multiplied by (ii) the amount by which the Merger Consideration exceeds the exercise price per share of such Co. Option, without interest and subject to any withholding taxes required by applicable law. Any Co. Option with an exercise price per share that was greater than or equal to the Merger Consideration was cancelled at the Effective Time for no consideration and with no payment due to the holder thereof.

**BRIDGFORD FOODS CORP.****Earnings, 6 mos. to (Consol. - \$000):**

	04/20/18	04/14/17
Net Sales	79,092	74,178
Cost & expenses	70,555	68,699
Operating income	8,537	5,479
Net before taxes	8,537	5,479
Income taxes	5,530	1,690
<b>Net income</b>	<b>3,007</b>	<b>3,789</b>
Earnings common share		
Primary	\$0.35	\$0.42
Fully Diluted	\$0.35	\$0.42
Common Shares:		
Full Diluted	9,077	9,077
Year-end	9,076	9,076

**BSQUARE CORP****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	20,678	22,841
Cost & expenses	23,156	22,800
Operating income	(2,478)	41
Other income (expense), net		55
Net before taxes		96
Income taxes		(106)
<b>Net income</b>	<b>(2,434)</b>	<b>202</b>
Earnings common share		
Primary	\$(0.19)	\$0.02
Fully Diluted	\$(0.19)	\$0.02
Common Shares:		
Full Diluted	12,673	12,848
Year-end	12,689	12,569

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	10,692
Current assets	39,913
Net property & equip.	954
Total assets	45,110
Liabilities:	

Current liabilities	15,289
Stockholders' equity	29,340
Net current assets	24,624

**CADIZ INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	2,528	4,150
Operating income	(2,486)	(4,113)
Net before taxes	(5,970)	(7,226)
Income taxes	1	1
<b>Net income</b>	<b>(5,971)</b>	<b>(7,227)</b>
Earnings common share		
Primary	\$(0.26)	\$(0.33)
Fully Diluted	\$(0.26)	\$(0.33)
Common Shares:		
Full Diluted	23,075	22,097
Year-end	23,217	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	8,577
Current assets	9,317
Net property & equip.	45,780
Total assets	62,869
Liabilities:	
Current liabilities	3,764
Long-term debt	140,326
Stockholders' equity	(82,894)
Net current assets	5,553

**CANTERBURY PARK HOLDING CORP (NEW)****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	10,228,048	9,935,539
Operating income	1,356,753	861,809
Interest income	12,407	12,188
Net before taxes	1,369,160	873,997
Income taxes	379,470	361,000
<b>Net income</b>	<b>989,690</b>	<b>512,997</b>
Earnings common share		
Primary	\$0.22	\$0.12
Fully Diluted	\$0.22	\$0.12
Common Shares:		
Full Diluted	4,490,863	4,392,015
Year-end	4,449,987	

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	9,909,686
Inventories	289,154
Current assets	16,015,715
Net property & equip.	38,166,173
Total assets	56,346,900
Liabilities:	
Current liabilities	11,305,948
Stockholders' equity	41,896,952
Net current assets	4,709,767

**CARA THERAPEUTICS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues		911
Cost & expenses	17,124	23,236
Operating income	(17,124)	(22,325)
Other income (expense), net		311
Net before taxes	(16,813)	(22,235)
Income taxes	(46)	(31)
<b>Net income</b>	<b>(16,767)</b>	<b>(22,204)</b>
Earnings common share		
Primary	\$(0.51)	\$(0.81)
Fully Diluted	\$(0.51)	\$(0.81)
Common Shares:		
Full Diluted	32,682	27,300
Year-end	32,700	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	11,877
Current assets	78,813
Net property & equip.	1,053
Total assets	80,635
Liabilities:	
Current liabilities	6,875
Long-term debt	1,657
Stockholders' equity	72,103
Net current assets	71,938

**CARDAX INC**

<b>Earnings, 3 mos. to Mar 31</b> (Consol. – \$):	2018	2017
Total Revenues	313,310	107,990
Cost & expenses	1,352,363	551,299
Deprec., depl. & amort.	9,605	7,401
Operating income	(1,048,658)	(450,710)
Other income (expense), net	556	
<b>Net income</b>	<b>(1,047,864)</b>	<b>(450,836)</b>
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	122,674,516	86,491,377
Year-end	122,859,700	88,446,769

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018	
Cash & equivalents	1,293,303	
Inventories	228,234	
Current assets	1,785,737	
Net property & equip.	813	
Total assets	2,209,881	
Liabilities:		
Current liabilities	4,533,597	
Stockholders' equity	(2,323,716)	
Net current assets	(2,747,860)	

**CAREDX INC**

<b>Earnings, 3 mos. to Mar 31</b> (Consol. – \$000):	2018	2017
Total Revenues	14,053	11,584
Cost & expenses	19,288	20,128
Operating income	(5,235)	(8,544)
Other income (expense), net	(1,488)	3,442
Net before taxes	(9,418)	(5,892)
Income taxes	(424)	(283)
<b>Net income</b>	<b>(8,994)</b>	<b>(5,609)</b>
Earnings common share		
Primary	\$(0.30)	\$(0.26)
Fully Diluted	\$(0.30)	\$(0.26)
Common Shares:		
Full Diluted	29,615	21,344
Year-end	35,241	21,358

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	
Cash & equivalents	18,695	
Inventories	5,011	
Current assets	32,697	
Net property & equip.	2,055	
Total assets	78,952	
Liabilities:		
Current liabilities	13,445	
Long-term debt	9,729	
Stockholders' equity	33,393	
Net current assets	19,252	

**CAS MEDICAL SYSTEMS INC**

<b>Earnings, 3 mos. to Mar 31</b> (Consol. – \$):	2018	2017
Net Sales	5,444,459	4,543,378
Cost & expenses	6,590,790	6,422,104
Operating income	(1,146,331)	(1,878,726)
Net before taxes	(2,138,278)	
Income taxes	(103,172)	
Income contin. oper.	(2,035,106)	
Income discount. oper.	191,606	
<b>Net income</b>	<b>(1,417,847)</b>	<b>(1,843,500)</b>
Balance for common	(1,832,662)	(2,230,506)
Earnings common share		
Primary	\$(0.07)	\$(0.08)
Fully Diluted	\$(0.07)	\$(0.08)
Common Shares:		
Full Diluted	27,611,787	27,025,915
Year-end	28,709,673	

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018	
Cash & equivalents	4,761,708	
Inventories	927,253	
Current assets	8,726,814	
Net property & equip.	2,134,180	
Total assets	11,657,657	
Liabilities:		
Current liabilities	5,677,039	

Long-term debt	4,183,415	
Stockholders' equity	1,477,203	
Net current assets	3,049,775	

**CASA SYSTEMS INC**

<b>Earnings, 3 mos. to Mar 31</b> (Consol. – \$000):	2018	2017
Total Revenues	89,074	72,729
Cost & expenses	66,105	49,932
Operating income	22,969	22,797
Interest income	1,095	504
Interest expense	4,672	4,193
Other income (expense), net	201	119
Foreign currency	(24)	30
Net before taxes	19,569	19,257
Income taxes	1,793	1,103
<b>Net income</b>	<b>17,776</b>	<b>18,154</b>
Earnings common share		
Primary	\$0.22	\$0.23
Fully Diluted	\$0.19	\$0.20
Common Shares:		
Full Diluted	93,594	43,299
Year-end	81,801	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	
Cash & equivalents	307,095	
Inventories	29,354	
Current assets	431,046	
Net property & equip.	29,166	
Total assets	473,869	
Liabilities:		
Current liabilities	81,460	
Long-term debt	294,915	
Stockholders' equity	71,833	
Net current assets	349,586	

**CATABASIS PHARMACEUTICALS INC**

<b>Earnings, 3 mos. to Mar 31</b> (Consol. – \$000):	2018	2017
Cost & expenses	7,639	7,761
Operating income	(7,639)	(7,761)
Interest income	32	39
Interest expense	57	149
Other income (expense), net	12	(5)
<b>Net income</b>	<b>(7,652)</b>	<b>(7,876)</b>
Earnings common share		
Primary	\$(0.29)	\$(0.41)
Fully Diluted	\$(0.29)	\$(0.41)
Common Shares:		
Full Diluted	26,556	19,093
Year-end	29,036	19,997

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	
Cash & equivalents	17,030	
Current assets	17,919	
Net property & equip.	258	
Total assets	18,290	
Liabilities:		
Current liabilities	5,277	
Stockholders' equity	12,931	
Net current assets	12,642	

**CECO ENVIRONMENTAL CORP.**

<b>Earnings, 3 mos. to Mar 31</b> (Consol. – \$):	2018	2017
Cost & expenses	59,086,000	83,978,000
Operating income	12,150,000	1,350,000
Interest expense	1,920,000	1,711,000
Other income (expense), net	(356,000)	(109,000)
Net before taxes	9,874,000	(470,000)
Income taxes	4,111,000	(508,000)
<b>Net income</b>	<b>5,763,000</b>	<b>38,000</b>
Earnings common share		
Primary	\$0.17	\$
Fully Diluted	\$0.17	\$
Common Shares:		
Full Diluted	34,641,390	34,563,139
Year-end	34,603,013	

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018	
Cash & equivalents	33,089,000	
Inventories	22,083,000	
Current assets	177,842,000	

Net property & equip.	23,042,000
Total assets	422,119,000
Liabilities:	
Current liabilities	103,955,000
Long-term debt	84,704,000
Stockholders' equity	194,573,000
Net current assets	73,887,000

**CELLDEX THERAPEUTICS, INC.**

<b>Earnings, 3 mos. to Mar 31</b> (Consol. – \$):	2018	2017
Total Revenues	4,068,000	1,534,000
Cost & expenses	123,521,000	36,422,000
Operating income	(119,677,000)	(35,112,000)
Other income (expense), net	780,000	851,000
Net before taxes	(118,897,000)	
Income taxes	(765,000)	
<b>Net income</b>	<b>(118,132,000)</b>	<b>(34,261,000)</b>
Earnings common share		
Primary	\$(0.84)	\$(0.28)
Fully Diluted	\$(0.84)	\$(0.28)
Common Shares:		
Full Diluted	140,548,000	122,648,000
Year-end	143,368,784	124,173,729

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018	
Cash & equivalents	39,824,000	
Current assets	130,972,000	
Net property & equip.	9,785,000	
Total assets	191,376,000	
Liabilities:		
Current liabilities	24,012,000	
Stockholders' equity	134,082,000	
Net current assets	106,960,000	

**CELSIUS HOLDINGS INC**

<b>Earnings, 3 mos. to Mar 31</b> (Consol. – \$):	2018	2017
Total Revenues	12,059,976	6,000,429
Cost & expenses	14,898,221	7,833,673
Operating income	(2,838,245)	(1,833,244)
Interest expense	38,259	48,056
<b>Net income</b>	<b>(2,876,504)</b>	<b>(1,881,300)</b>
Balance for common	(2,959,195)	(1,971,545)
Earnings common share		
Primary	\$(0.06)	\$(0.05)
Fully Diluted	\$(0.06)	\$(0.05)
Common Shares:		
Full Diluted	47,449,553	41,783,853
Year-end	50,956,869	43,905,241

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018	
Cash & equivalents	9,987,713	
Inventories	6,668,742	
Current assets	28,888,392	
Net property & equip.	66,406	
Total assets	28,954,798	
Liabilities:		
Current liabilities	10,407,367	
Long-term debt	3,500,000	
Stockholders' equity	15,047,431	
Net current assets	18,481,025	

**CERUS CORP.**

<b>Earnings, 3 mos. to Mar 31</b> (Consol. – \$000):	2018	2017
Cost & expenses	30,374	26,527
Operating income	(13,355)	(18,093)
Interest expense	915	531
Other income (expense), net	331	106
Foreign currency	108	(45)
Net before taxes	(13,831)	(18,563)
Income taxes	54	35
<b>Net income</b>	<b>(13,885)</b>	<b>(18,598)</b>
Earnings common share		
Primary	\$(0.11)	\$(0.18)
Fully Diluted	\$(0.11)	\$(0.18)
Common Shares:		
Full Diluted	124,814	103,564
Year-end	130,544	103,938

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	14,877
Inventories	13,165
Current assets	133,776
Net property & equip.	1,969
Total assets	144,421
Liabilities:	
Current liabilities	23,656
Long-term debt	28,387
Stockholders' equity	85,598
Net current assets	110,120

**CHEFS' WAREHOUSE INC (THE)**

Earnings, 3 mos. to (Consol. - \$000):

	03/30/18	03/31/17
Net Sales	318,615	287,690
Cost & expenses	312,875	284,569
Operating income	5,740	3,121
Interest expense	4,979	5,933
Net before taxes	761	(2,812)
Income taxes	217	(1,170)
Net income	544	(1,642)
Earnings common share		
Primary	\$0.02	\$(0.06)
Fully Diluted	\$0.02	\$(0.06)
Common Shares:		
Full Diluted	28,197	25,952
Year-end	28,707	26,371

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	45,074
Inventories	101,523
Current assets	290,269
Net property & equip.	69,544
Total assets	681,241
Liabilities:	
Current liabilities	100,907
Long-term debt	313,668
Stockholders' equity	248,588
Net current assets	189,362

**CHEMIBIO DIAGNOSTICS INC**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Total Revenues	7,717,132	6,325,167
Cost & expenses	8,371,450	7,954,124
Operating income	(654,318)	(1,628,957)
Interest income	5,044	13,382
Interest expense	3,069	
Net income	(652,343)	(1,615,575)
Earnings common share		
Primary	\$(0.05)	\$(0.13)
Fully Diluted	\$(0.05)	\$(0.13)
Common Shares:		
Full Diluted	13,267,246	12,270,679
Year-end	14,162,702	12,299,122

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	12,457,538
Inventories	5,802,350
Current assets	22,909,361
Net property & equip.	1,859,132
Total assets	28,671,754
Liabilities:	
Current liabilities	4,432,109
Long-term debt	99,480
Stockholders' equity	23,782,666
Net current assets	18,477,252

**CHIASMA INC**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Cost & expenses	7,297,000	7,115,000
Operating income	(7,297,000)	(7,115,000)
Other income (expense), net	230,000	160,000
Net before taxes	(7,067,000)	(6,955,000)
Income taxes	(24,000)	65,000
Net income	(7,043,000)	(7,020,000)
Earnings common share		
Primary	\$(0.29)	\$(0.29)
Fully Diluted	\$(0.29)	\$(0.29)
Common Shares:		
Full Diluted	24,381,924	24,359,584
Year-end	24,383,994	24,359,584

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	15,248,000
Current assets	62,186,000
Net property & equip.	175,000
Total assets	63,347,000
Liabilities:	
Current liabilities	6,704,000
Stockholders' equity	56,057,000
Net current assets	55,482,000

**CHILDREN'S PLACE INC (THE)**

Earnings, 3 mos. to (Consol. - \$000):

	05/05/18	04/29/17
Net Sales	436,314	436,676
Cost & expenses	395,850	378,700
Operating income	23,058	42,284
Interest income	366	470
Interest expense	663	508
Net before taxes	22,761	42,246
Income taxes	(8,776)	6,017
Net income	31,537	36,229
Earnings common share		
Primary	\$1.85	\$2.06
Fully Diluted	\$1.78	\$1.97
Common Shares:		
Full Diluted	17,734	18,401
Year-end	16,605	17,441

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	90,121
Inventories	334,680
Current assets	526,330
Net property & equip.	260,762
Total assets	810,927
Liabilities:	
Current liabilities	365,101
Stockholders' equity	343,137
Net current assets	161,229

**CHINA XD PLASTICS CO., LTD**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Total Revenues	310,453,033	237,840,197
Cost & expenses	271,561,493	216,491,611
Operating income	38,891,540	21,348,586
Interest income	2,312,623	1,163,259
Interest expense	12,894,205	10,021,976
Other income (expense), net	1,477,559	1,439,531
Net before taxes	25,310,728	13,453,315
Income taxes	6,210,827	3,552,326
Net income	19,099,901	9,900,989
Earnings common share		
Primary	\$0.29	\$0.15
Fully Diluted	\$0.29	\$0.15
Common Shares:		
Full Diluted	49,727,731	49,511,541
Year-end	49,727,731	

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	50,814,789
Inventories	556,919,906
Current assets	1,423,805,956
Net property & equip.	844,425,358
Total assets	2,539,232,651
Liabilities:	
Current liabilities	1,313,655,062
Long-term debt	145,577,201
Stockholders' equity	761,622,103
Net current assets	110,150,894

**CIDARA THERAPEUTICS INC**

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2018	2017
Cost & expenses	16,810	13,398
Operating income	(16,810)	(13,398)
Net income	(16,749)	(13,398)
Earnings common share		
Primary	\$(0.80)	\$(0.80)
Fully Diluted	\$(0.80)	\$(0.80)
Common Shares:		
Full Diluted	20,894	16,795
Year-end	21,390	16,805

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	53,010
Current assets	68,990
Net property & equip.	936
Total assets	70,247
Liabilities:	
Current liabilities	11,519
Long-term debt	7,809
Stockholders' equity	50,919
Net current assets	57,471

**CLEAN ENERGY FUELS CORP**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Total Revenues	102,403,000	89,491,000
Cost & expenses	73,633,000	84,634,000
Deprec., depl. & amort.	12,801,000	15,317,000
Operating income	15,969,000	(10,460,000)
Interest income	575,000	192,000
Interest expense	4,503,000	4,911,000
Other income (expense), net	(1,480,000)	2,992,000
Gains or losses		70,648,000
Net before taxes	10,561,000	58,461,000
Income taxes	88,000	(2,263,000)
Net income	10,473,000	60,724,000
Earnings common share		
Primary	\$0.08	\$0.41
Fully Diluted	\$0.08	\$0.40
Common Shares:		
Full Diluted	156,643,092	152,972,153
Year-end	152,514,550	

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	47,096,000
Inventories	37,792,000
Current assets	341,790,000
Net property & equip.	363,903,000
Total assets	818,755,000
Liabilities:	
Current liabilities	216,062,000
Long-term debt	125,491,000
Stockholders' equity	439,902,000
Net current assets	125,728,000

**CODEXIS INC**

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2018	2017
Total Revenues	14,042	7,971
Cost & expenses	18,749	15,447
Operating income	(4,707)	(7,476)
Interest income	71	18
Other income (expense), net	(60)	22
Net before taxes	(4,696)	(7,436)
Income taxes	(2)	24
Net income	(4,694)	(7,460)
Earnings common share		
Primary	\$(0.10)	\$(0.18)
Fully Diluted	\$(0.10)	\$(0.18)
Common Shares:		
Full Diluted	48,385	41,250
Year-end	48,925	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	24,300
Inventories	1,212
Current assets	35,967
Net property & equip.	2,620
Total assets	44,506
Liabilities:	
Current liabilities	21,553
Long-term debt	597
Stockholders' equity	15,068
Net current assets	14,414

**COLLEGIUM PHARMACEUTICALS INC**

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2018	2017
Cost & expenses	76,956	25,348
Operating income	(13,207)	(23,176)
Interest income	255	98
Interest expense	5,700	
Net income	(18,652)	(23,078)
Earnings common share		



Primary	\$(0.57)	\$(0.79)
Fully Diluted	\$(0.57)	\$(0.79)
Common Shares:		
Full Diluted	32,904	29,350
Year-end	33,028	
<b>Consolidated Balance Sheet Items, as of (\$000):</b>		
Assets:		
Cash & equivalents	128,249	2018
Inventories	7,902	
Current assets	207,713	
Net property & equip.	1,612	
Total assets	696,278	
Liabilities:		
Current liabilities	250,228	
Long-term debt	11,500	
Stockholders' equity	90,823	
Net current assets	(42,515)	

**COMMUNICATIONS SYSTEMS, INC.****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	16,773,685	20,800,079
Cost & expenses	18,747,906	22,259,907
Operating income	(1,974,221)	(1,459,828)
Other income (expense), net	104,121	41,686
Gains or losses	27,531	(17,800)
Net before taxes	(1,852,275)	(1,445,501)
Income taxes	7,570	70,011
<b>Net income</b>	<b>(1,859,845)</b>	<b>(1,515,512)</b>
Earnings common share		
Primary	\$(0.21)	\$(0.17)
Fully Diluted	\$(0.21)	\$(0.17)
Common Shares:		
Full Diluted	9,000,185	8,894,195
Year-end	9,122,986	8,937,640

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		
Cash & equivalents	11,592,110	2018
Inventories	14,229,000	
Current assets	45,449,617	
Net property & equip.	12,233,152	
Total assets	57,735,462	
Liabilities:		
Current liabilities	10,218,892	
Stockholders' equity	47,484,938	
Net current assets	35,230,725	

**COMSCORE INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	105,919	100,861
Cost & expenses	143,660	135,062
Operating income	(46,285)	(42,936)
Interest expense	2,905	154
Other income (expense), net	77	3,184
Foreign currency	(922)	(20)
Income taxes	1,415	866
<b>Net income</b>	<b>(51,450)</b>	<b>(40,792)</b>
Earnings common share		
Primary	\$(0.93)	\$(0.71)
Fully Diluted	\$(0.93)	\$(0.71)
Common Shares:		
Full Diluted	55,227	57,275
Year-end	55,018	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		
Cash & equivalents	74,830	2018
Current assets	198,545	
Net property & equip.	26,894	
Total assets	1,032,078	
Liabilities:		
Current liabilities	232,552	
Long-term debt	126,246	
Stockholders' equity	548,743	
Net current assets	(34,007)	

**CONIFER HOLDINGS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	24,823	25,063
Cost & expenses	24,647	26,959
Operating income	176	(1,896)
Net before taxes	176	(1,896)

Income taxes	18	6
<b>Net income</b>	<b>213</b>	<b>(1,798)</b>
Earnings common share		
Primary	\$0.02	\$(0.24)
Fully Diluted	\$0.02	\$(0.24)
Common Shares:		
Full Diluted	8,520	7,633
Year-end	8,520	7,633
<b>Consolidated Balance Sheet Items, as of (\$000):</b>		
Assets:		
Cash & equivalents	14,406	2018
Current assets	63,247	
Total assets	229,654	
Liabilities:		
Current liabilities	3,398	
Long-term debt	29,043	
Stockholders' equity	51,424	
Net current assets	59,849	

**CORBUS PHARMACEUTICALS HOLDINGS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	12,815,394	8,746,237
Operating income	(11,864,952)	(7,452,540)
Foreign currency	(33,854)	(14,265)
<b>Net income</b>	<b>(11,695,385)</b>	<b>(7,465,439)</b>
Balance for common	(11,695,385)	(7,465,439)
Earnings common share		
Primary	\$(0.21)	\$(0.16)
Fully Diluted	\$(0.21)	\$(0.16)
Common Shares:		
Full Diluted	56,367,548	46,381,482
Year-end	57,139,892	50,143,742

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		
Cash & equivalents	70,955,652	2018
Current assets	74,486,911	
Net property & equip.	2,593,172	
Total assets	77,139,722	
Liabilities:		
Current liabilities	10,276,703	
Stockholders' equity	65,539,604	
Net current assets	64,210,208	

**CRAFT BREW ALLIANCE INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	47,487,000	44,302,000
Cost & expenses	47,164,000	47,102,000
Operating income	323,000	(2,800,000)
Interest expense	134,000	181,000
Other income (expense), net	34,000	3,000
Net before taxes	223,000	(2,978,000)
Income taxes	62,000	(1,191,000)
<b>Net income</b>	<b>161,000</b>	<b>(1,787,000)</b>
Earnings common share		
Primary	\$0.01	\$(0.09)
Fully Diluted	\$0.01	\$(0.09)
Common Shares:		
Full Diluted	19,488,000	19,261,000
Year-end	19,309,829	19,261,245

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		
Cash & equivalents	2,814,000	2018
Inventories	15,910,000	
Current assets	49,801,000	
Net property & equip.	104,394,000	
Total assets	187,891,000	
Liabilities:		
Current liabilities	32,574,000	
Long-term debt	10,124,000	
Stockholders' equity	131,126,000	
Net current assets	17,227,000	

**CSI COMPRESSCO LP****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	85,417	65,552
Cost & expenses	66,283	50,827
Deprec., depl. & amort.	17,367	17,295
Operating income	(14,423)	(14,780)
Other income (expense), net	(4,757)	(1,827)
Net before taxes	(14,423)	(14,780)

Income taxes	1,314	813
<b>Net income</b>	<b>(15,737)</b>	<b>(15,593)</b>
Earnings common share		
Primary	\$(0.40)	\$(0.46)
Fully Diluted	\$(0.40)	\$(0.46)
Common Shares:		
Full Diluted	38,717	33,464
Year-end	39,428	33,717

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		
Cash & equivalents	90,100	2018
Inventories	53,068	
Current assets	210,686	
Net property & equip.	609,706	
Total assets	853,941	
Liabilities:		
Current liabilities	75,841	
Long-term debt	632,414	
Net current assets	134,845	

**CSP INC****Earnings, 6 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	43,981	45,232
Cost & expenses	44,697	44,712
Operating income	(716)	520
Other income (expense), net	(3)	(21)
Foreign currency	(101)	82
Net before taxes	(820)	581
Income taxes	974	196
<b>Net income</b>	<b>(1,794)</b>	<b>385</b>
Balance for common	(1,794)	357
Earnings common share		
Primary	\$(0.47)	\$0.10
Fully Diluted	\$(0.47)	\$0.09
Common Shares:		
Full Diluted	3,795	3,807
Year-end	4,006	3,918

**CUMBERLAND PHARMACEUTICALS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	8,587,605	9,636,755
Cost & expenses	10,403,692	9,683,113
Operating income	(2,452,222)	(657,802)
Interest income	82,494	52,535
Interest expense	18,302	31,715
Net before taxes	(2,388,030)	(636,982)
Income taxes	4,159	656,587
<b>Net income</b>	<b>(2,392,189)</b>	<b>(1,293,569)</b>
Earnings common share		
Primary	\$(0.15)	\$(0.08)
Fully Diluted	\$(0.15)	\$(0.08)
Common Shares:		
Full Diluted	15,689,240	16,042,219
Year-end	15,727,250	16,065,301

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		
Cash & equivalents	35,262,976	2018
Inventories	6,661,525	
Current assets	66,823,172	
Net property & equip.	566,907	
Total assets	91,094,840	
Liabilities:		
Current liabilities	16,289,856	
Long-term debt	12,000,000	
Stockholders' equity	61,085,817	
Net current assets	50,533,316	

**CURAEGIS TECHNOLOGIES INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	8,000	9,000
Cost & expenses	1,067,000	1,355,000
Operating income	(1,059,000)	(1,346,000)
Other income (expense), net	1,000	1,000
<b>Net income</b>	<b>(1,295,000)</b>	<b>(1,501,000)</b>
Balance for common	(1,349,000)	(1,563,000)
Earnings common share		
Primary	\$(0.03)	\$(0.03)
Fully Diluted	\$(0.03)	\$(0.03)
Common Shares:		
Full Diluted	49,031,000	47,161,000
Year-end	49,059,546	47,979,986

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	192,000
Inventories	1,741,000
Current assets	1,974,000
Net property & equip.	112,000
Total assets	2,157,000
Liabilities:	
Current liabilities	1,954,000
Long-term debt	4,685,000
Stockholders' equity	(4,482,000)
Net current assets	20,000

**CUTERA INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	34,125	29,299
Cost & expenses	38,874	30,712
Operating income	(4,749)	(1,413)
Other income (expense), net	154	154
Net before taxes	(4,651)	(1,140)
Income taxes	(2,619)	(118)
<b>Net income</b>	<b>(2,032)</b>	<b>(1,022)</b>
Earnings common share		
Primary	\$(0.15)	\$(0.07)
Fully Diluted	\$(0.15)	\$(0.07)
Common Shares:		
Full Diluted	13,587	13,840
Year-end	13,634	13,909

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	10,910
Inventories	30,979
Current assets	77,414
Net property & equip.	2,214
Total assets	108,126
Liabilities:	
Current liabilities	37,136
Stockholders' equity	67,855
Net current assets	40,278

**CYTOKINETICS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	5,268	4,153
Cost & expenses	31,399	27,404
Operating income	(26,131)	(23,251)
<b>Net income</b>	<b>(30,281)</b>	<b>(25,867)</b>
Earnings common share		
Primary	\$(0.56)	\$(0.62)
Fully Diluted	\$(0.56)	\$(0.62)
Common Shares:		
Full Diluted	54,062	41,578
Year-end	54,198	43,417

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	115,011
Current assets	272,339
Net property & equip.	3,156
Total assets	279,926
Liabilities:	
Current liabilities	38,546
Long-term debt	31,954
Stockholders' equity	99,599
Net current assets	233,793

**CYTMX THERAPEUTICS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	14,184	11,653
Cost & expenses	29,814	20,267
Operating income	(15,630)	(8,614)
Interest income	1,375	236
Other income (expense), net	(140)	120
Net before taxes	(14,395)	(8,258)
Income taxes	1,098	(1)
<b>Net income</b>	<b>(15,493)</b>	<b>(8,257)</b>
Earnings common share		
Primary	\$(0.40)	\$(0.23)
Fully Diluted	\$(0.40)	\$(0.23)
Common Shares:		
Full Diluted	38,648	36,539
Year-end	38,904	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	142,155
Current assets	367,031
Net property & equip.	4,622
Total assets	376,462
Liabilities:	
Current liabilities	69,707
Stockholders' equity	49,647
Net current assets	297,324

**DECIPHERA PHARMACEUTICALS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	21,951	7,726
Operating income	(21,951)	(7,726)
Interest expense	22	25
Other income (expense), net	543	42
<b>Net income</b>	<b>(21,430)</b>	<b>(7,709)</b>
Earnings common share		
Primary	\$(0.66)	\$(0.66)
Fully Diluted	\$(0.66)	\$(0.66)
Common Shares:		
Full Diluted	32,594	11,626
Year-end	32,594	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	179,873
Current assets	181,114
Net property & equip.	952
Total assets	182,141
Liabilities:	
Current liabilities	16,295
Long-term debt	1,248
Stockholders' equity	164,590
Net current assets	164,819

**DENALI THERAPEUTICS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	26,389	21,744
Operating income	(25,748)	(21,744)
Interest income	2,070	424
<b>Net income</b>	<b>(23,678)</b>	<b>(21,320)</b>
Earnings common share		
Primary	\$(0.26)	\$(0.36)
Fully Diluted	\$(0.26)	\$(0.36)
Common Shares:		
Full Diluted	89,561	9,017
Year-end	92,589	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	44,001
Current assets	377,422
Net property & equip.	14,860
Total assets	613,953
Liabilities:	
Current liabilities	17,167
Stockholders' equity	539,028
Net current assets	360,255

**DESTINATION XL GROUP INC****Earnings, 3 mos. to (Consol. - \$000):**

	05/05/18	04/29/17
Net Sales	113,331	107,629
Cost & expenses	108,233	105,109
Deprec., depl. & amort.	7,324	7,754
Operating income	(2,226)	(5,234)
Interest expense	886	802
Net before taxes	(3,112)	(6,036)
Income taxes	(2)	29
<b>Net income</b>	<b>(3,110)</b>	<b>(6,065)</b>
Earnings common share		
Primary	\$(0.06)	\$(0.12)
Fully Diluted	\$(0.06)	\$(0.12)
Common Shares:		
Full Diluted	48,791	49,735
Year-end	48,965	49,748

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	6,994
Inventories	106,219
Current assets	128,112

Net property & equip.	106,478
Total assets	242,148
Liabilities:	
Current liabilities	115,251
Long-term debt	10,446
Stockholders' equity	67,807
Net current assets	12,861

**DICERNA PHARMACEUTICALS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	17,412	14,239
Operating income	(15,867)	(14,239)
Interest income	288	38
<b>Net income</b>	<b>(15,579)</b>	<b>(14,201)</b>
Earnings common share		
Primary	\$(0.30)	\$(0.68)
Fully Diluted	\$(0.30)	\$(0.68)
Common Shares:		
Full Diluted	51,723	20,792
Year-end	51,781	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	43,046
Current assets	101,810
Net property & equip.	1,451
Total assets	104,074
Liabilities:	
Current liabilities	14,643
Stockholders' equity	87,886
Net current assets	87,167

**DOLLAR TREE INC****Earnings, 3 mos. to (Consol. - \$000):**

	05/05/18	04/29/17
Net Sales	5,553,700	5,287,100
Cost & expenses	5,116,100	4,898,300
Operating income	437,600	388,800
Interest expense	230,000	74,700
Other income (expense), net	(200)	(300)
Net before taxes	207,400	313,800
Income taxes	46,900	113,300
<b>Net income</b>	<b>160,500</b>	<b>200,500</b>
Balance for common	160,500	200,500
Earnings common share		
Primary	\$0.68	\$0.85
Fully Diluted	\$0.67	\$0.85
Common Shares:		
Full Diluted	238,500	237,300
Year-end	237,800	236,700

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	475,200
Inventories	3,248,200
Current assets	4,042,000
Net property & equip.	3,249,700
Total assets	15,827,100
Liabilities:	
Current liabilities	1,917,200
Long-term debt	5,040,100
Stockholders' equity	7,355,700
Net current assets	2,124,800

**DRONE AVIATION HOLDING CORP****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	869,023	367,653
Cost & expenses	2,477,002	1,763,499
Operating income	(1,607,979)	(1,395,846)
Interest expense	70,311	481,346
Other income (expense), net		753,798
<b>Net income</b>	<b>(1,678,290)</b>	<b>(1,123,394)</b>
Balance for common	(1,678,290)	(1,123,394)
Earnings common share		
Primary	\$(0.18)	\$(0.13)
Fully Diluted	\$(0.18)	\$(0.13)
Common Shares:		
Full Diluted	9,182,470	8,682,220
Year-end	9,182,470	8,682,220

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	938,692
Inventories	647,054
Current assets	1,720,909
Net property & equip.	77,603
Total assets	2,822,978
Liabilities:	
Current liabilities	2,781,564
Long-term debt	3,000,000
Stockholders' equity	(2,958,586)
Net current assets	(1,060,655)

**DURECT CORP****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	3,488	4,567
Cost & expenses	11,320	12,134
Operating income	(7,832)	(7,567)
Net income	(8,297)	(8,114)
Earnings common share		
Primary	\$(0.05)	\$(0.06)
Fully Diluted	\$(0.05)	\$(0.06)
Common Shares:		
Full Diluted	153,558	141,815
Year-end	161,709	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	39,325
Inventories	3,254
Current assets	52,008
Net property & equip.	845
Total assets	59,679
Liabilities:	
Current liabilities	11,292
Long-term debt	15,178
Stockholders' equity	30,395
Net current assets	40,716

**EAGLE PHARMACEUTICALS, INC.****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	46,626,000	76,793,000
Net Sales	10,838,000	15,286,000
Cost & expenses	44,321,000	44,097,000
Operating income	2,305,000	32,696,000
Interest income	27,000	3,000
Interest expense	675,000	27,000
Net before taxes	1,657,000	32,672,000
Income taxes	(959,000)	9,748,000
Net income	2,616,000	22,924,000
Earnings common share		
Primary	\$0.18	\$1.50
Fully Diluted	\$0.17	\$1.42
Common Shares:		
Full Diluted	15,478,335	16,165,361
Year-end	14,800,873	15,251,806

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	95,670,000
Inventories	6,141,000
Current assets	168,820,000
Net property & equip.	6,498,000
Total assets	249,296,000
Liabilities:	
Current liabilities	28,760,000
Long-term debt	41,624,000
Stockholders' equity	178,177,000
Net current assets	140,060,000

**ECHOLON CORP.****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	7,837	7,703
Cost & expenses	9,480	8,905
Operating income	(1,643)	(1,202)
Net before taxes	(1,385)	(1,267)
Income taxes	(6)	(6)
Net income	(1,379)	(1,261)
Earnings common share		
Primary	\$(0.30)	\$(0.28)
Fully Diluted	\$(0.30)	\$(0.28)
Common Shares:		
Full Diluted	4,527	4,434
Year-end	4,542	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	5,846
Inventories	3,566
Current assets	27,223
Net property & equip.	453
Total assets	28,902
Liabilities:	
Current liabilities	5,675
Stockholders' equity	22,611
Net current assets	21,548

**EDGEWATER TECHNOLOGY INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	25,129,000	29,130,000
Cost & expenses	28,547,000	33,721,000
Operating income	(4,054,000)	(5,399,000)
Other income (expense), net	(34,000)	(233,000)
Net before taxes	(4,088,000)	(5,632,000)
Income taxes	131,000	(2,945,000)
Net income	(4,219,000)	(2,687,000)
Earnings common share		
Primary	\$(0.30)	\$(0.21)
Fully Diluted	\$(0.30)	\$(0.21)
Common Shares:		
Full Diluted	14,137,000	12,971,000
Year-end	14,363,000	13,388,000

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	8,442,000
Current assets	35,986,000
Net property & equip.	424,000
Total assets	71,618,000
Liabilities:	
Current liabilities	22,026,000
Stockholders' equity	49,592,000
Net current assets	13,960,000

**EGALET CORP****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	6,261,000	5,427,000
Net Sales	6,261,000	5,427,000
Cost & expenses	19,647,000	25,594,000
Operating income	(13,923,000)	(20,670,000)
Interest expense	3,556,000	4,534,000
Other income (expense), net	5,125,000	12,000
Gains or losses		(181,000)
Net income	(12,354,000)	(25,373,000)
Earnings common share		
Primary	\$(0.26)	\$(1.02)
Fully Diluted	\$(0.26)	\$(1.02)
Common Shares:		
Full Diluted	47,303,659	24,766,147
Year-end	53,481,201	

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	74,465,000
Inventories	2,113,000
Current assets	94,704,000
Net property & equip.	9,252,000
Total assets	111,298,000
Liabilities:	
Current liabilities	41,384,000
Long-term debt	99,166,000
Stockholders' equity	(33,050,000)
Net current assets	53,320,000

**ENDOLOGIX INC.****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	42,284	42,612
Cost & expenses	55,355	58,274
Operating income	(13,071)	(15,662)
Interest income	3	44
Interest expense	5,807	4,295
Other income (expense), net	(807)	(1,247)
Net before taxes	(19,682)	(21,160)
Income taxes	85	154
Net income	(19,767)	(21,314)
Earnings common share		
Primary	\$(0.24)	\$(0.26)
Fully Diluted	\$(0.24)	\$(0.26)

**Common Shares:**

Full Diluted	83,706	82,928
Year-end	83,997	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	48,020
Inventories	45,809
Current assets	128,694
Net property & equip.	18,598
Total assets	349,343
Liabilities:	
Current liabilities	60,569
Long-term debt	210,587
Stockholders' equity	58,894
Net current assets	68,125

**ENGLOBAL CORP.****Earnings, 3 mos. to (Consol. - \$):**

	03/31/18	04/01/17
Total Revenues	13,188,000	12,473,000
Cost & expenses	14,357,000	14,148,000
Operating income	(1,169,000)	(1,675,000)
Other income (expense), net	(5,000)	3,000
Net before taxes	(1,183,000)	(1,737,000)
Income taxes	17,000	(859,000)
Net income	(1,200,000)	(878,000)
Earnings common share		
Primary	\$(0.04)	\$(0.03)
Fully Diluted	\$(0.04)	\$(0.03)
Common Shares:		
Full Diluted	27,514,000	27,188,000
Year-end	27,514,380	

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	6,767,000
Current assets	21,662,000
Net property & equip.	880,000
Total assets	25,719,000
Liabilities:	
Current liabilities	5,774,000
Stockholders' equity	19,945,000
Net current assets	15,888,000

**ENTEGR FINANCIAL CORP****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	11,933	10,403
Operating income	4,325	1,779
Net before taxes	4,325	1,779
Income taxes	743	479
Net income	3,582	1,300
Earnings common share		
Primary	\$0.52	\$0.20
Fully Diluted	\$0.51	\$0.20
Common Shares:		
Full Diluted	7,028	6,521
Year-end	6,888	6,455

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	123,597
Current assets	129,136
Net property & equip.	24,101
Total assets	1,625,444
Liabilities:	
Current liabilities	1,206,673
Long-term debt	247,018
Stockholders' equity	151,876
Net current assets	(1,077,537)

**ETSY INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	120,912	96,891
Cost & expenses	107,114	98,992
Operating income	13,798	(2,101)
Foreign currency	1,850	2,780
Net before taxes	12,981	(1,473)
Income taxes	14	(1,052)
Net income	12,967	(421)
Earnings common share		
Primary	\$0.11	\$.....
Fully Diluted	\$0.10	\$.....
Common Shares:		

Full Diluted	125,772	115,696
Year-end	119,955	
<b>Consolidated Balance Sheet Items, as of (\$000):</b>		
Assets:		2018
Cash & equivalents	533,855	
Current assets	704,997	
Net property & equip.	116,385	
Total assets	870,165	
Liabilities:		
Current liabilities	106,556	
Long-term debt	328,687	
Stockholders' equity	384,487	
Net current assets	598,441	

**EVELO BIOSCIENCES INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	10,425	5,208
Operating income	(10,425)	(5,208)
Other income (expense), net	(121)	(90)
<b>Net income</b>	<b>(10,500)</b>	<b>(5,370)</b>
Balance for common	(12,917)	(6,595)
Earnings common share		
Primary	\$(3.29)	\$(1.81)
Fully Diluted	\$(3.29)	\$(1.81)
Common Shares:		
Full Diluted	3,922	6,582
Year-end	3,944	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	
Cash & equivalents	114,311	
Current assets	115,187	
Net property & equip.	4,429	
Total assets	122,313	
Liabilities:		
Current liabilities	4,617	
Long-term debt	14,719	
Stockholders' equity	(64,525)	
Net current assets	110,570	

**EVERBRIDGE INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	30,519	22,844
Cost & expenses	41,451	29,037
Operating income	(10,932)	(6,193)
Interest income	456	51
Interest expense	1,572	1
Other income (expense), net	(198)	(32)
Net before taxes	(12,246)	(6,175)
Income taxes	96	27
<b>Net income</b>	<b>(12,342)</b>	<b>(6,202)</b>
Earnings common share		
Primary	\$(0.43)	\$(0.23)
Fully Diluted	\$(0.43)	\$(0.23)
Common Shares:		
Full Diluted	28,435	27,171
Year-end	28,723	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	
Cash & equivalents	103,633	
Current assets	186,856	
Net property & equip.	2,481	
Total assets	246,846	
Liabilities:		
Current liabilities	92,270	
Long-term debt	90,615	
Stockholders' equity	60,498	
Net current assets	94,586	

**EXONE CO. (THE)****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	11,893	10,869
Cost & expenses	18,274	17,528
Operating income	(6,381)	(6,659)
Interest expense	33	22
Other income (expense), net	46	(110)
Net before taxes	(6,368)	
Income taxes	17	
<b>Net income</b>	<b>(6,385)</b>	<b>(6,791)</b>
Earnings common share		
Primary	\$(0.40)	\$(0.42)

Fully Diluted	\$(0.40)	\$(0.42)
Common Shares:		
Full Diluted	16,139	16,029
Year-end	16,150	16,046

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	
Cash & equivalents	15,222	
Inventories	18,603	
Current assets	43,919	
Net property & equip.	47,536	
Total assets	92,325	
Liabilities:		
Current liabilities	20,200	
Long-term debt	1,519	
Stockholders' equity	70,605	
Net current assets	23,719	

**EXTREME NETWORKS INC****Earnings, 9 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	704,842	428,177
Cost & expenses	733,220	430,288
Operating income	(34,839)	(9,621)
Interest income	2,104	374
Interest expense	8,763	3,000
Other income (expense), net	2,125	551
Net before taxes	(39,373)	(11,696)
Income taxes	1,787	3,252
<b>Net income</b>	<b>(41,160)</b>	<b>(14,948)</b>
Earnings common share		
Primary	\$(0.36)	\$(0.14)
Fully Diluted	\$(0.36)	\$(0.14)
Common Shares:		
Full Diluted	113,641	107,531
Year-end	115,753	

**EYEPOINT PHARMACEUTICALS INC****Earnings, 9 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	2,246,000	6,838,000
Cost & expenses	18,738,000	19,278,000
Operating income	(16,492,000)	(12,440,000)
Other income (expense), net	(2,325,000)	
<b>Net income</b>	<b>(18,743,000)</b>	<b>(12,369,000)</b>
Earnings common share		
Primary	\$(0.43)	\$(0.36)
Fully Diluted	\$(0.43)	\$(0.36)
Common Shares:		
Full Diluted	43,184,000	34,238,000
Year-end	53,909,917	35,668,685

**FAMOUS DAVE'S OF AMERICA INC.****Earnings, 3 mos. to (Consol. - \$):**

	04/01/18	04/02/17
Total Revenues	12,844,000	16,948,000
Cost & expenses	10,992,000	18,530,000
Operating income	1,459,000	(2,145,000)
Interest income	5,000	
Interest expense	145,000	187,000
Net before taxes	1,319,000	(2,332,000)
Income taxes	321,000	(904,000)
Income contin. oper.		(1,428,000)
<b>Net income</b>	<b>998,000</b>	<b>(1,246,000)</b>
Earnings common share		
Primary	\$0.13	\$(0.18)
Fully Diluted	\$0.13	\$(0.18)
Common Shares:		
Full Diluted	7,407,000	6,954,000
Year-end	7,467,000	

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018	
Cash & equivalents	8,924,000	
Inventories	594,000	
Current assets	17,566,000	
Net property & equip.	10,326,000	
Total assets	37,023,000	
Liabilities:		
Current liabilities	10,638,000	
Long-term debt	7,738,000	
Stockholders' equity	13,193,000	
Net current assets	6,928,000	

**FARMER BROS. CO.****Earnings, 9 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	457,006	407,700
Cost & expenses	458,686	367,227
Operating income	(1,680)	40,473
Other income (expense), net	799	74
Gains or losses	7	(354)
Net before taxes	(3,158)	39,198
Income taxes	20,497	15,910
<b>Net income</b>	<b>(23,655)</b>	<b>23,288</b>
Balance for common	(23,899)	23,253
Earnings common share		
Primary	\$(1.43)	\$1.40
Fully Diluted	\$(1.43)	\$1.39
Common Shares:		
Full Diluted	16,728	16,704
Year-end	16,928	16,842

**FATE THERAPEUTICS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	15,080	10,998
Operating income	(14,054)	(9,971)
Interest income	331	111
Interest expense	412	266
<b>Net income</b>	<b>(14,135)</b>	<b>(10,126)</b>
Earnings common share		
Primary	\$(0.27)	\$(0.24)
Fully Diluted	\$(0.27)	\$(0.24)
Common Shares:		
Full Diluted	52,763	41,388
Year-end	52,858	41,401

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	
Cash & equivalents	32,912	
Current assets	90,625	
Net property & equip.	2,649	
Total assets	93,420	
Liabilities:		
Current liabilities	12,588	
Long-term debt	14,069	
Stockholders' equity	64,995	
Net current assets	78,037	

**FIBROCELL SCIENCE INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	2,981,000	4,454,000
Operating income	(2,981,000)	(4,454,000)
Interest expense	190,000	183,000
Other income (expense), net	270,000	(370,000)
<b>Net income</b>	<b>(2,901,000)</b>	<b>(5,007,000)</b>
Balance for common	(3,104,000)	(8,761,000)
Earnings common share		
Primary	\$(0.55)	\$(3.00)
Fully Diluted	\$(0.55)	\$(3.00)
Common Shares:		
Full Diluted	5,671,270	2,939,442
Year-end	5,671,270	2,939,015

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018	
Cash & equivalents	12,201,000	
Current assets	12,698,000	
Net property & equip.	1,408,000	
Total assets	14,145,000	
Liabilities:		
Current liabilities	1,887,000	
Stockholders' equity	6,259,000	
Net current assets	10,811,000	

**FLUENT INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	55,989,000	49,194,000
Cost & expenses	55,822,000	53,594,000
Operating income	(3,164,000)	(7,605,000)
Interest expense	2,394,000	2,227,000
Income contin. oper.	(5,558,000)	(9,832,000)
<b>Net income</b>	<b>(26,682,000)</b>	<b>(12,725,000)</b>
Earnings common share		
Primary	\$(0.40)	\$(0.24)
Fully Diluted	\$(0.40)	\$(0.24)
Common Shares:		
Full Diluted	67,311,784	53,811,688
Year-end	75,941,291	

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	5,368,000
Current assets	42,809,000
Net property & equip.	586,000
Total assets	275,228,000
Liabilities:	
Current liabilities	23,162,000
Long-term debt	60,546,000
Stockholders' equity	191,520,000
Net current assets	19,647,000

**FORTERRA INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	289,960	338,302
Cost & expenses	306,263	360,667
Operating income	(16,303)	(22,365)
Interest expense	13,308	13,542
Other income (expense), net	6,016	
Net before taxes	(23,595)	(35,907)
Income taxes	(3,685)	(13,364)
Net income	(19,910)	(22,543)
Earnings common share		
Primary	\$(0.31)	\$(0.35)
Fully Diluted	\$(0.31)	\$(0.35)
Common Shares:		
Full Diluted	63,838	63,789
Year-end	64,227	64,174

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	53,355
Inventories	268,659
Current assets	547,993
Net property & equip.	414,266
Total assets	1,766,640
Liabilities:	
Current liabilities	225,986
Long-term debt	1,179,963
Stockholders' equity	113,091
Net current assets	322,007

**FORTRESS BIOTECH INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	55,425	44,682
Net Sales	5,509	2,085
Cost & expenses	90,052	61,753
Deprec., depl. & amort.	859	506
Operating income	(35,486)	(17,577)
Interest income	284	136
Interest expense	2,083	698
Other income (expense), net	(933)	3,577
Net income	(38,218)	(14,562)
Balance for common	(21,018)	(11,982)
Earnings common share		
Primary	\$(0.49)	\$(0.30)
Fully Diluted	\$(0.49)	\$(0.30)
Common Shares:		
Full Diluted	42,518	40,358
Year-end	52,687	50,320

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	125,061
Inventories	222
Current assets	200,157
Net property & equip.	12,278
Total assets	265,075
Liabilities:	
Current liabilities	79,326
Long-term debt	73,444
Stockholders' equity	41,651
Net current assets	120,831

**FOSSIL GROUP INC****Earnings, 3 mos. to (Consol. - \$):**

	03/31/18	04/01/17
Net Sales	569,156,000	581,790,000
Cost & expenses	597,437,000	627,053,000
Operating income	(28,281,000)	(45,263,000)
Other income (expense), net	(1,888,000)	5,638,000
Net before taxes	(40,860,000)	(48,009,000)
Income taxes	6,645,000	(1,220,000)
Net income	(47,505,000)	(46,789,000)

**Earnings common share**

Primary	\$(0.99)	\$(1.00)
Fully Diluted	\$(0.99)	\$(1.00)
Common Shares:		
Full Diluted	48,712,000	48,313,000
Year-end	48,900,000	

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	229,863,000
Inventories	530,706,000
Current assets	1,156,424,000
Net property & equip.	208,477,000
Total assets	1,515,671,000
Liabilities:	
Current liabilities	523,897,000
Long-term debt	335,536,000
Stockholders' equity	521,448,000
Net current assets	632,527,000

**GAMING PARTNERS INTERNATIONAL CORP****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	18,683,000	18,913,000
Cost & expenses	18,413,000	17,454,000
Operating income	270,000	1,459,000
Other income (expense), net	(10,000)	17,000
Foreign currency	(193,000)	(50,000)
Net before taxes	4,000	1,366,000
Income taxes	1,000	434,000
Net income	3,000	932,000
Earnings common share		
Primary	\$0.12	\$0.12
Fully Diluted	\$0.12	\$0.12
Common Shares:		
Full Diluted	8,043,000	8,059,000
Year-end	7,932,794	7,928,594

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	16,463,000
Inventories	14,268,000
Current assets	41,112,000
Net property & equip.	23,823,000
Total assets	84,489,000
Liabilities:	
Current liabilities	18,015,000
Long-term debt	4,912,000
Stockholders' equity	61,364,000
Net current assets	23,097,000

**GCI LIBERTY INC****Earnings, 3 mos. to Mar 31(Consol. - \$Millions):**

	2018	2017
Total Revenues	61	4
Cost & expenses	53	16
Deprec., depl. & amort.	16	1
Operating income	(7)	(13)
Other income (expense), net	(1)	(38)
Gains or losses	(71)	702
Net before taxes	(88)	636
Income taxes	83	220
Net income	(171)	416
Earnings common share		
Primary	\$(1.58)	\$4.89
Fully Diluted	\$(1.58)	\$4.84
Common Shares:		
Full Diluted	108	86
Year-end	109	85

**Consolidated Balance Sheet Items, as of (\$Millions):**

Assets:	2018
Cash & equivalents	403
Current assets	705
Net property & equip.	1,194
Total assets	9,585
Liabilities:	
Current liabilities	417
Long-term debt	2,607
Stockholders' equity	5,109
Net current assets	288

**GELTECH SOLUTIONS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

Primary	\$(0.04)	\$(0.05)
---------	----------	----------

	2018	2017
Net Sales	262,879	389,036
Cost & expenses	1,101,915	1,150,455
Operating income	(839,036)	(761,419)
Interest income		5
Interest expense	177,507	212,532
Net income	(1,016,543)	(973,946)

**Earnings common share**

Primary	\$(0.01)	\$(0.02)
Fully Diluted	\$(0.01)	\$(0.02)
Common Shares:		
Full Diluted	78,179,403	54,701,836
Year-end	80,994,920	56,191,660

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	149,292
Inventories	959,388
Current assets	1,407,474
Net property & equip.	165,855
Total assets	2,600,842
Liabilities:	
Current liabilities	1,019,005
Long-term debt	6,370,609
Stockholders' equity	(4,788,772)
Net current assets	388,469

**GENERAL FINANCE CORP****Earnings, 9 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	253,468,000	203,589,000
Net Sales	95,030,000	73,105,000
Cost & expenses	192,219,000	159,982,000
Deprec., depl. & amort.	29,671,000	29,237,000
Operating income	31,578,000	14,370,000
Interest income	81,000	54,000
Interest expense	24,667,000	15,096,000
Other income (expense), net	(4,906,000)	(70,000)
Net before taxes	2,086,000	(742,000)
Income taxes	519,000	(297,000)
Net income	1,567,000	(445,000)
Balance for common	(398,000)	(4,855,000)
Earnings common share		
Primary	\$(0.02)	\$(0.18)
Fully Diluted	\$(0.02)	\$(0.18)
Common Shares:		
Full Diluted	26,210,697	26,307,066
Year-end	26,753,254	26,440,688

**GENOMIC HEALTH INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	97,013	86,804
Operating income	(4,388)	(2,825)
Other income (expense), net	436	95
Gains or losses		2,807
Net before taxes	(3,535)	235
Income taxes	240	1,041
Net income	(3,775)	(806)
Earnings common share		
Primary	\$(0.11)	\$(0.02)
Fully Diluted	\$(0.11)	\$(0.02)
Common Shares:		
Full Diluted	35,198	34,009
Year-end	35,381	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	42,085
Current assets	190,989
Net property & equip.	40,824
Total assets	242,939
Liabilities:	
Current liabilities	38,648
Stockholders' equity	200,392
Net current assets	152,341

**GERON CORP.****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	7,755	8,031
Operating income	(7,437)	(7,494)
Other income (expense), net	(125)	
Net income	(7,186)	(7,183)
Earnings common share		
Primary	\$(0.04)	\$(0.05)

Fully Diluted	\$(0.04)	\$(0.05)
Common Shares:		
Full Diluted	160,526	159,162
Year-end	173,081	
<b>Consolidated Balance Sheet Items, as of (\$000):</b>		
Assets:		2018
Cash & equivalents		7,912
Current assets		91,129
Net property & equip.		86
Total assets		105,513
Liabilities:		
Current liabilities		4,385
Stockholders' equity		101,128
Net current assets		86,744

**GEVO INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	8,243,000	5,616,000
Cost & expenses	13,242,000	12,798,000
Operating income	(4,999,000)	(7,182,000)
Other income (expense), net	3,322,000	1,962,000
<b>Net income</b>	<b>(2,502,000)</b>	<b>(5,934,000)</b>
Earnings common share		
Primary	\$(2.20)	\$(10.20)
Fully Diluted	\$(2.20)	\$(10.20)
Common Shares:		
Full Diluted	1,126,736	579,230
Year-end	1,134,806	753,278

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents		7,029,000
Inventories		4,356,000
Current assets		13,306,000
Net property & equip.		68,764,000
Total assets		82,873,000
Liabilities:		
Current liabilities		7,307,000
Long-term debt		13,893,000
Stockholders' equity		61,556,000
Net current assets		5,999,000

**GLOBAL WATER RESOURCES INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	7,425	6,791
Cost & expenses	4,262	4,044
Operating income	1,364	1,101
Interest income	7	4
Interest expense	1,231	1,312
Other income (expense), net	321	566
Net before taxes	461	359
Income taxes	141	170
<b>Net income</b>	<b>320</b>	<b>189</b>
Earnings common share		
Primary	\$0.02	\$0.01
Fully Diluted	\$0.02	\$0.01
Common Shares:		
Full Diluted	19,670	19,623
Year-end	19,631	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents		6,915
Current assets		11,215
Net property & equip.		212,766
Total assets		239,394
Liabilities:		
Current liabilities		10,818
Long-term debt		114,444
Stockholders' equity		13,887
Net current assets		397

**GLOWPOINT INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	3,474,000	4,080,000
Cost & expenses	4,122,000	3,891,000
Operating income	(880,000)	(270,000)
Net before taxes	(641,000)	(641,000)
Income taxes	27,000	
<b>Net income</b>	<b>(1,285,000)</b>	<b>(668,000)</b>
Balance for common	(1,288,000)	(671,000)
Earnings common share		

Primary	\$(0.03)	\$(0.02)
Fully Diluted	\$(0.03)	\$(0.02)
Common Shares:		
Full Diluted	46,232,000	36,181,000
Year-end	46,485,000	36,535,000
<b>Consolidated Balance Sheet Items, as of (\$):</b>		
Assets:		2018
Cash & equivalents		3,068,000
Current assets		5,059,000
Net property & equip.		1,007,000
Total assets		13,768,000
Liabilities:		
Current liabilities		1,270,000
Stockholders' equity		12,498,000
Net current assets		3,789,000

**GLU MOBILE INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	81,443	56,788
Cost & expenses	88,223	79,442
Operating income	(6,780)	(22,654)
Other income (expense), net	(251)	(122)
Net before taxes	(7,031)	(22,776)
Income taxes	175	(12)
<b>Net income</b>	<b>(7,206)</b>	<b>(22,764)</b>
Earnings common share		
Primary	\$(0.05)	\$(0.17)
Fully Diluted	\$(0.05)	\$(0.17)
Common Shares:		
Full Diluted	139,108	134,336
Year-end	139,654	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents		48,306
Current assets		119,501
Net property & equip.		14,073
Total assets		278,832
Liabilities:		
Current liabilities		104,274
Stockholders' equity		162,410
Net current assets		15,227

**GOLDEN ENTERTAINMENT INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	214,789,000	105,883,000
Cost & expenses	172,871,000	94,013,000
Operating income	5,149,000	5,318,000
Other income (expense), net	3,211,000	
Net before taxes	5,149,000	3,635,000
Income taxes	1,219,000	(1,707,000)
<b>Net income</b>	<b>3,930,000</b>	<b>5,342,000</b>
Earnings common share		
Primary	\$0.14	\$0.24
Fully Diluted	\$0.13	\$0.23
Common Shares:		
Full Diluted	29,528,000	22,767,000
Year-end	27,388,000	

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents		133,694,000
Inventories		5,363,000
Current assets		171,983,000
Net property & equip.		883,978,000
Total assets		1,390,938,000
Liabilities:		
Current liabilities		74,175,000
Long-term debt		962,305,000
Stockholders' equity		351,295,000
Net current assets		97,808,000

**GRANITE CITY FOOD & BREWERY LTD****Earnings, 3 mos. to (Consol. - \$):**

	03/27/18	03/28/17
Net Sales	33,537,159	37,501,449
Cost & expenses	32,271,548	35,938,305
Deprec., depl. & amort.	1,745,767	2,066,255
Operating income	(480,155)	(503,111)
Net before taxes	(1,477,100)	
Income taxes	8,550	
<b>Net income</b>	<b>(1,519,896)</b>	<b>(1,485,650)</b>
Earnings common share		

Primary	\$(0.11)	\$(0.10)
Common Shares:		
Year-end	14,360,981	14,360,981

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents		3,457,407
Inventories		1,752,199
Current assets		6,335,316
Net property & equip.		37,742,201
Total assets		57,113,959
Liabilities:		
Current liabilities		53,545,799
Long-term debt		17,779,253
Stockholders' equity		(19,133,559)
Net current assets		(47,210,483)

**GREAT ELM CAPITAL CORP****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	3,632	3,221
<b>Net income</b>	<b>3,866</b>	<b>4,094</b>
Earnings common share		
Primary	\$0.36	\$0.32
Fully Diluted	\$0.36	\$0.32
Common Shares:		
Full Diluted	10,652	12,636
Year-end	10,652	12,545

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents		6,030
Current assets		13,469
Total assets		257,114
Liabilities:		
Current liabilities		54,833
Long-term debt		75,771
Stockholders' equity		125,596
Net current assets		(41,364)

**GREAT ELM CAPITAL GROUP INC****Earnings, 9 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	3,844	3,308
Cost & expenses	11,189	5,424
Operating income	(7,907)	(4,680)
Interest expense	360	6,211
Other income (expense), net	5	(9)
Gains or losses	(2,753)	(7,619)
Net before taxes	(9,001)	(17,703)
Income taxes	(182)	(1,049)
Income contin. oper.	(8,819)	(16,654)
Income discont. oper.	(155)	2,308
<b>Net income</b>	<b>(8,974)</b>	<b>(14,346)</b>
Balance for common	(8,559)	(13,902)
Earnings common share		
Primary	\$(0.36)	\$(0.98)
Fully Diluted	\$(0.36)	\$(0.98)
Common Shares:		
Full Diluted	24,132	14,177
Year-end	24,706	23,200

**GREEN BANCORP INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	40,624	33,892
Operating income	11,684	11,154
Net before taxes	11,684	11,154
Income taxes	2,322	3,942
<b>Net income</b>	<b>9,362</b>	<b>7,212</b>
Earnings common share		
Primary	\$0.25	\$0.19
Fully Diluted	\$0.25	\$0.19
Common Shares:		
Full Diluted	37,586	37,238
Year-end	37,235	37,015

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents		142,144
Current assets		180,558
Net property & equip.		23,694
Total assets		4,225,247
Liabilities:		
Current liabilities		3,692,306
Long-term debt		47,878

Stockholders' equity	468,878
Net current assets	(3,511,748)

**GULF RESOURCES INC**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Total Revenues	2,247,267	32,788,493
Cost & expenses	10,544,247	21,975,496
Operating income	(8,296,980)	10,812,997
Interest income	169,478	125,860
Interest expense	43,344	41,911
Net before taxes	(8,170,846)	10,896,946
Income taxes	(1,193,746)	2,821,826
Net income	(6,977,100)	8,075,120
Earnings common share		
Primary	\$(0.15)	\$0.17
Fully Diluted	\$(0.15)	\$0.17
Common Shares:		
Full Diluted	46,826,388	46,804,241
Year-end	46,803,791	46,793,791

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	236,720,969
Inventories	193,801
Current assets	249,369,691
Net property & equip.	94,051,877
Total assets	397,339,967
Liabilities:	
Current liabilities	4,444,786
Long-term debt	2,394,174
Stockholders' equity	385,532,007
Net current assets	244,924,905

**HACKETT GROUP INC**

Earnings, 3 mos. to (Consol. - \$):

	03/30/18	03/31/17
Total Revenues	72,733,000	71,429,000
Cost & expenses	64,413,000	63,465,000
Operating income	8,320,000	7,964,000
Interest expense	179,000	90,000
Net before taxes	8,141,000	
Income taxes	774,000	
Net income	7,367,000	7,874,000
Earnings common share		
Primary	\$0.25	\$0.27
Fully Diluted	\$0.23	\$0.24
Common Shares:		
Full Diluted	31,814,813	32,292,414
Year-end	29,393,838	29,189,767

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	23,666,000
Current assets	79,065,000
Net property & equip.	20,652,000
Total assets	191,049,000
Liabilities:	
Current liabilities	48,423,000
Long-term debt	19,000,000
Stockholders' equity	115,384,000
Net current assets	30,642,000

**HALOZYME THERAPEUTICS INC**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Total Revenues	30,872,000	29,568,000
Net Sales	6,801,000	11,434,000
Cost & expenses	54,584,000	57,094,000
Operating income	(23,712,000)	(27,526,000)
Interest expense	5,230,000	5,448,000
Other income (expense), net	1,668,000	287,000
Net before taxes	(27,274,000)	(32,687,000)
Income taxes	187,000	210,000
Net income	(27,461,000)	(32,897,000)
Earnings common share		
Primary	\$(0.19)	\$(0.26)
Fully Diluted	\$(0.19)	\$(0.26)
Common Shares:		
Full Diluted	142,656,000	128,615,000
Year-end	143,886,000	129,822,000

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	98,012,000
Inventories	4,393,000

Current assets	484,470,000
Net property & equip.	4,937,000
Total assets	495,469,000
Liabilities:	
Current liabilities	119,224,000
Long-term debt	102,696,000
Stockholders' equity	265,064,000
Net current assets	365,246,000

**HARDINGE INC**

**Merger Completed** On May 25, 2018, Hardinge Holdings, LLC ("Parent"), an affiliate of Privet Fund LP and Privet Fund Management LLC, wholly-owned subsidiary, Hardinge Merger Sub, Inc. ("Acquisition Sub"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Parent. As the result of the merger, each share of common stock of Co., par value \$0.01 per share ("Common Stock") (other than shares of Common Stock previously owned by Privet Fund LP which were contributed to Parent prior to the Effective Time), outstanding immediately prior to the Effective Time was automatically converted into the right to receive \$18.50 per share in cash, without interest (the "Merger Consideration"). The holders of certificates or book-entry shares that immediately prior to the Effective Time represented Common Stock ceased to have any rights with respect to the Common Stock other than the right to receive, upon surrender of such certificates or book-entry shares, the Merger Consideration. The total aggregate consideration in the merger was approximately \$245,000,000.

**HARVARD BIOSCIENCE INC.**

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2018	2017
Total Revenues	26,759	18,086
Cost & expenses	26,922	18,060
Operating income	(1,266)	(350)
Other income (expense), net	(2,738)	(94)
Foreign currency	(347)	(143)
Net before taxes	(5,245)	(750)
Income taxes	605	(7)
Income contin. oper.	(5,850)	(743)
Income discount. oper.	1,786	(323)
Net income	(4,064)	(1,066)
Earnings common share		
Primary	\$(0.11)	\$(0.03)
Fully Diluted	\$(0.11)	\$(0.03)
Common Shares:		
Full Diluted	35,463	34,579
Year-end	35,664	

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	5,991
Inventories	27,902
Current assets	55,810
Net property & equip.	5,821
Total assets	170,947
Liabilities:	
Current liabilities	22,284
Long-term debt	61,569
Stockholders' equity	79,294
Net current assets	33,526

**HAWAIIAN TELCOM HOLDCO INC**

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2018	2017
Total Revenues	89,222	94,510
Cost & expenses	69,713	70,823
Deprec., depl. & amort.	23,333	21,269
Operating income	(3,824)	2,418
Interest expense	4,136	3,993
Other income (expense), net	710	(1,763)
Net before taxes	(7,250)	(3,338)
Income taxes	(1,514)	(1,386)
Net income	(5,736)	(1,952)
Earnings common share		
Primary	\$(0.49)	\$(0.17)
Fully Diluted	\$(0.49)	\$(0.17)
Common Shares:		
Full Diluted	11,598	11,529
Year-end	11,635	11,588

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	19,191
Inventories	6,805
Current assets	57,941
Net property & equip.	607,087

Total assets	714,343
Liabilities:	
Current liabilities	88,655
Long-term debt	294,804
Stockholders' equity	218,300
Net current assets	(30,714)

**HELIUS MEDICAL TECHNOLOGIES INC**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Cost & expenses	4,717,000	5,034,000
Operating income	(4,717,000)	(5,034,000)
Other income (expense), net	2,584,000	(516,000)
Foreign currency	968,000	(128,000)
Net income	(1,165,000)	(5,678,000)
Earnings common share		
Primary	\$(0.06)	\$(0.32)
Fully Diluted	\$(0.08)	\$(0.32)
Common Shares:		
Full Diluted	20,460,656	17,573,966
Year-end	20,797,309	18,249,335

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	4,395,000
Current assets	5,455,000
Net property & equip.	190,000
Total assets	5,663,000
Liabilities:	
Current liabilities	7,892,000
Stockholders' equity	(2,229,000)
Net current assets	(2,437,000)

**HEMISPHERE MEDIA GROUP INC**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Total Revenues	29,035,000	33,159,000
Cost & expenses	20,241,000	21,987,000
Deprec., depl. & amort.	3,997,000	4,115,000
Operating income	4,797,000	7,057,000
Interest expense	2,884,000	2,628,000
Other income (expense), net	(9,795,000)	
Net before taxes	(7,882,000)	4,429,000
Income taxes	(323,000)	1,684,000
Net income	(7,559,000)	2,745,000
Earnings common share		
Primary	\$(0.19)	\$0.07
Fully Diluted	\$(0.19)	\$0.07
Common Shares:		
Full Diluted	38,955,000	40,760,000
Year-end	40,580,804	42,139,215

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	107,377,000
Current assets	152,030,000
Net property & equip.	25,416,000
Total assets	490,398,000
Liabilities:	
Current liabilities	30,179,000
Long-term debt	205,121,000
Stockholders' equity	233,477,000
Net current assets	121,851,000

**HIGHPOWER INTERNATIONAL INC.**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Net Sales	49,783,453	41,866,848
Cost & expenses	51,883,562	38,756,697
Operating income	(2,100,109)	3,110,151
Interest expense	241,852	603,317
Other income (expense), net	1,213,346	693,473
Net before taxes	(1,128,615)	3,200,307
Income taxes	(9,679)	587,765
Net income	(1,118,936)	2,612,542
Earnings common share		
Primary	\$(0.07)	\$0.17
Fully Diluted	\$(0.07)	\$0.17
Common Shares:		
Full Diluted	15,509,658	15,299,029
Year-end	15,509,658	15,176,252

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	18,859,355
Inventories	55,347,466
Current assets	176,278,649
Net property & equip.	48,189,218
Total assets	244,523,573
Liabilities:	
Current liabilities	175,352,347
Stockholders' equity	69,171,226
Net current assets	926,302

**HOUSTON WIRE & CABLE CO****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	85,026	78,709
Cost & expenses	81,211	78,099
Operating income	3,270	(250)
Interest expense	644	450
Net before taxes	2,626	(700)
Income taxes	679	(247)
Net income	1,947	(453)
Earnings common share		
Primary	\$0.12	\$(0.03)
Fully Diluted	\$0.12	\$(0.03)
Common Shares:		
Full Diluted	16,423	16,241
Year-end	16,482	16,502

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Inventories	93,402
Current assets	151,372
Net property & equip.	11,457
Total assets	197,330
Liabilities:	
Current liabilities	22,873
Long-term debt	80,183
Stockholders' equity	92,787
Net current assets	128,499

**HUDSON GLOBAL INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	16,215	13,992
Cost & expenses	18,873	14,208
Deprec., depl. & amort.		81
Operating income	(2,658)	(297)
Other income (expense), net	(67)	(36)
Net before taxes	(2,725)	(333)
Income taxes	172	146
Income contin. oper.	(2,897)	(479)
Net income	10,721	(1,314)
Earnings common share		
Primary	\$0.33	\$(0.04)
Fully Diluted	\$0.33	\$(0.04)
Common Shares:		
Full Diluted	32,146	32,161
Year-end	31,578	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	42,864
Current assets	57,330
Total assets	57,970
Liabilities:	
Current liabilities	11,125
Stockholders' equity	43,978
Net current assets	46,205

**I.D. SYSTEMS, INC. (DE)****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	13,379,000	7,999,000
Cost & expenses	14,356,000	9,869,000
Operating income	(977,000)	(1,870,000)
Interest income	77,000	56,000
Interest expense	57,000	73,000
Other income (expense), net	(33,000)	1,000
Net income	(990,000)	(1,886,000)
Earnings common share		
Primary	\$(0.06)	\$(0.14)
Fully Diluted	\$(0.06)	\$(0.14)
Common Shares:		
Full Diluted	16,981,000	13,261,000
Year-end	17,635,000	

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	4,545,000
Inventories	4,737,000
Current assets	30,727,000
Net property & equip.	2,613,000
Total assets	60,368,000
Liabilities:	
Current liabilities	19,206,000
Stockholders' equity	32,057,000
Net current assets	11,521,000

**IDENTIV INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	16,528	13,392
Cost & expenses	18,275	14,338
Operating income	(1,747)	(946)
Other income (expense), net		977
Foreign currency	(38)	(152)
Net before taxes	(2,261)	(795)
Income taxes	40	(118)
Net income	(2,301)	(677)
Earnings common share		
Primary	\$(0.15)	\$(0.06)
Fully Diluted	\$(0.15)	\$(0.06)
Common Shares:		
Full Diluted	15,111	11,127
Year-end	15,143	11,160

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	16,685
Inventories	11,556
Current assets	42,612
Net property & equip.	2,151
Total assets	61,932
Liabilities:	
Current liabilities	31,774
Long-term debt	2,622
Stockholders' equity	24,588
Net current assets	10,838

**INFINERA CORP****Earnings, 3 mos. to (Consol. - \$000):**

	03/31/18	04/01/17
Total Revenues	202,681	175,522
Cost & expenses	227,359	213,349
Operating income	(24,678)	(37,827)
Interest income	897	751
Interest expense	3,683	3,403
Other income (expense), net	506	(130)
Net before taxes	(26,958)	(40,609)
Income taxes	(678)	(158)
Net income	(26,280)	(40,451)
Earnings common share		
Primary	\$(0.17)	\$(0.28)
Fully Diluted	\$(0.17)	\$(0.28)
Common Shares:		
Full Diluted	150,333	145,786
Year-end	151,163	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	151,436
Inventories	215,888
Current assets	686,113
Net property & equip.	135,196
Total assets	1,132,657
Liabilities:	
Current liabilities	397,070
Stockholders' equity	671,209
Net current assets	289,043

**INFORMATION SERVICES GROUP INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	68,877,000	66,555,000
Cost & expenses	65,212,000	62,411,000
Operating income	1,763,000	1,181,000
Interest expense	1,737,000	1,709,000
Foreign currency	(24,000)	(80,000)
Net before taxes	109,000	(563,000)
Income taxes	(55,000)	8,000
Net income	164,000	(571,000)
Balance for common	164,000	(606,000)

**Earnings common share**

Primary	\$	\$(0.01)
Fully Diluted	\$	\$(0.01)
Common Shares:		
Full Diluted	45,861,000	42,316,000
Year-end	43,835,000	

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	31,099,000
Current assets	101,143,000
Net property & equip.	7,514,000
Total assets	222,911,000
Liabilities:	
Current liabilities	48,070,000
Long-term debt	96,974,000
Stockholders' equity	67,542,000
Net current assets	53,073,000

**INGLES MARKETS INC****Earnings, 6 mos. to (Consol. - \$):**

	03/31/18	03/25/17
Net Sales	1,998,348,252	928,910,306
Cost & expenses	1,938,905,577	871,692,011
Operating income	59,442,675	57,218,295
Other income (expense), net	1,818,439	1,439,451
Net before taxes	37,596,527	35,625,334
Income taxes	(16,845,000)	(12,650,000)
Net income	54,441,527	22,975,334
Earnings common share		
Primary	\$2.76	\$2.23
Fully Diluted	\$2.69	\$1.13
Common Shares:		
Full Diluted	20,259,776	20,259,776
Year-end	20,259,776	20,259,776
Consolidated Balance Sheet Items, as of (\$):		
Assets:	2018	
Cash & equivalents	69	
Current assets	69	
Total assets	69	
Liabilities:		
Net current assets	69	

**INNERSCOPE HEARING TECHNOLOGIES INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	55,977	144,460
Cost & expenses	469,094	307,295
Operating income	(413,116)	(162,835)
Interest income		112
Other income (expense), net	(151,259)	
Gains or losses	(2,305)	160,000
Net income	(697,943)	(3,091)
Earnings common share		
Primary	\$(0.01)	\$
Fully Diluted	\$(0.01)	\$
Common Shares:		
Full Diluted	61,631,452	60,906,000
Year-end	61,763,406	60,906,000

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	23,385
Inventories	28,734
Current assets	251,437
Net property & equip.	1,362
Total assets	1,478,397
Liabilities:	
Current liabilities	2,561,733
Long-term debt	977,494
Stockholders' equity	(2,060,830)
Net current assets	(2,310,296)

**INNODATA INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	14,120,000	14,953,000
Cost & expenses	13,810,000	16,348,000
Operating income	306,000	(1,383,000)
Net before taxes	306,000	(1,383,000)
Income taxes	582,000	445,000
Net income	(276,000)	(1,828,000)
Earnings common share		
Primary	\$(0.01)	\$(0.07)
Fully Diluted	\$(0.01)	\$(0.07)



<b>Common Shares:</b>	
Full Diluted .....	25,878,000
Year-end .....	25,878,000

<b>Consolidated Balance Sheet Items, as of (\$):</b>	
<b>Assets:</b>	
Cash & equivalents .....	12,179,000
Current assets .....	24,434,000
Net property & equip. ....	7,027,000
Total assets .....	46,555,000
<b>Liabilities:</b>	
Current liabilities .....	15,348,000
Long-term debt .....	(680,000)
Stockholders' equity .....	30,373,000
Net current assets .....	9,086,000

**INNOVATIVE SOLUTIONS AND SUPPORT INC****Earnings, 6 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales .....	6,815,188	8,019,769
Cost & expenses .....	9,010,260	6,629,146
Operating income .....	(2,195,072)	1,390,623
Other income (expense), net .....	37,096	4,159,326
Net before taxes .....	(2,136,671)	5,569,772
Income taxes .....	61,819	834,319
<b>Net income</b> .....	<b>(2,198,490)</b>	<b>4,735,453</b>

<b>Earnings common share</b>		
Primary .....	\$(0.13)	\$0.28
Fully Diluted .....	\$(0.13)	\$0.28

<b>Common Shares:</b>		
Full Diluted .....	16,791,687	16,835,756
Year-end .....	16,840,599	16,781,129

**INOVIO PHARMACEUTICALS INC.****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues .....	1,529,644	10,376,185
Cost & expenses .....	34,275,766	32,310,093
Operating income .....	(32,746,122)	(21,933,908)
Other income (expense), net .....	(127,841)	116,477
Gains or losses .....	2,380,423	(1,608,817)
Net before taxes .....	(30,181,017)	.....
Income taxes .....	2,169,811	.....
<b>Net income</b> .....	<b>(32,350,828)</b>	<b>(23,085,907)</b>

<b>Earnings common share</b>		
Primary .....	\$(0.36)	\$(0.31)
Fully Diluted .....	\$(0.36)	\$(0.31)

<b>Common Shares:</b>		
Full Diluted .....	90,451,791	74,300,884
Year-end .....	90,704,931	74,627,013

<b>Consolidated Balance Sheet Items, as of (\$):</b>	
<b>Assets:</b>	
Cash & equivalents .....	37,508,863
Current assets .....	123,836,168
Net property & equip. ....	17,486,103
Total assets .....	173,664,840
<b>Liabilities:</b>	
Current liabilities .....	51,375,343
Stockholders' equity .....	112,998,294
Net current assets .....	72,460,825

**INSYS THERAPEUTICS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues .....	23,911,000	35,962,000
Cost & expenses .....	44,144,000	48,273,000
Operating income .....	(20,233,000)	(12,311,000)
Other income (expense), net .....	(469,000)	26,000
Net before taxes .....	(20,199,000)	(11,850,000)
Income taxes .....	171,000	(5,326,000)
<b>Net income</b> .....	<b>(20,370,000)</b>	<b>(6,524,000)</b>

<b>Earnings common share</b>		
Primary .....	\$(0.28)	\$(0.09)
Fully Diluted .....	\$(0.28)	\$(0.09)

<b>Common Shares:</b>		
Full Diluted .....	73,745,202	71,945,743
Year-end .....	73,808,821	72,114,799

<b>Consolidated Balance Sheet Items, as of (\$):</b>	
<b>Assets:</b>	
Cash & equivalents .....	18,549,000
Inventories .....	16,300,000
Current assets .....	166,694,000
Net property & equip. ....	54,777,000
Total assets .....	253,939,000

<b>Liabilities:</b>	
Current liabilities .....	197,811,000
Stockholders' equity .....	47,363,000
Net current assets .....	(31,117,000)

**INTELGENX TECHNOLOGIES CORP****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues .....	239,000	1,353,000
Cost & expenses .....	2,077,000	1,640,000
Operating income .....	(2,021,000)	(457,000)
<b>Net income</b> .....	<b>(2,264,000)</b>	<b>(512,000)</b>

<b>Earnings common share</b>		
Primary .....	\$(0.03)	\$(0.01)
Fully Diluted .....	\$(0.03)	\$(0.01)

<b>Common Shares:</b>		
Full Diluted .....	67,404,467	65,305,520
Year-end .....	67,731,467	65,422,020

<b>Consolidated Balance Sheet Items, as of (\$):</b>	
<b>Assets:</b>	
Cash & equivalents .....	618,000
Current assets .....	3,796,000
Net property & equip. ....	6,433,000
Total assets .....	10,966,000
<b>Liabilities:</b>	
Current liabilities .....	2,097,000
Long-term debt .....	6,886,000
Stockholders' equity .....	1,933,000
Net current assets .....	1,699,000

**INTERLINK ELECTRONICS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues .....	2,573	2,884
Cost & expenses .....	2,354	2,353
Operating income .....	219	531
Other income (expense), net .....	(46)	19
Net before taxes .....	173	550
Income taxes .....	55	186
<b>Net income</b> .....	<b>118</b>	<b>364</b>

<b>Earnings common share</b>		
Primary .....	\$0.02	\$0.05
Fully Diluted .....	\$0.02	\$0.05

<b>Common Shares:</b>		
Full Diluted .....	7,416	7,412
Year-end .....	7,342	.....

<b>Consolidated Balance Sheet Items, as of (\$000):</b>	
<b>Assets:</b>	
Cash & equivalents .....	7,965
Inventories .....	1,068
Current assets .....	10,712
Net property & equip. ....	639
Total assets .....	11,920
<b>Liabilities:</b>	
Current liabilities .....	722
Stockholders' equity .....	11,198
Net current assets .....	9,990

**INTERMOLECULAR INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues .....	9,675	9,945
Cost & expenses .....	10,490	15,932
Operating income .....	(815)	(5,987)
Other income (expense), net .....	87	97
Net before taxes .....	(622)	(5,835)
Income taxes .....	1	1
<b>Net income</b> .....	<b>(623)</b>	<b>(5,836)</b>

<b>Earnings common share</b>		
Primary .....	\$(0.01)	\$(0.12)
Fully Diluted .....	\$(0.01)	\$(0.12)

<b>Common Shares:</b>		
Full Diluted .....	49,582	49,519
Year-end .....	49,601	49,572

<b>Consolidated Balance Sheet Items, as of (\$000):</b>	
<b>Assets:</b>	
Cash & equivalents .....	4,421
Current assets .....	32,401
Net property & equip. ....	4,940
Total assets .....	43,229
<b>Liabilities:</b>	
Current liabilities .....	4,135
Stockholders' equity .....	36,188
Net current assets .....	28,266

**INTERSECTIONS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues .....	39,078,000	40,449,000
Cost & expenses .....	35,727,000	42,794,000
Operating income .....	1,849,000	(3,692,000)
Other income (expense), net .....	(48,000)	34,000
Net before taxes .....	1,270,000	(4,250,000)
Income taxes .....	(523,000)	(10,000)
Income contin. oper. ....	.....	(4,240,000)
<b>Net income</b> .....	<b>1,793,000</b>	<b>(4,802,000)</b>

<b>Earnings common share</b>		
Primary .....	\$0.07	\$(0.20)
Fully Diluted .....	\$0.07	\$(0.20)

<b>Common Shares:</b>		
Full Diluted .....	24,529,000	23,675,000
Year-end .....	24,264,000	.....

<b>Consolidated Balance Sheet Items, as of (\$):</b>	
<b>Assets:</b>	
Cash & equivalents .....	8,437,000
Current assets .....	19,670,000
Net property & equip. ....	10,591,000
Total assets .....	42,070,000
<b>Liabilities:</b>	
Current liabilities .....	18,182,000
Long-term debt .....	21,124,000
Stockholders' equity .....	681,000
Net current assets .....	1,488,000

**INTRICON CORP****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales .....	25,363,000	21,215,000
Cost & expenses .....	24,011,000	21,403,000
Operating income .....	1,352,000	(188,000)
Interest expense .....	188,000	182,000
Other income (expense), net .....	(220,000)	56,000
Net before taxes .....	944,000	(314,000)
Income taxes .....	187,000	64,000
Income contin. oper. ....	.....	(378,000)
<b>Net income</b> .....	<b>757,000</b>	<b>(655,000)</b>

<b>Earnings common share</b>		
Primary .....	\$0.11	\$(0.04)
Fully Diluted .....	\$0.10	\$(0.04)

<b>Common Shares:</b>		
Full Diluted .....	7,843,000	6,826,000
Year-end .....	6,944,000	.....

<b>Consolidated Balance Sheet Items, as of (\$):</b>	
<b>Assets:</b>	
Cash & equivalents .....	381,000
Inventories .....	14,862,000
Current assets .....	33,313,000
Net property & equip. ....	7,547,000
Total assets .....	60,002,000
<b>Liabilities:</b>	
Current liabilities .....	21,818,000
Long-term debt .....	10,948,000
Stockholders' equity .....	23,148,000
Net current assets .....	11,495,000

**IRHYTHM TECHNOLOGIES INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues .....	30,565	21,437
Cost & expenses .....	41,207	26,182
Operating income .....	(10,642)	(4,745)
Interest expense .....	858	822
Other income (expense), net .....	383	264
<b>Net income</b> .....	<b>(11,117)</b>	<b>(5,303)</b>

<b>Earnings common share</b>		
Primary .....	\$(0.47)	\$(0.24)
Fully Diluted .....	\$(0.47)	\$(0.24)

<b>Common Shares:</b>		
Full Diluted .....	23,480	22,152
Year-end .....	23,592	.....

<b>Consolidated Balance Sheet Items, as of (\$000):</b>	
<b>Assets:</b>	
Cash & equivalents .....	16,473
Inventories .....	1,857
Current assets .....	111,542
Net property & equip. ....	6,860
Total assets .....	122,321
<b>Liabilities:</b>	

Current liabilities	16,938
Long-term debt	32,533
Stockholders' equity	72,623
Net current assets	94,604

Long-term debt	3,232,000
Stockholders' equity	51,020,000
Net current assets	28,213,000

Liabilities:	
Current liabilities	46,734
Stockholders' equity	95,529
Net current assets	86,579

**JAKKS PACIFIC INC.****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	93,004,000	94,505,000
Cost & expenses	128,662,000	110,229,000
Operating income	(35,658,000)	(15,724,000)
Other income (expense), net	72,000	23,000
Gains or losses	(1,021,000)	
Net before taxes	(38,529,000)	(18,629,000)
Income taxes	(2,336,000)	(344,000)
<b>Net income</b>	<b>(36,193,000)</b>	<b>(18,285,000)</b>
Earnings common share		
Primary	\$(1.57)	\$(1.01)
Fully Diluted	\$(1.57)	\$(1.01)
Common Shares:		
Full Diluted	23,100,000	18,104,000
Year-end	26,057,073	20,095,695

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	46,779,000
Inventories	53,997,000
Current assets	215,516,000
Net property & equip.	22,956,000
Total assets	313,891,000
Liabilities:	
Current liabilities	112,679,000
Long-term debt	134,716,000
Stockholders' equity	58,942,000
Net current assets	102,837,000

**JOUNCE THERAPEUTICS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	24,964	20,536
Operating income	(13,769)	(247)
Other income (expense), net	741	632
<b>Net income</b>	<b>(13,028)</b>	<b>385</b>
Earnings common share		
Primary	\$(0.40)	\$(0.02)
Fully Diluted	\$(0.40)	\$(0.02)
Common Shares:		
Full Diluted	32,373	23,543
Year-end	32,451	32,135

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	122,805
Current assets	257,607
Net property & equip.	15,842
Total assets	276,117
Liabilities:	
Current liabilities	70,957
Stockholders' equity	110,286
Net current assets	186,650

**JUNIPER PHARMACEUTICALS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	15,524,000	11,247,000
Cost & expenses	14,508,000	12,702,000
Operating income	1,016,000	(1,455,000)
Other income (expense), net	(199,000)	42,000
<b>Net income</b>	<b>772,000</b>	<b>(1,441,000)</b>
Balance for common	772,000	(1,448,000)
Earnings common share		
Primary	\$0.07	\$(0.13)
Fully Diluted	\$0.06	\$(0.13)
Common Shares:		
Full Diluted	12,287,000	10,803,000
Year-end	11,101,000	10,844,000

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	20,685,000
Inventories	6,318,000
Current assets	38,415,000
Net property & equip.	15,880,000
Total assets	64,539,000
Liabilities:	
Current liabilities	10,202,000

**KALA PHARMACEUTICALS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	11,139	9,571
Operating income	(11,139)	(9,571)
Interest income	209	46
Interest expense	367	198
Other income (expense), net		(36)
<b>Net income</b>	<b>(11,297)</b>	<b>(9,759)</b>
Earnings common share		
Primary	\$(0.46)	\$(8.26)
Fully Diluted	\$(0.46)	\$(8.26)
Common Shares:		
Full Diluted	24,542	1,181
Year-end	24,556	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	100,525
Current assets	101,414
Net property & equip.	1,079
Total assets	104,989
Liabilities:	
Current liabilities	4,972
Long-term debt	19,746
Stockholders' equity	80,271
Net current assets	96,442

**KANDI TECHNOLOGIES GROUP INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	8,335,907	4,274,573
Cost & expenses	8,097,308	33,054,576
Operating income	238,599	(28,780,003)
Other income (expense), net	3,593,466	(65,618)
Net before taxes	4,224,641	(28,929,432)
Income taxes	496,646	(4,775,997)
<b>Net income</b>	<b>3,727,995</b>	<b>(24,153,435)</b>
Earnings common share		
Primary	\$0.07	\$(0.51)
Fully Diluted	\$0.07	\$(0.51)
Common Shares:		
Full Diluted	50,643,423	47,732,388
Year-end	51,008,875	47,772,138

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	1,041,781
Inventories	17,439,458
Current assets	224,103,964
Net property & equip.	72,931,478
Total assets	465,721,928
Liabilities:	
Current liabilities	173,977,442
Long-term debt	31,846,373
Stockholders' equity	253,286,072
Net current assets	50,126,522

**KARYOPHARM THERAPEUTICS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	10,000	68
Cost & expenses	48,942	30,347
Operating income	(38,942)	(30,279)
Interest income	509	400
Other income (expense), net	(14)	(15)
Net before taxes	(38,447)	(29,894)
Income taxes	12	23
<b>Net income</b>	<b>(38,459)</b>	<b>(29,917)</b>
Earnings common share		
Primary	\$(0.78)	\$(0.71)
Fully Diluted	\$(0.78)	\$(0.71)
Common Shares:		
Full Diluted	49,603	41,895
Year-end	49,670	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	37,499
Current assets	133,313
Net property & equip.	2,454
Total assets	146,373

**KEMPHARM INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	14,769	7,380
Operating income	(14,769)	(7,380)
Other income (expense), net	(9,741)	(7,216)
Net before taxes	(26,227)	(16,326)
Income taxes	(8)	(4)
<b>Net income</b>	<b>(26,219)</b>	<b>(16,322)</b>
Earnings common share		
Primary	\$(1.77)	\$(1.11)
Fully Diluted	\$(1.77)	\$(1.11)
Common Shares:		
Full Diluted	14,792	14,647
Year-end	15,105	14,647

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	8,750
Current assets	39,079
Net property & equip.	1,924
Total assets	42,649
Liabilities:	
Current liabilities	13,810
Long-term debt	90,303
Stockholders' equity	(79,683)
Net current assets	25,269

**KEY TRONIC CORP****Earnings, 9 mos. to (Consol. - \$000):**

	03/31/18	04/01/17
Net Sales	329,294	349,253
Cost & expenses	325,700	342,067
Operating income	3,594	7,186
Interest expense	1,866	1,707
Net before taxes	1,728	5,479
Income taxes	876	1,198
<b>Net income</b>	<b>852</b>	<b>4,281</b>
Earnings common share		
Primary	\$0.08	\$0.40
Fully Diluted	\$0.08	\$0.39
Common Shares:		
Full Diluted	10,760	10,916
Year-end	10,760	10,760

**KRATOS DEFENSE & SECURITY SOLUTIONS, INC.****Earnings, 3 mos. to (Consol. - \$000):**

	04/01/18	03/26/17
Total Revenues	143,000	132,000
Cost & expenses	136,000	130,600
Operating income	7,000	1,400
Interest expense	5,100	8,200
Other income (expense), net	300	(1,900)
Net before taxes	2,200	(8,700)
Income taxes	900	1,400
Income contin. oper.	1,300	(10,100)
<b>Net income</b>	<b>(2,200)</b>	<b>(10,000)</b>

**Earnings common share**

Primary	\$(0.02)	\$(0.13)
Fully Diluted	\$(0.02)	\$(0.13)
Common Shares:		
Full Diluted	105,700	77,300
Year-end	103,513	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	127,800
Inventories	48,200
Current assets	457,100
Net property & equip.	61,500
Total assets	1,011,200
Liabilities:	
Current liabilities	175,000
Long-term debt	293,600
Stockholders' equity	512,500
Net current assets	282,100

**KULICKE & SOFFA INDUSTRIES, INC.****Earnings, 6 mos. to (Consol. - \$000):**

Net Sales	03/31/18	04/01/17	Accounts payable	1,248,000	638,000	Common Shares:		
Cost & expenses	435,463	349,252	Accrued compensation & benefits	2,345,000	1,907,000	Full Diluted	75,000	75,000
Operating income	77,595	55,562	Accrued research & development expenses	3,852,000	1,669,000	Year-end	75,057	
Interest income	4,961	2,751	Other accrued expenses	839,000	467,000	<b>Consolidated Balance Sheet Items, as of (\$000):</b>		
Interest expense	536	523	Accounts payable & accrued expenses	8,284,000	4,681,000	Assets:		
Equity earnings	23		Accounts payable & accrued expenses, related party	216,000	770,000	Cash & equivalents		2018
Net before taxes	82,020	57,790	Current portion of long-term debt, net	1,531,000				656,000
Income taxes	115,212	7,724	Total current liabilities	10,031,000	5,451,000	Current assets		1,005,000
<b>Net income</b>	<b>(33,215)</b>	<b>50,066</b>	Long-term debt, net	5,567,000	7,324,000	Net property & equip.		162,000
Earnings common share			Other long-term liabilities	388,000	170,000	Total assets		5,392,000
Primary	\$(0.47)	\$0.71	Total liabilities	15,986,000	12,945,000	Liabilities:		
Fully Diluted	\$(0.47)	\$0.69	Common stock	3,000	2,000	Current liabilities		535,000
Common Shares:			Additional paid-in capital	169,201,000	110,748,000	Long-term debt		477,000
Full Diluted	70,467	72,039	Accumulated comprehensive income (loss)	(49,000)	(18,000)	Stockholders' equity		387,000
Year-end	69,787		Retained earnings (accumulated deficit)	(89,290,000)	(53,856,000)	Net current assets		470,000

**KURA ONCOLOGY INC****Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

	2017	2016	2015
		(revised)	(revised)
Research & development	25,114,000	16,575,000	13,905,000
Research & development, related party	1,312,000	3,829,000	3,872,000
General & administrative expenses	9,404,000	7,861,000	6,019,000
General & administrative, related party	247,000	102,000	69,000
Total operating expenses	36,077,000	28,367,000	23,865,000
Management fee income, related party	780,000	885,000	1,200,000
Interest income	751,000	499,000	128,000
Interest expense, related party	888,000	577,000	42,000
Total other income (expense)	643,000	807,000	1,240,000
<b>Net income (loss)</b>	<b>(35,434,000)</b>	<b>(27,560,000)</b>	<b>(22,625,000)</b>
Weighted average shares outstanding			
- basic	23,237,000	18,701,000	9,933,000
Weighted average shares outstanding - diluted	23,237,000	18,701,000	9,933,000
Year end shares outstanding	29,424,000	19,348,000	18,138,000
Net income (loss) per share - basic	\$(1.52)	\$(1.47)	\$(2.28)
Net income (loss) per share - diluted	\$(1.52)	\$(1.47)	\$(2.28)
Number of full time employees	31	22	21
Number of part time employees	1	3	3
Number of common stockholders	236	283	344

□ Approximately; □ As of March 9, 2018; □ As of March 10, 2017; □ As of March 11, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

	2017	2016
		(revised)
Cash & cash equivalents	11,433,000	9,725,000
Short-term investments	81,712,000	58,065,000
Accounts receivable, related party	216,000	295,000
Prepaid expenses & other current assets	1,280,000	725,000
Total current assets	94,641,000	68,810,000
Computer software & equipment	92,000	92,000
Less: accumulated depreciation	82,000	52,000
Property & equipment, net	10,000	40,000
Other long-term assets	1,200,000	971,000
Total assets	95,851,000	69,821,000

Accounts payable	1,248,000	638,000
Accrued compensation & benefits	2,345,000	1,907,000
Accrued research & development expenses	3,852,000	1,669,000
Other accrued expenses	839,000	467,000
Accounts payable & accrued expenses	8,284,000	4,681,000
Accounts payable & accrued expenses, related party	216,000	770,000
Current portion of long-term debt, net	1,531,000	
Total current liabilities	10,031,000	5,451,000
Long-term debt, net	5,567,000	7,324,000
Other long-term liabilities	388,000	170,000
Total liabilities	15,986,000	12,945,000
Common stock	3,000	2,000
Additional paid-in capital	169,201,000	110,748,000
Accumulated comprehensive income (loss)	(49,000)	(18,000)
Retained earnings (accumulated deficit)	(89,290,000)	(53,856,000)
Total stockholders' equity (deficit)	79,865,000	56,876,000

□ Reclassified to conform with 2017 presentation

**Recent Dividends:****1. Kura Oncology Inc common.**

No dividends paid.

**Annual Dividends:****1. Kura Oncology Inc common.**

No dividends paid.

**LAUREATE EDUCATION INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	885,288	855,933
Cost & expenses	912,747	918,799
Operating income	(27,459)	(62,866)
Interest income	6,129	4,694
Interest expense	69,465	102,633
Other income (expense), net	(5,075)	(1,079)
Gains or losses	278,701	12,147
Foreign currency	(8,754)	2,290
Net before taxes	174,077	(147,447)
Income taxes	2,532	(27,094)
<b>Net income</b>	<b>171,545</b>	<b>(120,353)</b>
Balance for common	111,476	(161,683)
Earnings common share		
Primary	\$0.59	\$(1.05)
Fully Diluted	\$0.59	\$(1.05)
Common Shares:		
Full Diluted	188,228	154,301
Year-end	187,699	168,404

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents		664,000
Current assets		1,493,215
Net property & equip.		1,895,352
Total assets		7,516,758
Liabilities:		
Current liabilities		1,591,766
Long-term debt		2,891,846
Stockholders' equity		1,772,924
Net current assets		(98,551)

**LIBERTY TRIPADVISOR HOLDINGS, INC.****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	378,000	378,000
Cost & expenses	330,000	329,000
Operating income	9,000	(7,000)
Interest expense	6,000	5,000
Other income (expense), net	1,000	1,000
Gains or losses	(23,000)	6,000
Net before taxes	(19,000)	(5,000)
Income taxes	16,000	4,000
<b>Net income</b>	<b>(35,000)</b>	<b>(9,000)</b>
Earnings common share		
Primary	\$(0.41)	\$(0.04)
Fully Diluted	\$(0.41)	\$(0.04)

Common Shares:		
Full Diluted	75,000	75,000
Year-end	75,057	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents		656,000
Current assets		1,005,000
Net property & equip.		162,000
Total assets		5,392,000
Liabilities:		
Current liabilities		535,000
Long-term debt		477,000
Stockholders' equity		387,000
Net current assets		470,000

**LIFETIME BRANDS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	118,169	113,356
Cost & expenses	131,485	115,230
Operating income	(13,316)	(1,874)
Other income (expense), net	(66)	
Equity earnings	(77)	(540)
Net before taxes	(15,485)	(2,815)
Income taxes	(3,810)	(944)
<b>Net income</b>	<b>(11,598)</b>	<b>(1,331)</b>
Earnings common share		
Primary	\$(0.70)	\$(0.09)
Fully Diluted	\$(0.70)	\$(0.09)
Common Shares:		
Full Diluted	16,601	14,396
Year-end	20,606	14,572

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents		11,904
Inventories		177,567
Current assets		293,355
Net property & equip.		27,052
Total assets		726,915
Liabilities:		
Current liabilities		85,247
Long-term debt		308,628
Stockholders' equity		277,741
Net current assets		208,108

**LIFEWAY FOODS, INC.****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	28,742,000	32,117,000
Cost & expenses	28,428,000	31,683,000
Operating income	151,000	266,000
Interest expense	63,000	57,000
Other income (expense), net	5,000	
Gains or losses	15,000	(5,000)
Net before taxes	108,000	204,000
Income taxes	38,000	80,000
<b>Net income</b>	<b>70,000</b>	<b>124,000</b>
Earnings common share		
Primary	\$0.01	\$0.01
Fully Diluted	\$0.01	\$0.01
Common Shares:		
Full Diluted	16,019,000	16,156,000
Year-end	15,893,000	16,154,000

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents		3,722,000
Inventories		7,515,000
Current assets		23,388,000
Net property & equip.		24,827,000
Total assets		63,245,000
Liabilities:		
Current liabilities		10,086,000
Long-term debt		6,069,000
Stockholders' equity		45,710,000
Net current assets		13,302,000

**LIGHTWAVE LOGIC INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	1,476,267	1,188,927
Operating income	(1,476,267)	(1,188,927)
Other income (expense), net	(37,194)	(24,754)
<b>Net income</b>	<b>(1,513,399)</b>	<b>(1,213,619)</b>

Earnings common share		
Primary .....	\$(0.02)	\$(0.02)
Fully Diluted .....	\$(0.02)	\$(0.02)
Common Shares:		
Full Diluted .....	74,543,897	68,948,694
Year-end .....	75,000,557	69,720,530

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents .....	2,810,761	
Current assets .....	3,377,720	
Net property & equip. ....	1,632,395	
Total assets .....	5,625,674	
Liabilities:		
Current liabilities .....	788,387	
Long-term debt .....	101,165	
Stockholders' equity .....	4,736,122	
Net current assets .....	2,589,333	

**LINCOLN EDUCATIONAL SERVICES CORP**

**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues .....	61,889	65,279
Cost & expenses .....	68,151	71,007
Operating income .....	(6,262)	(5,728)
Interest income .....	10	31
Interest expense .....	572	5,182
Net before taxes .....	(6,824)	(10,879)
Income taxes .....	50	50
Net income .....	(6,874)	(10,929)
Earnings common share		
Primary .....	\$(0.28)	\$(0.46)
Fully Diluted .....	\$(0.28)	\$(0.46)
Common Shares:		
Full Diluted .....	24,138	23,609
Year-end .....	30,570	30,498

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents .....	4,863	
Inventories .....	1,910	
Current assets .....	37,855	
Net property & equip. ....	54,017	
Total assets .....	116,871	
Liabilities:		
Current liabilities .....	46,501	
Long-term debt .....	22,300	
Stockholders' equity .....	39,219	
Net current assets .....	(8,646)	

**LSI INDUSTRIES INC.**

**Earnings, 9 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales .....	258,614	247,973
Cost & expenses .....	278,138	244,863
Operating income .....	(19,524)	3,110
Interest income .....	24	80
Interest expense .....	1,244	209
Net before taxes .....	(20,744)	2,981
Income taxes .....	(3,867)	677
Net income .....	(16,877)	2,304
Earnings common share		
Primary .....	\$(0.65)	\$0.09
Fully Diluted .....	\$(0.65)	\$0.09
Common Shares:		
Full Diluted .....	25,835	25,909
Year-end .....	25,624	25,375

**MANNKIND CORP**

**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues .....	3,465	3,009
Cost & expenses .....	30,254	22,611
Operating income .....	(26,789)	(19,602)
Interest income .....	106	55
Other income (expense), net .....	(794)	6,643
Net income .....	(30,385)	(16,324)
Earnings common share		
Primary .....	\$(0.25)	\$(0.17)
Fully Diluted .....	\$(0.25)	\$(0.17)
Common Shares:		
Full Diluted .....	120,911	95,744
Year-end .....	126,013	95,776

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents .....	26,706	
Inventories .....	3,891	
Current assets .....	35,028	
Net property & equip. ....	26,481	
Total assets .....	61,877	
Liabilities:		
Current liabilities .....	80,669	
Long-term debt .....	96,615	
Stockholders' equity .....	(223,208)	
Net current assets .....	(45,641)	

**MARCHEX INC**

**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues .....	21,896,000	24,375,000
Cost & expenses .....	23,051,000	27,890,000
Operating income .....	(1,155,000)	(3,515,000)
Other income (expense), net .....	240,000	17,000
Net before taxes .....	(915,000)	(3,498,000)
Income taxes .....	11,000	12,000
Net income .....	(926,000)	(3,510,000)
Balance for common .....	(926,000)	(3,510,000)
Earnings common share		
Primary .....	\$(0.02)	\$(0.08)
Fully Diluted .....	\$(0.02)	\$(0.08)
Common Shares:		
Full Diluted .....	43,095,000	42,225,000
Year-end .....	44,097,145	43,224,640

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents .....	84,562,000	
Current assets .....	101,234,000	
Net property & equip. ....	2,635,000	
Total assets .....	104,403,000	
Liabilities:		
Current liabilities .....	13,035,000	
Stockholders' equity .....	90,240,000	
Net current assets .....	88,199,000	

**MAXWELL TECHNOLOGIES INC**

**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues .....	28,416	26,686
Cost & expenses .....	37,782	35,873
Operating income .....	(9,366)	(9,187)
Other income (expense), net .....	221	156
Foreign currency .....	(89)	(97)
Net before taxes .....	(10,227)	(9,191)
Income taxes .....	(1,022)	1,208
Net income .....	(9,205)	(10,399)
Earnings common share		
Primary .....	\$(0.25)	\$(0.32)
Fully Diluted .....	\$(0.25)	\$(0.32)
Common Shares:		
Full Diluted .....	37,522	32,197
Year-end .....	38,001	32,541

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents .....	40,103	
Inventories .....	37,485	
Current assets .....	113,457	
Net property & equip. ....	30,174	
Total assets .....	204,676	
Liabilities:		
Current liabilities .....	50,923	
Long-term debt .....	35,556	
Stockholders' equity .....	103,066	
Net current assets .....	62,534	

**MERCADOLIBRE INC**

**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues .....	320,976,000	269,675,000
Cost & expenses .....	350,395,000	206,361,000
Operating income .....	(29,419,000)	63,314,000
Foreign currency .....	5,601,000	663,000
Net before taxes .....	(25,357,000)	69,663,000
Income taxes .....	(12,438,000)	21,145,000
Net income .....	(12,919,000)	48,518,000
Earnings common share		
Primary .....	\$(0.29)	\$1.10
Fully Diluted .....	\$(0.29)	\$1.10
Common Shares:		

Full Diluted .....	44,157,364	44,157,364
Year-end .....	44,157,364	44,157,364

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents .....	350,411,000	
Inventories .....	3,362,000	
Current assets .....	1,285,560,000	
Net property & equip. ....	122,859,000	
Total assets .....	1,719,687,000	
Liabilities:		
Current liabilities .....	1,085,851,000	
Long-term debt .....	314,953,000	
Stockholders' equity .....	252,867,000	
Net current assets .....	199,709,000	

**MERITAGE HOSPITALITY GROUP INC**

**Earnings, 3 mos. to (Consol. - \$):**

	04/01/18	04/02/17
Cost & expenses .....	92,750,970	56,824,327
Deprec., depl. & amort. ....	2,760,254	1,778,701
Operating income .....	4,193,959	3,412,258
Interest expense .....	2,496,641	656,422
Other income (expense), net .....	(321,732)	(54,902)
Net before taxes .....	1,375,586	2,700,934
Income taxes .....	(37,330)	834,802
Net income .....	1,412,916	1,866,132
Earnings common share		
Common Shares:		
Year-end .....	6,202,443	6,031,278

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents .....	17,139,291	
Inventories .....	2,913,109	
Current assets .....	26,810,005	
Net property & equip. ....	110,725,355	
Total assets .....	317,049,920	
Liabilities:		
Current liabilities .....	78,152,145	
Long-term debt .....	160,109,135	
Stockholders' equity .....	46,744,702	
Net current assets .....	(51,342,140)	

**MERSANA THERAPEUTICS INC**

**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues .....	3,064	4,290
Cost & expenses .....	15,827	12,402
Interest income .....	360	51
Net income .....	(12,403)	(8,061)
Balance for common .....	(12,403)	(8,061)
Earnings common share		
Primary .....	\$(0.54)	\$(6.02)
Fully Diluted .....	\$(0.54)	\$(6.02)
Common Shares:		
Full Diluted .....	22,817	1,338
Year-end .....	22,870	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents .....	32,354	
Current assets .....	111,358	
Net property & equip. ....	2,593	
Total assets .....	115,755	
Liabilities:		
Current liabilities .....	29,337	
Stockholders' equity .....	56,547	
Net current assets .....	82,021	

**MICROCHIP TECHNOLOGY INC**

**Merger Completed** On May 29, 2018, Co.'s wholly-owned subsidiary, Maple Acquisition Corp. ("Merger Subsidiary"), merged with and into Microsemi Corp. ("Microsemi"), with Microsemi continuing as the surviving corporation and became a wholly-owned subsidiary of Co. (the "Surviving Corporation"). As the result of the merger, each share of common stock, par value \$0.20, of Microsemi ("Microsemi Stock") (other than (1) treasury stock held by Microsemi or shares of Microsemi Stock held by Co. or any subsidiary of Microsemi or Co., was cancelled without consideration and (2) shares of Microsemi Stock held by stockholders, if any, who properly exercise their appraisal rights under the General Corporation Law of the State of Delaware) outstanding immediately prior to the Merger) was automatically cancelled and converted into the right an amount equal to \$68.78 in cash, without interest (the "Merger Consideration"). In addition, (a) each

outstanding option to purchase shares of Microsemi Stock (other than options held by individuals subject to China State Administration of Foreign Exchange ("SAFE") regulations) and stock appreciation right ("SAR") related to Microsemi Stock, whether vested or unvested, was assumed by Co. and became subject to the same terms and conditions as applied to the related option or SAR immediately prior to the Effective Time, except that (i) the number of shares of Co.'s common stock subject to each assumed option or assumed SAR became equal to the product of the number of shares of Microsemi Stock underlying such assumed option or assumed SAR as of immediately prior to the Effective Time multiplied by the ratio of the Merger Consideration to the average closing sales price per share of Co.'s common stock over the period of ten trading days ending on the last trading day before the closing of the Merger (the "equity award exchange ratio") and (ii) the per share exercise price of each assumed option or assumed SAR was determined by dividing the per share exercise price of the assumed option or assumed SAR immediately prior to the Effective Time by the equity award exchange ratio; (b) each award of time-based vesting stock units with respect to shares of Microsemi Stock ("RSUs") that was outstanding and vested immediately prior to the Effective Time (including those RSUs that became vested by their terms immediately prior to or as of the Effective Time) was canceled and converted into the right to receive an amount in cash equal to (i) the number of vested RSUs subject to the award multiplied by (ii) the Merger Consideration; (c) each award of RSUs that was outstanding and unvested at the Effective Time (other than outstanding and unvested RSUs held by individuals subject to SAFE regulations) was assumed by Co. and converted into a number of restricted stock units with respect to Co.'s common stock determined by multiplying the number of unvested RSUs by the equity award exchange ratio; (d) each award of performance-based vesting stock units with respect to shares of Microsemi Stock ("PSUs") that was outstanding immediately prior to the Effective Time became vested as to a percentage of the total number of shares of Microsemi Stock subject to such award to be determined prior to the Effective Time by the compensation committee of Microsemi's board of directors (the "Board") (which percentage was not less than 100% or greater than the maximum possible vesting percentage under the terms of the award) and was canceled and converted into the right to receive an amount in cash equal to (i) the number of vested PSUs subject to the award multiplied by (ii) the Merger Consideration; (e) each share of Microsemi Stock awarded pursuant to a Microsemi restricted stock award that was outstanding and unvested as of immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, provided that the right of the award holder to receive such cash payment was subject to the same vesting conditions (including any applicable acceleration provisions provided under the terms of the award) as applied to the share of Microsemi Stock to which such payment of the Merger Consideration relates; (f) each option to purchase shares of Microsemi Stock held by an individual subject to SAFE regulations that was outstanding and vested at the Effective Time was canceled and converted into the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per share of such unvested option, multiplied by (ii) the number of shares of Microsemi Stock issuable upon the exercise in full of such unvested option; provided that the right of the award holder to receive such cash payment was subject to the same vesting conditions (including any applicable acceleration provisions provided under the terms of the award) as applied to the option to which such payment of the Merger Consideration relates; and (h) each award of RSUs that was outstanding and unvested at the Effective Time held by an individual subject to SAFE regulations was canceled and converted into the right to receive an amount in cash equal to the product of (i) the number of vested RSUs subject to the award multiplied by (ii) the Merger Consideration; provided that the right of the award holder to receive such cash payment was subject to the same vesting conditions (including any applicable acceleration provisions provided under the terms of the award) as applied to the RSU to which such payment of the Merger Consideration relates. The aggregate value of the cash merger consideration paid to former equityholders of Microsemi by Co. in the Merger at the Effective Time, including for PSUs, vested RSUs and certain vested options, was approximately \$8,200,000,000,

without giving effect to related transaction fees and expenses.

#### MICROSEMI CORP

**Merger Completed** On May 29, 2018, Microchip Technology Inc. ("Parent") wholly-owned subsidiary, Maple Acquisition Corp. ("Merger Subsidiary"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Parent (the "Surviving Corporation"). As the result of the merger, each share of common stock, par value \$0.20, of Co. ("Co. Stock") (other than (1) treasury stock held by Co. or shares of Co. Stock held by Parent or any subsidiary of Co. or Parent, was cancelled without consideration and (2) shares of Co. Stock held by stockholders, if any, who properly exercise their appraisal rights under the General Corporation Law of the State of Delaware) outstanding immediately prior to the Merger) was automatically cancelled and converted into the right an amount equal to \$68.78 in cash, without interest (the "Merger Consideration"). In addition, (a) each outstanding option to purchase shares of Co. Stock (other than options held by individuals subject to China State Administration of Foreign Exchange ("SAFE") regulations) and stock appreciation right ("SAR") related to Co. Stock, whether vested or unvested, was assumed by Parent and became subject to the same terms and conditions as applied to the related option or SAR immediately prior to the Effective Time, except that (i) the number of shares of Parent's common stock subject to each assumed option or assumed SAR became equal to the product of the number of shares of Co. Stock underlying such assumed option or assumed SAR as of immediately prior to the Effective Time multiplied by the ratio of the Merger Consideration to the average closing sales price per share of Parent's common stock over the period of ten trading days ending on the last trading day before the closing of the Merger (the "equity award exchange ratio") and (ii) the per share exercise price of each assumed option or assumed SAR was determined by dividing the per share exercise price of the assumed option or assumed SAR immediately prior to the Effective Time by the equity award exchange ratio; (b) each award of time-based vesting stock units with respect to shares of Co. Stock ("RSUs") that was outstanding and vested immediately prior to the Effective Time (including those RSUs that became vested by their terms immediately prior to or as of the Effective Time) was canceled and converted into the right to receive an amount in cash equal to (i) the number of vested RSUs subject to the award multiplied by (ii) the Merger Consideration; (c) each award of RSUs that was outstanding and unvested at the Effective Time (other than outstanding and unvested RSUs held by individuals subject to SAFE regulations) was assumed by Parent and converted into a number of restricted stock units with respect to Parent's common stock determined by multiplying the number of unvested RSUs by the equity award exchange ratio; (d) each award of performance-based vesting stock units with respect to shares of Co. Stock ("PSUs") that was outstanding immediately prior to the Effective Time became vested as to a percentage of the total number of shares of Co. Stock subject to such award to be determined prior to the Effective Time by the compensation committee of Co.'s board of directors (the "Board") (which percentage was not less than 100% or greater than the maximum possible vesting percentage under the terms of the award) and was canceled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Merger Consideration over the exercise price per share of such unvested option, multiplied by (ii) the number of shares of Co. Stock issuable upon the exercise in full of such unvested option; provided that the right of the award holder to receive such cash payment was subject to the same vesting conditions (including any applicable acceleration provisions provided under the terms of the award) as applied to the option to which such payment of the Merger Consideration relates; (f) each option to purchase shares of Co. Stock held by an individual subject to SAFE regulations that was outstanding and unvested at the Effective Time was canceled and converted into the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per share of such unvested option, multiplied by (ii) the number of shares of Co. Stock issuable upon the exercise in full of such unvested option; provided that the right of the award holder to receive such cash payment was subject to the same vesting conditions (including any applicable acceleration provisions

provided under the terms of the award) as applied to the option to which such payment of the Merger Consideration relates; and (h) each award of RSUs that was outstanding and unvested at the Effective Time held by an individual subject to SAFE regulations was canceled and converted into the right to receive an amount in cash equal to the product of (i) the number of vested RSUs subject to the award multiplied by (ii) the Merger Consideration; provided that the right of the award holder to receive such cash payment was subject to the same vesting conditions (including any applicable acceleration provisions provided under the terms of the award) as applied to the RSU to which such payment of the Merger Consideration relates. The aggregate value of the cash merger consideration paid to former equityholders of Co. by Parent in the Merger at the Effective Time, including for PSUs, vested RSUs and certain vested options, was approximately \$8,200,000,000, without giving effect to related transaction fees and expenses.

#### MICROVISION INC.

**Earnings, 3 mos. to Mar 31**(Consol. – \$):

	2018	2017
Total Revenues	2,188,000	568,000
Cost & expenses	9,308,000	6,514,000
Operating income	(7,120,000)	(5,946,000)
Other income (expense), net	(12,000)	(3,000)
<b>Net income</b>	<b>(7,132,000)</b>	<b>(5,949,000)</b>
Earnings common share		
Primary	\$(0.09)	\$(0.09)
Fully Diluted	\$(0.09)	\$(0.09)
Common Shares:		
Full Diluted	78,610,000	68,113,000
Year-end	78,613,000	

#### Consolidated Balance Sheet Items, as of (\$):

	2018	2017
Assets:		
Cash & equivalents	7,228,000	
Inventories	4,519,000	
Current assets	16,054,000	
Net property & equip.	2,950,000	
Total assets	22,518,000	
Liabilities:		
Current liabilities	18,703,000	
Stockholders' equity	3,286,000	
Net current assets	(2,649,000)	

#### MINDBODY INC

**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Total Revenues	53,823	42,214
Cost & expenses	57,977	45,687
Operating income	(4,154)	(3,473)
Other income (expense), net	39	(80)
Net before taxes	(3,749)	(3,767)
Income taxes	(2,058)	142
<b>Net income</b>	<b>(1,691)</b>	<b>(3,909)</b>
Balance for common	(1,691)	(3,909)
Earnings common share		
Primary	\$(0.04)	\$(0.10)
Fully Diluted	\$(0.04)	\$(0.10)
Common Shares:		
Full Diluted	47,106	40,757
Year-end	47,420	40,957

#### Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	217,708	
Current assets	237,235	
Net property & equip.	33,185	
Total assets	312,066	
Liabilities:		
Current liabilities	29,287	
Long-term debt	14,789	
Stockholders' equity	263,788	
Net current assets	207,948	

#### MOBILEIRON INC

**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Total Revenues	43,689	42,109
Cost & expenses	60,215	55,457
Operating income	(16,526)	(13,348)
Other income (expense), net	503	174
Net before taxes	(16,023)	(13,174)
Income taxes	347	199
<b>Net income</b>	<b>(16,370)</b>	<b>(13,373)</b>
Earnings common share		
Primary	\$(0.17)	\$(0.15)
Fully Diluted	\$(0.17)	\$(0.15)

Common Shares:		
Full Diluted	98,645	90,439
Year-end	100,608	
<b>Consolidated Balance Sheet Items, as of (\$000):</b>		
Assets:	2018	
Cash & equivalents	96,311	
Current assets	150,215	
Net property & equip.	8,205	
Total assets	175,654	
Liabilities:		
Current liabilities	92,124	
Stockholders' equity	58,380	
Net current assets	58,091	

**NANOSTRING TECHNOLOGIES INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	23,085	18,063
Net Sales	18,045	15,765
Cost & expenses	40,964	35,529
Operating income	(17,879)	(17,466)
Interest income	238	147
Interest expense	1,563	1,501
Other income (expense), net	65	13
Net before taxes	(19,139)	(18,807)
Income taxes	63	45
<b>Net income</b>	(19,202)	(18,852)
Earnings common share		
Primary	\$(0.75)	\$(0.87)
Fully Diluted	\$(0.75)	\$(0.87)
Common Shares:		
Full Diluted	25,479	21,588
Year-end	25,696	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	
Cash & equivalents	15,649	
Inventories	19,065	
Current assets	101,661	
Net property & equip.	14,450	
Total assets	116,797	
Liabilities:		
Current liabilities	30,924	
Long-term debt	49,325	
Stockholders' equity	25,013	
Net current assets	70,737	

**NANTHEALTH INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	22,263	19,104
Cost & expenses	36,956	37,879
Operating income	(15,747)	(19,829)
Interest expense	4,197	3,969
Other income (expense), net	(3,081)	(4,291)
Net before taxes	(23,025)	(28,089)
Income taxes	(1,050)	37
Income contin. oper.	(21,975)	(28,126)
<b>Net income</b>	(22,168)	(41,115)
Earnings common share		
Primary	\$(0.20)	\$(0.34)
Fully Diluted	\$(0.20)	\$(0.34)
Common Shares:		
Full Diluted	108,579	121,618
Year-end	108,592	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	
Cash & equivalents	46,390	
Inventories	805	
Current assets	69,545	
Net property & equip.	23,570	
Total assets	431,325	
Liabilities:		
Current liabilities	36,615	
Long-term debt	196,652	
Stockholders' equity	171,038	
Net current assets	32,930	

**NAPCO SECURITY TECHNOLOGIES, INC.****Earnings, 9 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	60,349	58,774
Operating income	4,137	2,916
Interest expense	67	59

Net before taxes	4,070	2,857
Income taxes	118	480
<b>Net income</b>	3,952	2,377
Earnings common share		
Primary	\$0.21	\$0.13
Fully Diluted	\$0.21	\$0.13
Common Shares:		
Full Diluted	18,845	18,844
Year-end	18,717	18,845

**NATERA INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	62,340	49,382
Cost & expenses	92,857	83,932
Operating income	(30,517)	(34,550)
Other income (expense), net	137	1,300
Net before taxes	(32,769)	(33,433)
Income taxes	104	47
<b>Net income</b>	(32,873)	(33,480)
Earnings common share		
Primary	\$(0.61)	\$(0.63)
Fully Diluted	\$(0.61)	\$(0.65)
Common Shares:		
Full Diluted	54,132	53,043
Year-end	54,251	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	
Cash & equivalents	33,674	
Inventories	11,911	
Current assets	187,523	
Net property & equip.	26,878	
Total assets	218,655	
Liabilities:		
Current liabilities	104,383	
Long-term debt	82,686	
Stockholders' equity	(3,876)	
Net current assets	83,140	

**NATIONAL COMMERCE CORP****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	28,250	20,738
Operating income	12,315	9,253
Net before taxes	12,315	9,253
Income taxes	2,776	2,841
<b>Net income</b>	9,539	6,412
Earnings common share		
Primary	\$0.53	\$0.46
Fully Diluted	\$0.52	\$0.45
Common Shares:		
Full Diluted	17,612	13,283
Year-end	17,229	12,949

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	
Cash & equivalents	132,825	
Current assets	132,825	
Net property & equip.	65,500	
Total assets	3,113,766	
Liabilities:		
Current liabilities	2,551,517	
Long-term debt	31,567	
Stockholders' equity	498,335	
Net current assets	(2,418,692)	

**NATURAL ALTERNATIVES INTERNATIONAL, INC.****Earnings, 9 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	93,224,000	89,761,000
Cost & expenses	86,537,000	82,119,000
Operating income	6,687,000	7,642,000
Interest income	823,000	358,000
Interest expense	6,000	1,000
Other income (expense), net	(18,000)	(21,000)
Foreign currency	(413,000)	158,000
Net before taxes	7,073,000	8,136,000
Income taxes	4,906,000	2,435,000
<b>Net income</b>	2,167,000	5,701,000
Earnings common share		
Primary	\$0.33	\$0.87
Fully Diluted	\$0.32	\$0.86
Common Shares:		
Full Diluted	6,860,870	6,648,091
Year-end	7,568,817	6,933,352

**NCS MULTISTAGE HOLDINGS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	70,686	58,636
Cost & expenses	53,266	42,126
Operating income	13,000	9,924
Interest expense	457	1,509
Other income (expense), net	84	974
Foreign currency	183	(941)
Net before taxes	12,810	8,448
Income taxes	945	2,100
<b>Net income</b>	11,865	6,348

**Earnings common share**

Primary	\$0.24	\$0.18
Fully Diluted	\$0.23	\$0.18
Common Shares:		
Full Diluted	47,114	36,746
Year-end	44,631	34,006

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	
Cash & equivalents	23,680	
Inventories	30,397	
Current assets	117,665	
Net property & equip.	24,385	
Total assets	455,969	
Liabilities:		
Current liabilities	31,876	
Long-term debt	22,060	
Stockholders' equity	364,110	
Net current assets	85,789	

**NET 1 UEPS TECHNOLOGIES INC****Earnings, 9 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	463,695	455,010
Cost & expenses	387,788	341,576
Operating income	48,877	82,317
Interest income	14,903	14,489
Interest expense	6,872	1,773
Equity earnings	(7,389)	(778)
Net before taxes	56,908	95,033
Income taxes	31,280	32,320
<b>Net income</b>	33,017	63,491
Earnings common share		
Primary	\$0.57	\$1.16
Fully Diluted	\$0.56	\$1.16
Common Shares:		
Full Diluted	55,928	52,181
Year-end	56,855	57,590

**NEWLINK GENETICS CORP****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	9,900	2,761
Cost & expenses	28,606	23,959
Operating income	(18,706)	(21,198)
Interest income	385	85
Interest expense	13	106
Other income (expense), net	24	(4)
Net before taxes	(18,310)	(21,223)
Income taxes	(310)	
<b>Net income</b>	(18,310)	(20,913)
Balance for common	(18,310)	(20,913)
Earnings common share		
Primary	\$(0.49)	\$(0.72)
Fully Diluted	\$(0.49)	\$(0.72)
Common Shares:		
Full Diluted	37,155	29,213
Year-end	37,165	29,220

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	
Cash & equivalents	143,891	
Current assets	160,199	
Net property & equip.	4,698	
Total assets	165,037	
Liabilities:		
Current liabilities	20,018	
Long-term debt	90	
Stockholders' equity	137,954	
Net current assets	140,181	



Current liabilities	9,110
Long-term debt	6,973
Stockholders' equity	24,424
Net current assets	29,975

**OFS CAPITAL CORP****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	9,003	8,034
Cost & expenses	5,187	4,694
<b>Net income</b>	<b>3,816</b>	<b>3,340</b>
Earnings common share		
Primary	\$0.29	\$0.34
Fully Diluted	\$0.29	\$0.34
Common Shares:		
Full Diluted	13,341	9,700
Year-end	13,349	9,703

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	31,926
Current assets	34,841
Total assets	374,701
Liabilities:	
Current liabilities	3,832
Long-term debt	188,266
Stockholders' equity	182,453
Net current assets	31,009

**OPHTHOTECH CORP****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	1,662	1,662
Cost & expenses	13,331	45,138
Operating income	(13,331)	(43,476)
Other income (expense), net	(16)	(21)
Net before taxes	(12,874)	(43,119)
Income taxes	199	3
<b>Net income</b>	<b>(13,073)</b>	<b>(43,122)</b>
Earnings common share		
Primary	\$(0.36)	\$(1.20)
Fully Diluted	\$(0.36)	\$(1.20)
Common Shares:		
Full Diluted	36,153	35,804
Year-end	36,164	35,820

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	154,911
Current assets	157,747
Net property & equip.	468
Total assets	161,551
Liabilities:	
Current liabilities	8,474
Stockholders' equity	28,077
Net current assets	149,273

**ORIGIN BANCORP INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	35,053	35,576
Operating income	16,191	9,827
Net before taxes	16,191	9,827
Income taxes	2,784	2,580
<b>Net income</b>	<b>13,407</b>	<b>7,247</b>
Balance for common	11,739	5,865
Earnings common share		
Primary	\$0.60	\$0.30
Fully Diluted	\$0.60	\$0.30
Common Shares:		
Full Diluted	19,678	19,595
Year-end	19,525	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	247,257
Current assets	247,257
Net property & equip.	76,648
Total assets	4,214,899
Liabilities:	
Current liabilities	3,712,962
Long-term debt	9,625
Stockholders' equity	427,833
Net current assets	(3,465,705)

**OTC MARKETS GROUP INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	9,540,000	8,743,000
Deprec., depl. & amort.	252,000	395,000
Operating income	4,550,000	4,238,000
Interest income	7,000	3,000
Other income (expense), net	10,000	11,000
Net before taxes	4,567,000	4,252,000
Income taxes	820,000	1,202,000
<b>Net income</b>	<b>3,747,000</b>	<b>3,050,000</b>
Earnings common share		
Primary	\$0.33	\$0.27
Fully Diluted	\$0.31	\$0.26
Common Shares:		
Full Diluted	11,609,635	11,519,624
Year-end	11,506,948	11,421,242

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	22,740,000
Current assets	30,929,000
Net property & equip.	1,873,000
Total assets	34,645,000
Liabilities:	
Current liabilities	17,820,000
Stockholders' equity	15,447,000
Net current assets	13,109,000

**OTONOMY INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	301	358
Cost & expenses	12,079	27,740
Operating income	(11,778)	(27,382)
Interest income	354	304
<b>Net income</b>	<b>(11,424)</b>	<b>(27,078)</b>
Earnings common share		
Primary	\$(0.37)	\$(0.89)
Fully Diluted	\$(0.37)	\$(0.89)
Common Shares:		
Full Diluted	30,569	30,257
Year-end	30,578	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	23,217
Current assets	112,714
Net property & equip.	4,517
Total assets	118,472
Liabilities:	
Current liabilities	6,946
Stockholders' equity	108,604
Net current assets	105,768

**OID THERAPEUTICS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	13,429,864	34,262,293
Operating income	(13,429,864)	(34,262,293)
<b>Net income</b>	<b>(13,182,758)</b>	<b>(34,238,810)</b>
Balance for common	(13,182,758)	(34,238,810)
Earnings common share		
Primary	\$(0.54)	\$(3.48)
Fully Diluted	\$(0.54)	\$(3.48)
Common Shares:		
Full Diluted	24,609,050	9,838,590
Year-end	24,617,979	9,838,590

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	29,202,559
Current assets	75,688,240
Net property & equip.	52,083
Total assets	78,667,463
Liabilities:	
Current liabilities	6,579,264
Stockholders' equity	72,088,199
Net current assets	69,108,976

**PAIN THERAPEUTICS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	2,167,000	2,764,000
Operating income	(2,167,000)	(2,764,000)
<b>Net income</b>	<b>(2,160,000)</b>	<b>(2,743,000)</b>
Earnings common share		
Primary	\$(0.33)	\$(0.42)

Fully Diluted	\$(0.33)	\$(0.42)
Common Shares:		
Full Diluted	6,638,000	6,534,571
Year-end	6,895,509	6,591,705

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	10,734,000
Current assets	10,889,000
Net property & equip.	139,000
Total assets	11,058,000
Liabilities:	
Current liabilities	758,000
Stockholders' equity	10,300,000
Net current assets	10,131,000

**PAPA MURPHY'S HOLDINGS INC****Earnings, 3 mos. to (Consol. - \$000):**

	04/02/18	04/03/17
Total Revenues	34,772	40,173
Cost & expenses	29,127	44,673
Deprec., depl. & amort.	2,141	3,117
Operating income	3,504	(7,617)
Other income (expense), net	(51)	(43)
Net before taxes	2,161	(8,887)
Income taxes	581	(3,680)
<b>Net income</b>	<b>1,580</b>	<b>(5,207)</b>
Earnings common share		
Primary	\$0.09	\$(0.31)
Fully Diluted	\$0.09	\$(0.31)
Common Shares:		
Full Diluted	16,945	16,839
Year-end	16,971	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	1,519
Inventories	819
Current assets	9,450
Net property & equip.	7,978
Total assets	259,892
Liabilities:	
Current liabilities	30,317
Long-term debt	98,339
Stockholders' equity	95,907
Net current assets	(20,867)

**PARATEK PHARMACEUTICALS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	26,722,000	26,789,000
Operating income	(26,712,000)	(26,771,000)
Interest expense	1,507,000	1,132,000
Other income (expense), net	(6,000)	(7,000)
<b>Net income</b>	<b>(27,750,000)</b>	<b>(27,670,000)</b>
Earnings common share		
Primary	\$(0.91)	\$(1.14)
Fully Diluted	\$(0.91)	\$(1.14)
Common Shares:		
Full Diluted	30,566,694	24,196,158
Year-end	31,443,149	

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	49,273,000
Current assets	188,228,000
Net property & equip.	1,583,000
Total assets	191,292,000
Liabilities:	
Current liabilities	23,365,000
Long-term debt	51,684,000
Stockholders' equity	110,767,000
Net current assets	164,863,000

**PARK-OHIO HOLDINGS CORP.****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	405,700	343,800
Cost & expenses	383,600	323,300
Operating income	22,100	20,500
Interest expense	8,400	7,400
Other income (expense), net	2,300	1,700
Net before taxes	16,000	14,800
Income taxes	5,800	4,700
<b>Net income</b>	<b>10,200</b>	<b>10,100</b>
Earnings common share		



Primary .....	\$0.80	\$0.80
Fully Diluted .....	\$0.78	\$0.79
Common Shares:		
Full Diluted .....	12,500	12,500
Year-end .....	12,488	12,558

<b>Consolidated Balance Sheet Items, as of (\$000):</b>		
Assets:		
Cash & equivalents .....	89,200	2018
Inventories .....	299,700	2017
Current assets .....	740,600	
Net property & equip. ....	196,400	
Total assets .....	1,233,700	
Liabilities:		
Current liabilities .....	299,600	
Long-term debt .....	568,700	
Stockholders' equity .....	292,400	
Net current assets .....	441,000	

**PATRIOT TRANSPORTATION HOLDING INC (NEW)**

<b>Earnings, 6 mos. to Mar 31(Consol. - \$000):</b>		
	2018	2017
Total Revenues .....	55,880	56,151
Cost & expenses .....	50,875	49,719
Operating income .....	452	1,573
Interest income .....	33	3
Interest expense .....	19	64
Net before taxes .....	466	1,512
Income taxes .....	(2,938)	340
<b>Net income</b> .....	3,404	1,172
Earnings common share		
Primary .....	\$1.03	\$0.36
Fully Diluted .....	\$1.03	\$0.35
Common Shares:		
Full Diluted .....	3,311	3,303
Year-end .....	3,323	3,304

**PATTERN ENERGY GROUP INC**

<b>Earnings, 3 mos. to Mar 31(Consol. - \$):</b>		
	2018	2017
Total Revenues .....	111,659,000	100,833,000
Cost & expenses .....	111,978,000	87,460,000
Operating income .....	(319,000)	13,373,000
Interest expense .....	25,444,000	22,555,000
Other income (expense), net .....	21,025,000	16,808,000
Gains or losses .....	(1,098,000)	(312,000)
Net before taxes .....	(5,836,000)	7,314,000
Income taxes .....	6,784,000	4,775,000
<b>Net income</b> .....	(12,620,000)	2,539,000
Balance for common .....	135,801,000	5,630,000
Earnings common share		
Primary .....	\$1.39	\$0.06
Fully Diluted .....	\$1.32	\$0.06
Common Shares:		
Full Diluted .....	105,564,491	87,131,280
Year-end .....	98,096,760	87,616,747

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		
Cash & equivalents .....	162,144,000	2018
Current assets .....	315,113,000	2017
Net property & equip. ....	4,340,973,000	
Total assets .....	5,421,642,000	
Liabilities:		
Current liabilities .....	460,936,000	
Long-term debt .....	2,128,063,000	
Stockholders' equity .....	1,188,366,000	
Net current assets .....	(145,823,000)	

**PC-TEL INC**

<b>Earnings, 3 mos. to Mar 31(Consol. - \$):</b>		
	2018	2017
Total Revenues .....	21,731,000	22,970,000
Cost & expenses .....	22,828,000	22,824,000
Operating income .....	(1,221,000)	22,000
Other income (expense), net .....	1,000	(2,000)
Foreign currency .....	(69,000)	(12,000)
Net before taxes .....	(1,170,000)	50,000
Income taxes .....	(312,000)	(134,000)
Income contin. oper. ....		184,000
<b>Net income</b> .....	(858,000)	(30,000)
Earnings common share		
Primary .....	\$(0.05)	\$.....
Fully Diluted .....	\$(0.05)	\$.....
Common Shares:		
Full Diluted .....	17,056,000	16,340,000

Year-end .....	18,258,643
----------------	------------

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	
Cash & equivalents .....	12,452,000
Inventories .....	12,582,000
Current assets .....	68,219,000
Net property & equip. ....	12,537,000
Total assets .....	94,043,000
Liabilities:	
Current liabilities .....	11,013,000
Long-term debt .....	155,000
Stockholders' equity .....	82,545,000
Net current assets .....	57,206,000

**PCM, INC**

<b>Earnings, 3 mos. to Mar 31(Consol. - \$000):</b>		
	2018	2017
Net Sales .....	542,832	522,760
Cost & expenses .....	536,590	518,049
Operating income .....	6,242	4,711
Interest expense .....	2,462	1,653
Other income (expense), net .....	175	138
Net before taxes .....	3,955	3,196
Income taxes .....	1,144	(976)
<b>Net income</b> .....	2,811	4,172
Earnings common share		
Primary .....	\$0.24	\$0.34
Fully Diluted .....	\$0.23	\$0.31
Common Shares:		
Full Diluted .....	12,153	13,452
Year-end .....	11,830	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	
Cash & equivalents .....	12,225
Inventories .....	75,469
Current assets .....	536,865
Net property & equip. ....	70,733
Total assets .....	712,241
Liabilities:	
Current liabilities .....	538,409
Long-term debt .....	31,984
Stockholders' equity .....	131,074
Net current assets .....	(1,544)

**PDF SOLUTIONS INC.**

<b>Earnings, 3 mos. to Mar 31(Consol. - \$000):</b>		
	2018	2017
Total Revenues .....	24,737	24,289
Cost & expenses .....	25,102	24,612
Operating income .....	(474)	(415)
Net before taxes .....	(805)	(645)
Income taxes .....	(381)	(1,162)
<b>Net income</b> .....	(424)	517
Earnings common share		
Primary .....	\$(0.01)	\$0.02
Fully Diluted .....	\$(0.01)	\$0.02
Common Shares:		
Full Diluted .....	32,168	33,594
Year-end .....	31,964	32,124

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	
Cash & equivalents .....	98,522
Current assets .....	166,612
Net property & equip. ....	26,536
Total assets .....	226,540
Liabilities:	
Current liabilities .....	18,535
Stockholders' equity .....	202,059
Net current assets .....	148,077

**PDL BIOPHARMA INC**

<b>Earnings, 3 mos. to Mar 31(Consol. - \$):</b>		
	2018	2017
Total Revenues .....	38,518,000	45,440,000
Cost & expenses .....	27,933,000	20,920,000
Operating income .....	4,292,000	18,505,000
Net before taxes .....	2,621,000	13,746,000
Income taxes .....	1,019,000	6,552,000
<b>Net income</b> .....	1,602,000	7,194,000
Earnings common share		
Primary .....	\$0.01	\$0.04
Fully Diluted .....	\$0.01	\$0.04
Common Shares:		

Full Diluted .....	152,579,000	163,992,000
Year-end .....	152,812,000	163,724,000

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	
Cash & equivalents .....	405,078,000
Inventories .....	14,012,000
Current assets .....	510,944,000
Net property & equip. ....	7,557,000
Total assets .....	1,100,401,000
Liabilities:	
Current liabilities .....	50,963,000
Long-term debt .....	119,166,000
Stockholders' equity .....	843,109,000
Net current assets .....	459,981,000

**PENNANTPARK INVESTMENT CORPORATION**

<b>Earnings, 6 mos. to Mar 31(Consol. - \$):</b>		
	2018	2017
Cost & expenses .....	28,310,544	34,374,359
<b>Net income</b> .....	27,583,490	31,209,544
Earnings common share		
Primary .....	\$0.39	\$0.44
Fully Diluted .....	\$0.39	\$0.44
Common Shares:		
Full Diluted .....	71,060,836	71,060,836
Year-end .....	71,060,836	71,060,836

**PERFORMANT FINANCIAL CORP**

<b>Earnings, 3 mos. to Mar 31(Consol. - \$000):</b>		
	2018	2017
Total Revenues .....	57,021	33,109
Cost & expenses .....	44,801	34,137
Operating income .....	12,220	(1,028)
Interest income .....	6	
Interest expense .....	1,270	1,606
Net before taxes .....	10,956	(2,634)
Income taxes .....	2,501	325
<b>Net income</b> .....	8,455	(2,959)
Earnings common share		
Primary .....	\$0.16	\$(0.06)
Fully Diluted .....	\$0.16	\$(0.06)
Common Shares:		
Full Diluted .....	53,455	50,304
Year-end .....	51,495	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	
Cash & equivalents .....	8,663
Current assets .....	37,194
Net property & equip. ....	21,071
Total assets .....	146,279
Liabilities:	
Current liabilities .....	15,272
Long-term debt .....	38,321
Stockholders' equity .....	89,236
Net current assets .....	21,922

**PERNIX THERAPEUTICS HOLDINGS INC**

<b>Earnings, 3 mos. to Mar 31(Consol. - \$):</b>		
	2018	2017
Total Revenues .....	28,139,000	29,742,000
Cost & expenses .....	27,340,000	31,289,000
Deprec., depl. & amort. ....	9,865,000	18,547,000
Operating income .....	(9,066,000)	(20,094,000)
Interest expense .....	9,460,000	8,959,000
Other income (expense), net .....	(19,000)	(354,000)
Net before taxes .....	(18,545,000)	(29,407,000)
Income taxes .....	39,000	55,000
<b>Net income</b> .....	(18,584,000)	(29,462,000)
Earnings common share		
Primary .....	\$(1.57)	\$(2.94)
Fully Diluted .....	\$(1.57)	\$(2.94)
Common Shares:		
Full Diluted .....	11,869,000	10,016,000
Year-end .....	11,873,562	10,015,641

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	
Cash & equivalents .....	26,942,000
Inventories .....	5,407,000
Current assets .....	76,713,000
Net property & equip. ....	670,000
Total assets .....	178,401,000
Liabilities:	
Current liabilities .....	87,475,000

Long-term debt	278,829,000
Stockholders' equity	(192,441,000)
Net current assets	(10,762,000)

**PERSHING GOLD CORP****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	4,029,825	3,320,630
Operating income	(4,029,825)	(3,320,630)
Foreign currency	(1,097)	(11,155)
<b>Net income</b>	<b>(4,028,590)</b>	<b>(3,333,739)</b>
Balance for common	(4,028,590)	(3,333,739)
Earnings common share		
Primary	\$(0.12)	\$(0.12)
Fully Diluted	\$(0.12)	\$(0.12)
Common Shares:		
Full Diluted	33,578,179	28,388,153
Year-end	33,629,260	28,384,043

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	9,602,191
Current assets	10,627,161
Net property & equip.	3,157,873
Total assets	40,413,570
Liabilities:	
Current liabilities	2,060,070
Stockholders' equity	37,381,384
Net current assets	8,567,091

**PIONEER POWER SOLUTIONS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	23,475,000	25,057,000
Cost & expenses	23,319,000	23,924,000
Operating income	156,000	1,133,000
Other income (expense), net	(116,000)	(98,000)
Net before taxes	(609,000)	486,000
Income taxes	(28,000)	280,000
Income contin. oper.	(581,000)	206,000
<b>Net income</b>	<b>(574,000)</b>	<b>109,000</b>
Earnings common share		
Primary	\$(0.07)	\$0.01
Fully Diluted	\$(0.07)	\$0.01
Common Shares:		
Full Diluted	8,726,000	8,737,000
Year-end	8,726,045	

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	268,000
Inventories	24,570,000
Current assets	48,662,000
Net property & equip.	6,175,000
Total assets	75,460,000
Liabilities:	
Current liabilities	49,142,000
Long-term debt	3,817,000
Stockholders' equity	16,942,000
Net current assets	(480,000)

**PIXELWORKS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	15,292	22,710
Cost & expenses	16,586	19,363
Operating income	(1,294)	3,347
Other income (expense), net	1,272	
Net before taxes	(322)	3,254
Income taxes	276	433
<b>Net income</b>	<b>(598)</b>	<b>2,821</b>
Earnings common share		
Primary	\$(0.02)	\$0.10
Fully Diluted	\$(0.02)	\$0.09
Common Shares:		
Full Diluted	35,183	31,146
Year-end	35,583	29,558

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	20,611
Inventories	2,589
Current assets	31,387
Net property & equip.	5,871
Total assets	62,463
Liabilities:	

Current liabilities	16,021
Stockholders' equity	42,916
Net current assets	15,366

**PLURALSIGHT INC****Annual Report****Consolidated Income Statement, Years Ended Dec. 31****(\$000):**

	2017	2016
Total revenues	166,824	131,841
Cost of revenues	49,828	40,161
Gross profit	116,996	91,680
Sales & marketing expenses	103,478	51,234
Technology & content	49,293	36,159
General & administrative expenses	46,971	18,130
Total operating expenses	199,742	105,523
Income (loss) from operations	...	(13,843)
Interest expense	11,665	6,320
Gain (loss) on debt extinguishment	(1,882)	...
Other (expense)/income, net	81	45
Income before income taxes - Domestic	(96,814)	(20,466)
Income before income taxes - Foreign	602	348
Income (loss) before provision for income taxes	(96,212)	(20,118)
Current state income taxes	10	15
Current foreign income taxes	397	479
Current income taxes	407	494
Deferred foreign income taxes	(83)	...
Deferred income taxes	(83)	...
Income tax expense (benefit)	324	494
<b>Net income (loss)</b>	<b>(96,536)</b>	<b>(20,612)</b>
Less: accretion of series A redeemable convertible preferred units	63,800	6,325
Net income (loss) attributable to common units	(160,336)	(26,937)
Weighted average units outstanding - basic	47,957	47,480
Weighted average units outstanding - diluted	47,957	47,480
Year end units outstanding	48,408	47,782
Net earnings (loss) per unit - basic	\$(3.34)	\$(0.57)
Net earnings (loss) per unit - diluted	\$(3.34)	\$(0.57)
Total number of employees	279	...

□ As is; □ As of March 31, 2018

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**

	2017	2016
Cash & cash equivalents	28,267	19,397
Accounts receivable, gross	39,781	23,658
Allowance	1,552	708
Accounts receivable, net	38,229	22,950
Prepaid expenses	4,586	2,424
Other current assets	539	134
Prepaid expenses & other current assets	5,125	2,558
Total current assets	71,621	44,905
Computer equipment	7,482	5,075
Software	1,982	1,788
Capitalized internal-use software costs	8,631	5,074
Furniture & fixtures	5,234	4,784
Buildings	11,251	11,251
Leasehold improvements	1,324	1,283
Construction in progress	587	749

Total property & equipment, gross	36,491	30,004
Less: Accumulated depreciation	14,034	7,359
Property & equipment, net	22,457	22,645
Content library, net	13,441	19,593
Intangible assets, net	2,854	4,372
Goodwill	123,119	123,119
Other assets	2,928	338
Total assets	236,420	214,972
Accounts payable	6,029	2,936
Accrued compensation	18,568	755
Accrued income & other taxes payable	3,492	2,220
Accrued other current liabilities	4,454	4,034
Accrued expenses	36,514	7,009
Accrued author fees	7,879	5,748
Deferred revenues	103,107	71,966
Current maturities of long-term debt	...	10,000
Total current liabilities	143,529	97,659
Deferred revenue, net of current portion	8,194	717
Long-term debt, net	116,037	74,069
Facility financing obligation	7,513	7,529
Other liabilities	458	262
Total liabilities	275,731	180,236
Redeemable convertible preferred units	405,766	341,966
Accumulated other comprehensive income (loss)	25	(8)
Retained earnings (accumulated deficit)	(445,102)	(307,222)
Total members' deficit	(445,077)	(307,230)

**Recent Dividends:****1. Pluralsight Inc class A common.**

No dividends paid.

**2. Pluralsight Inc class C common.**

No dividends paid.

**3. Pluralsight Inc class B common.**

No dividends paid.

**Annual Dividends:****1. Pluralsight Inc class A common.**

No dividends paid.

**2. Pluralsight Inc class C common.**

No dividends paid.

**3. Pluralsight Inc class B common.**

No dividends paid.

**PLURALSIGHT INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	49,644	37,239
Cost & expenses	68,970	45,507
Operating income	(19,326)	(8,268)
Interest expense	3,710	1,527
Other income (expense), net	(13)	48
Net before taxes	(23,049)	(9,747)
Income taxes	109	58
<b>Net income</b>	<b>(23,158)</b>	<b>(9,805)</b>
Balance for common	(42,683)	(11,455)
Earnings common share		
Primary	\$(0.88)	\$(0.24)
Fully Diluted	\$(0.88)	\$(0.24)
Common Shares:		
Full Diluted	48,408	47,783
Year-end	48,408	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	32,359
Current assets	70,428
Net property & equip.	22,014
Total assets	234,002
Liabilities:	
Current liabilities	141,519
Long-term debt	142,986
Stockholders' equity	(483,398)
Net current assets	(71,091)









Assets:		2018
Cash & equivalents	985,824	
Inventories	1,600,058	
Current assets	3,652,242	
Net property & equip.	2,657,937	
Total assets	6,972,813	
Liabilities:		
Current liabilities	860,740	
Long-term debt	2,353,703	
Stockholders' equity	3,470,719	
Net current assets	2,791,502	

**STRATTEC SECURITY CORP.****Earnings, 9 mos. to (Consol. – \$000):**

	04/01/18	04/02/17
Net Sales	322,465	308,895
Cost & expenses	312,192	297,105
Operating income	10,273	11,790
Interest income	8	132
Other income (expense), net	2,486	1,000
Gains or losses	1,159	(1,271)
Foreign currency	(173)	1,775
Net before taxes	12,992	13,150
Income taxes	1,956	4,060
<b>Net income</b>	<b>11,036</b>	<b>9,090</b>
Balance for common	8,307	5,422
Earnings common share		
Primary	\$2.29	\$1.51
Fully Diluted	\$2.24	\$1.48
Common Shares:		
Full Diluted	3,702	3,666
Year-end	3,634	3,594

**SUNPOWER CORP****Earnings, 3 mos. to (Consol. – \$000):**

	04/01/18	04/02/17
Total Revenues	391,888	329,095
Cost & expenses	525,930	472,387
Operating income	(134,042)	(143,292)
Interest income	529	938
Interest expense	25,106	20,902
Other income (expense), net	15,794	(74,088)
Equity earnings	2,144	(2,488)
Net before taxes	(142,825)	(237,344)
Income taxes	2,628	2,031
<b>Net income</b>	<b>(147,597)</b>	<b>(236,887)</b>
Earnings common share		
Primary	\$(0.83)	\$(1.58)
Fully Diluted	\$(0.83)	\$(1.58)
Common Shares:		
Full Diluted	140,212	138,902
Year-end	140,848	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents	260,672	
Inventories	354,611	
Current assets	1,204,963	
Net property & equip.	1,137,083	
Total assets	3,782,723	
Liabilities:		
Current liabilities	964,731	
Long-term debt	1,248,585	
Stockholders' equity	477,159	
Net current assets	240,232	

**SUNRUN INC****Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	144,363	105,109
Cost & expenses	200,023	152,780
Operating income	(56,711)	(48,722)
Interest expense	28,198	20,558
Other income (expense), net	1,692	(475)
Net before taxes	(83,217)	(69,755)
Income taxes	8,203	5,400
<b>Net income</b>	<b>(91,420)</b>	<b>(75,155)</b>
Earnings common share		
Primary	\$0.26	\$0.09
Fully Diluted	\$0.25	\$0.09
Common Shares:		
Full Diluted	110,781	106,469
Year-end	108,681	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents	203,189	
Inventories	87,902	
Current assets	459,815	
Net property & equip.	33,291	
Total assets	4,101,231	
Liabilities:		
Current liabilities	300,288	
Long-term debt	1,492,669	
Stockholders' equity	934,679	
Net current assets	159,527	

**SURFACE ONCOLOGY INC****Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	45,495	1,672
Cost & expenses	14,452	10,226
Operating income	31,043	(8,554)
Other income (expense), net	169	142
Net before taxes	(8,412)	(8,412)
Income taxes	214	
<b>Net income</b>	<b>31,212</b>	<b>(8,626)</b>
Balance for common	4,335	(8,636)
Earnings common share		
Primary	\$1.59	\$(3.60)
Fully Diluted	\$1.05	\$(3.60)
Common Shares:		
Full Diluted	4,135	2,399
Year-end	2,767	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents	59,288	
Current assets	101,230	
Net property & equip.	7,072	
Total assets	112,016	
Liabilities:		
Current liabilities	24,176	
Stockholders' equity	(20,979)	
Net current assets	77,054	

**SURGERY PARTNERS INC****Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	417,369	286,183
Cost & expenses	360,457	233,354
Deprec., depl. & amort.	15,749	11,108
Operating income	41,163	41,721
Interest expense	34,276	25,182
Net before taxes	6,887	16,539
Income taxes	1,762	2,117
<b>Net income</b>	<b>5,125</b>	<b>14,422</b>
Balance for common	(25,293)	(2,754)
Earnings common share		
Primary	\$(0.53)	\$(0.06)
Fully Diluted	\$(0.53)	\$(0.06)
Common Shares:		
Full Diluted	48,007	48,020
Year-end	48,898	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents	112,816	
Inventories	48,101	
Current assets	490,579	
Net property & equip.	400,385	
Total assets	4,594,884	
Liabilities:		
Current liabilities	285,752	
Long-term debt	2,122,447	
Stockholders' equity	630,664	
Net current assets	204,827	

**SYNACOR, INC.****Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	32,915	26,540
Cost & expenses	32,857	30,485
Deprec., depl. & amort.	2,435	2,184
Operating income	(2,377)	(6,129)
Interest expense	97	87
Other income (expense), net	119	6
Net before taxes	(2,355)	(6,210)
Income taxes	20	446
<b>Net income</b>	<b>(2,375)</b>	<b>(6,656)</b>
Earnings common share		

Primary	\$(0.06)	\$(0.21)
Fully Diluted	\$(0.06)	\$(0.21)
Common Shares:		
Full Diluted	38,794	31,045
Year-end	38,797	31,822

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents	16,425	
Current assets	46,345	
Net property & equip.	20,621	
Total assets	95,724	
Liabilities:		
Current liabilities	34,142	
Long-term debt	2,770	
Stockholders' equity	54,930	
Net current assets	12,203	

**SYNDAX PHARMACEUTICALS INC****Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	379	305
Cost & expenses	20,130	13,482
Operating income	(19,751)	(13,177)
Other income (expense), net	(122)	(53)
<b>Net income</b>	<b>(19,398)</b>	<b>(12,971)</b>
Balance for common	(19,398)	(12,971)
Earnings common share		
Primary	\$(0.79)	\$(0.71)
Fully Diluted	\$(0.79)	\$(0.71)
Common Shares:		
Full Diluted	24,478	18,232
Year-end	24,698	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents	27,981	
Current assets	119,306	
Net property & equip.	422	
Total assets	119,957	
Liabilities:		
Current liabilities	16,907	
Stockholders' equity	86,950	
Net current assets	102,399	

**TABULA RASA HEALTHCARE INC****Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	43,944	27,977
Cost & expenses	55,277	28,634
Operating income	(15,381)	(2,422)
Interest expense	63	76
Net before taxes	(15,444)	(2,498)
Income taxes	2,650	95
<b>Net income</b>	<b>(18,094)</b>	<b>(2,593)</b>
Balance for common	(18,094)	(2,593)
Earnings common share		
Primary	\$(0.96)	\$(0.16)
Fully Diluted	\$(0.96)	\$(0.16)
Common Shares:		
Full Diluted	18,789	16,239
Year-end	19,985	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents	4,252	
Inventories	2,671	
Current assets	32,939	
Net property & equip.	9,873	
Total assets	183,417	
Liabilities:		
Current liabilities	73,362	
Long-term debt	820	
Stockholders' equity	105,773	
Net current assets	(40,423)	

**TCP CAPITAL CORP****Earnings, 3 mos. to Mar 31(Consol. – \$):**

	2018	2017
Total Revenues	44,215,046	39,343,014
Cost & expenses	22,649,933	14,461,126
<b>Net income</b>	<b>21,565,113</b>	<b>24,881,888</b>
Earnings common share		
Primary	\$0.46	\$0.37
Fully Diluted	\$0.46	\$0.37
Common Shares:		

Full Diluted	58,844,381	53,041,902	Long-term debt	3,202,715	Current liabilities	16,902
Year-end	58,836,148	53,042,047	Stockholders' equity	1,576,008	Long-term debt	1,972
<b>Consolidated Balance Sheet Items, as of (\$):</b>			Net current assets	(180,728)	Stockholders' equity	59,678
Assets:	2018				Net current assets	60,216
Cash & equivalents	13,736,624		<b>TESLA INC</b>			
Current assets	35,081,870		<b>Earnings, 3 mos. to Mar 31(Consol. – \$000):</b>			
Total assets	1,665,615,764			2018	2017	
Liabilities:			Total Revenues	3,408,751	2,696,270	
Current liabilities	786,992,346		Cost & expenses	4,005,725	2,953,819	
Stockholders' equity	876,575,015		Operating income	(596,974)	(257,549)	
Net current assets	(751,910,476)		Other income (expense), net	(37,716)	(18,098)	
			Net before taxes	(779,022)	(371,903)	
			Income taxes	5,605	25,278	
<b>TECHTARGET INC</b>			<b>Net income</b>	(784,627)	(397,181)	
<b>Earnings, 3 mos. to Mar 31(Consol. – \$000):</b>			Earnings common share			
	2018	2017	Primary	\$(4.19)	\$(2.04)	
Total Revenues	27,299	23,577	Fully Diluted	\$(4.19)	\$(2.04)	
Cost & expenses	23,597	22,628	Common Shares:			
Operating income	2,594	(182)	Full Diluted	169,146	162,129	
Net before taxes	2,394	(345)	Year-end	169,750	169,750	
Income taxes	300	(316)	<b>Consolidated Balance Sheet Items, as of (\$000):</b>			
<b>Net income</b>	2,094	(29)	Assets:	2018		
Earnings common share			Cash & equivalents	2,665,673		
Primary	\$0.08	\$0.00	Inventories	2,565,826		
Fully Diluted	\$0.07	\$0.00	Current assets	6,383,920		
Common Shares:			Net property & equip.	10,519,226		
Full Diluted	28,512	27,532	Total assets	27,271,429		
Year-end	27,483	27,430	Liabilities:			
<b>Consolidated Balance Sheet Items, as of (\$000):</b>			Current liabilities	8,650,359		
Assets:	2018		Long-term debt	8,763,726		
Cash & equivalents	25,422		Stockholders' equity	4,450,695		
Current assets	62,203		Net current assets	(2,266,439)		
Net property & equip.	10,869					
Total assets	168,535		<b>THE TRADE DESK INC</b>			
Liabilities:			<b>Earnings, 3 mos. to Mar 31(Consol. – \$000):</b>			
Current liabilities	19,950			2018	2017	
Long-term debt	19,867		Total Revenues	85,668	53,352	
Stockholders' equity	122,750		Cost & expenses	75,738	51,416	
Net current assets	42,253		Operating income	9,930	1,936	
			Interest expense	156	364	
			Foreign currency	(544)	(428)	
			Net before taxes	9,230	1,144	
			Income taxes	160	(3,765)	
			<b>Net income</b>	9,070	4,909	
<b>TELENAV, INC.</b>			Earnings common share			
<b>Earnings, 9 mos. to Mar 31(Consol. – \$000):</b>			Primary	\$0.22	\$0.13	
	2018	2017	Fully Diluted	\$0.20	\$0.11	
Total Revenues	89,561	129,293	Common Shares:			
Cost & expenses	151,863	164,092	Full Diluted	44,543	43,557	
Operating income	(62,302)	(34,799)	Year-end	42,069	39,788	
Other income (expense), net	400	1,152	<b>Consolidated Balance Sheet Items, as of (\$000):</b>			
Net before taxes	(61,902)	(33,647)	Assets:	2018		
Income taxes	611	805	Cash & equivalents	138,952		
<b>Net income</b>	(62,513)	(34,452)	Current assets	706,522		
Earnings common share			Net property & equip.	18,046		
Primary	\$(1.41)	\$(0.80)	Total assets	739,056		
Fully Diluted	\$(1.41)	\$(0.80)	Liabilities:			
Common Shares:			Current liabilities	469,741		
Full Diluted	44,396	43,189	Stockholders' equity	262,931		
Year-end	44,744	43,735	Net current assets	236,781		
<b>TERRAFORM POWER INC</b>						
<b>Earnings, 3 mos. to Mar 31(Consol. – \$000):</b>			<b>TOCAGEN INC</b>			
	2018	2017	<b>Earnings, 3 mos. to Mar 31(Consol. – \$000):</b>			
Total Revenues	127,547	151,135		2018	2017	
Cost & expenses	84,006	78,080	Cost & expenses	12,855	8,564	
Operating income	(22,049)	12,068	Operating income	(12,846)	(8,553)	
Interest expense	53,554	68,312	Interest income	315	37	
Other income (expense), net	(849)	(360)	Interest expense	349	616	
Foreign currency	(891)	(587)	Other income (expense), net	59	59	
Net before taxes	(77,343)	(57,191)	<b>Net income</b>	(12,880)	(9,073)	
Income taxes	(976)	(918)	Earnings common share			
<b>Net income</b>	(76,367)	(56,273)	Primary	\$(0.65)	\$(4.11)	
Balance for common	83,233	(31,769)	Fully Diluted	\$(0.65)	\$(4.11)	
Earnings common share			Common Shares:			
Primary	\$0.56	\$(0.37)	Full Diluted	19,906	2,208	
Fully Diluted	\$0.56	\$(0.37)	Year-end	19,912	2,227	
Common Shares:			<b>Consolidated Balance Sheet Items, as of (\$000):</b>			
Full Diluted	148,166	92,072	Assets:	2018		
Year-end	148,086		Cash & equivalents	17,793		
<b>Consolidated Balance Sheet Items, as of (\$000):</b>			Current assets	77,118		
Assets:	2018		Net property & equip.	1,387		
Cash & equivalents	157,833		Total assets	78,739		
Current assets	323,543		Liabilities:			
Net property & equip.	4,719,808		Current liabilities	26,638,000		
Total assets	6,258,781		Stockholders' equity	16,884,000		
Liabilities:			Net current assets	11,815,000		
Current liabilities	504,271					

**TONIX PHARMACEUTICALS HOLDING CORP**

<b>Earnings, 3 mos. to Mar 31(Consol. – \$):</b>						
	2018	2017				
Cost & expenses	6,988,000	5,091,000				
Operating income	(6,988,000)	(5,091,000)				
<b>Net income</b>	(6,935,000)	(5,064,000)				
Earnings common share						
Primary	\$(0.88)	\$(1.27)				
Fully Diluted	\$(0.88)	\$(1.27)				
Common Shares:						
Full Diluted	7,850,298	3,985,529				
Year-end	8,010,790					

<b>Consolidated Balance Sheet Items, as of (\$):</b>						
Assets:	2018					
Cash & equivalents	19,253,000					
Current assets	20,682,000					
Net property & equip.	78,000					
Total assets	20,980,000					
Liabilities:						
Current liabilities	2,364,000					
Stockholders' equity	18,611,000					
Net current assets	18,318,000					

**TRANSACT TECHNOLOGIES INC.**

<b>Earnings, 3 mos. to Mar 31(Consol. – \$000):</b>						
	2018	2017				
Net Sales	12,243	13,997				
Cost & expenses	11,387	12,581				
Operating income	856	1,416				
Other income (expense), net	10	(6)				
Net before taxes	858	1,402				
Income taxes	178	459				
<b>Net income</b>	680	943				
Earnings common share						
Primary	\$0.09	\$0.13				
Fully Diluted	\$0.09	\$0.13				
Common Shares:						
Full Diluted	7,901	7,445				
Year-end	7,401	7,346				

<b>Consolidated Balance Sheet Items, as of (\$000):</b>						
Assets:	2018					
Cash & equivalents	4,669					
Inventories	8,881					
Current assets	23,130					
Net property & equip.	2,361					
Total assets	30,875					
Liabilities:						
Current liabilities	5,823					
Stockholders' equity	24,467					
Net current assets	17,307					

**TRAVELZOO**

<b>Earnings, 3 mos. to Mar 31(Consol. – \$):</b>						
	2018	2017				
Total Revenues	30,884,000	28,429,000				
Cost & expenses	27,227,000	26,367,000				
Operating income	3,657,000	2,062,000				
Other income (expense), net	161,000	7,000				
Net before taxes	3,818,000	2,069,000				
Income taxes	1,316,000	1,209,000				
Income contin. oper.		860,000				
<b>Net income</b>	2,502,000	2,744,000				
Earnings common share						
Primary	\$0.20	\$0.21				
Fully Diluted	\$0.20	\$0.21				
Common Shares:						
Full Diluted	12,462,000	13,288,000				
Year-end	12,462,000	13,246,000				

<b>Consolidated Balance Sheet Items, as of (\$):</b>						
Assets:	2018					
Cash & equivalents	23,103,000					
Current assets	38,453,000					
Net property & equip.	4,641,000					
Total assets	46,636,000					
Liabilities:						
Current liabilities	26,638,000					
Stockholders' equity	16,884,000					
Net current assets	11,815,000					





Balance for common	(13,049)	(6,920)
Earnings common share		
Primary	\$(0.81)	\$(3.09)
Fully Diluted	\$(0.81)	\$(3.09)
Common Shares:		
Full Diluted	16,070	2,239
Year-end	16,254	2,780

<b>Consolidated Balance Sheet Items, as of (\$000):</b>		
Assets:		
Cash & equivalents		2018
Current assets		2018
Net property & equip.		2018
Total assets		2018
Liabilities:		
Current liabilities		2018
Stockholders' equity		2018
Net current assets		2018

**VIKING THERAPEUTICS INC**

<b>Earnings, 3 mos. to Mar 31(Consol. - \$):</b>		
	2018	2017
Cost & expenses	4,805,000	4,968,662
Operating income	(4,805,000)	(4,968,662)
Other income (expense), net	1,361,000	277,698
<b>Net income</b>	<b>(3,551,000)</b>	<b>(5,221,900)</b>
Earnings common share		
Primary	\$(0.08)	\$(0.23)
Fully Diluted	\$(0.10)	\$(0.23)
Common Shares:		
Full Diluted	45,306,000	22,352,921
Year-end	50,933,195	23,925,425

<b>Consolidated Balance Sheet Items, as of (\$):</b>		
Assets:		
Cash & equivalents		2018
Current assets		2018
Net property & equip.		2018
Total assets		2018
Liabilities:		
Current liabilities		2018
Stockholders' equity		2018
Net current assets		2018

**VOYAGER THERAPEUTICS INC**

<b>Earnings, 3 mos. to Mar 31(Consol. - \$000):</b>		
	2018	2017
Cost & expenses	22,035	18,986
Operating income	(21,093)	(17,522)
Other income (expense), net	399	395
Net before taxes	(20,106)	(16,874)
Income taxes	(180)	(226)
<b>Net income</b>	<b>(19,926)</b>	<b>(16,648)</b>
Balance for common		(16,648)
Earnings common share		
Primary	\$(0.63)	\$(0.65)
Fully Diluted	\$(0.63)	\$(0.65)
Common Shares:		
Full Diluted	31,760	25,792
Year-end	31,889	

<b>Consolidated Balance Sheet Items, as of (\$000):</b>		
Assets:		
Cash & equivalents		2018
Current assets		2018
Net property & equip.		2018
Total assets		2018
Liabilities:		
Current liabilities		2018
Stockholders' equity		2018
Net current assets		2018

**VYCOR MEDICAL INC**

<b>Earnings, 3 mos. to Mar 31(Consol. - \$):</b>		
	2018	2017
Cost & expenses	597,648	658,749
Operating income	(314,550)	(299,722)
Foreign currency	(60)	(348)
<b>Net income</b>	<b>(326,636)</b>	<b>(312,791)</b>
Balance for common	(488,821)	(474,977)
Earnings common share		
Primary	\$(0.02)	\$(0.03)
Fully Diluted	\$(0.02)	\$(0.03)
Common Shares:		
Full Diluted	19,985,877	15,247,264
Year-end	20,071,988	17,585,443

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents		2018
Inventories		2018
Current assets		2018
Net property & equip.		2018
Total assets		2018
Liabilities:		2018
Current liabilities		2018
Stockholders' equity		2018
Net current assets		2018

**WAYSIDE TECHNOLOGY GROUP INC**

<b>Earnings, 3 mos. to Mar 31(Consol. - \$000):</b>		
	2018	2017
Net Sales	40,552	38,091
Cost & expenses	38,705	36,299
Operating income	1,847	1,792
Gains or losses	2	
Net before taxes	2,087	1,940
Income taxes	489	621
<b>Net income</b>	<b>1,598</b>	<b>1,319</b>
Balance for common	1,531	1,257
Earnings common share		
Primary	\$0.36	\$0.29
Fully Diluted	\$0.36	\$0.29
Common Shares:		
Full Diluted	4,301	4,359
Year-end	4,506	

<b>Consolidated Balance Sheet Items, as of (\$000):</b>		
Assets:		
Cash & equivalents		2018
Inventories		2018
Current assets		2018
Net property & equip.		2018
Total assets		2018
Liabilities:		
Current liabilities		2018
Stockholders' equity		2018
Net current assets		2018

**WORKDAY INC**

<b>Earnings, 3 mos. to Apr 30(Consol. - \$000):</b>		
	2018	2017
Total Revenues	618,643	479,861
Cost & expenses	689,907	540,061
Operating income	(71,264)	(60,200)
Other income (expense), net	2,218	1,294
Net before taxes	(75,112)	(61,863)
Income taxes	(702)	2,181
<b>Net income</b>	<b>(74,410)</b>	<b>(64,044)</b>
Earnings common share		
Primary	\$(0.35)	\$(0.31)
Fully Diluted	\$(0.35)	\$(0.31)
Common Shares:		
Full Diluted	213,055	203,818
Year-end	216,000	207,000

<b>Consolidated Balance Sheet Items, as of (\$000):</b>		
Assets:		
Cash & equivalents		2018
Current assets		2018
Net property & equip.		2018
Total assets		2018
Liabilities:		
Current liabilities		2018
Long-term debt		2018
Stockholders' equity		2018
Net current assets		2018

**XCEL BRANDS, INC.**

<b>Earnings, 3 mos. to Mar 31(Consol. - \$):</b>		
	2018	2017
Total Revenues	8,766,000	8,430,000
Cost & expenses	7,143,000	7,601,000
Operating income	1,212,000	435,000
Interest expense	286,000	378,000
Net before taxes	926,000	57,000
Income taxes	426,000	456,000
<b>Net income</b>	<b>500,000</b>	<b>(399,000)</b>
Earnings common share		
Primary	\$0.03	\$(0.02)
Fully Diluted	\$0.03	\$(0.02)
Common Shares:		
Full Diluted	18,716,802	18,674,943
Year-end	18,367,149	18,447,692

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents		2018
Current assets		2018
Net property & equip.		2018
Total assets		2018
Liabilities:		2018
Current liabilities		2018
Long-term debt		2018
Stockholders' equity		2018
Net current assets		2018

**XOMA CORP**

<b>Earnings, 3 mos. to Mar 31(Consol. - \$000):</b>		
	2018	2017
Total Revenues	463	260
Cost & expenses	5,600	11,180
Operating income	(5,137)	(10,920)
Interest expense	170	609
Other income (expense), net	1,501	(500)
Gains or losses		1,314
<b>Net income</b>	<b>(3,806)</b>	<b>(10,715)</b>
Balance for common	(3,806)	(16,318)
Earnings common share		
Primary	\$(0.46)	\$(2.37)
Fully Diluted	\$(0.46)	\$(2.37)
Common Shares:		
Full Diluted	8,313	6,887
Year-end	8,332	7,586

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents		2018
Current assets		2018
Net property & equip.		2018
Total assets		2018
Liabilities:		2018
Current liabilities		2018
Long-term debt		2018
Stockholders' equity		2018
Net current assets		2018

**XTANT MEDICAL HOLDINGS INC**

<b>Earnings, 3 mos. to Mar 31(Consol. - \$):</b>		
	2018	2017
Total Revenues	17,934,000	22,083,000
Cost & expenses	18,587,000	23,369,000
Operating income	(1,657,000)	(2,567,000)
Interest expense	3,545,000	3,400,000
Other income (expense), net	(51,000)	182,000
<b>Net income</b>	<b>(5,253,000)</b>	<b>(5,785,000)</b>
Earnings common share		
Primary	\$(0.70)	\$(3.87)
Fully Diluted	\$(0.70)	\$(3.87)
Common Shares:		
Full Diluted	7,481,550	1,494,443
Year-end	13,077,468	1,507,717

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents		2018
Inventories		2018
Current assets		2018
Net property & equip.		2018
Total assets		2018
Liabilities:		2018
Current liabilities		2018
Long-term debt		2018
Stockholders' equity		2018
Net current assets		2018

**ZAFGEN INC**

<b>Earnings, 3 mos. to Mar 31(Consol. - \$000):</b>		
	2018	2017
Cost & expenses	15,702	13,265
Operating income	(15,702)	(13,265)
Interest expense	267	227
Interest expense	458	73
Foreign currency	(63)	100
<b>Net income</b>	<b>(15,956)</b>	<b>(13,011)</b>
Earnings common share		
Primary	\$(0.58)	\$(0.48)
Fully Diluted	\$(0.58)	\$(0.48)
Common Shares:		
Full Diluted	27,542	27,351
Year-end	27,559	27,351

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents .....	45,731
Current assets .....	91,422
Net property & equip.....	479
Total assets .....	92,614
Liabilities:	
Current liabilities .....	7,457
Long-term debt .....	20,160
Stockholders' equity .....	64,997
Net current assets .....	83,965

**ZION OIL & GAS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses .....	2,512,000	3,523,000
Operating income .....	(2,512,000)	(3,523,000)
Other income (expense), net.....	(3,707,000)	117,000
Foreign currency .....	(32,000)	31,000
<b>Net income</b> .....	<b>(6,251,000)</b>	<b>(3,375,000)</b>
Earnings common share		
Primary .....	\$(0.11)	\$(0.07)
Fully Diluted .....	\$(0.11)	\$(0.07)
Common Shares:		
Full Diluted .....	57,504,000	47,237,000
Year-end .....	57,344,379	47,520,071

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents .....	4,770,000
Current assets .....	7,114,000
Net property & equip.....	26,124,000
Total assets .....	34,473,000
Liabilities:	
Current liabilities .....	8,716,000
Long-term debt .....	2,052,000
Stockholders' equity .....	23,417,000
Net current assets .....	(1,602,000)

**ZOGENIX INC.****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses .....	31,050	23,795
Operating income .....	(31,050)	(21,099)
Other income (expense), net.....	43	567
Net before taxes .....		(21,109)
Income taxes .....		17
Income contin. oper. ....		(21,126)
Income discount. oper. ....		(181)
<b>Net income</b> .....	<b>(30,180)</b>	<b>(21,307)</b>
Earnings common share		
Primary .....	\$(0.87)	\$(0.86)
Fully Diluted .....	\$(0.87)	\$(0.86)
Common Shares:		
Full Diluted .....	34,841	24,813
Year-end .....	34,973	24,813

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents .....	271,953
Current assets .....	281,327
Net property & equip.....	287
Total assets .....	391,857
Liabilities:	
Current liabilities .....	23,076
Stockholders' equity .....	273,772
Net current assets .....	258,251

\*

*MERGENT OTC INDUSTRIAL News Reports 0027-0865* is published weekly online on Tuesdays and printed the last Friday of the month by Mergent, Inc., 444 Madison Ave., New York, NY 10022. The News Reports are part of the OTC INDUSTRIAL Manual and provide periodic updates. Send address changes to MERGENT OTC INDUSTRIAL, 580 Kingsley Park Drive, Fort Mill, SC 29715.

Copyright©2018 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.